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Summary
The interaction of B-cyclodextrin with a number of pharmaceutical and other racemates has 
been investigated in three ways: (i) by HPLC using 13-cyclodextrin-containing eluents, (ii) by 
HPLC using a B-cyclodextrin stationary phase (Cyclobond I) and (iii) in NMR experiments. 
Previously unreported chiral discriminations have been achieved in numerous cases by each 
technique, namely 24 cases using B-cyclodextrin eluents, 20 examples using Cyclobond I, 
and 35 cases in NMR.
The application of B-cyclodextrin-containing mobile phases in HPLC to the semi-preparative 
resolution of pharmaceutical racemates has been investigated. An on-line solid-phase 
extraction recovery system was designed, which allowed recovery of resolved enantiomers 
free from mobile phase additives. Optical purities of 88% or greater were achieved in the 
four cases investigated, at throughputs of 1-5mg racemate per hour. The potential 
applicability of this technique to other chiral separations has been discussed.
The influence of mobile phase composition and stationary phase type on resolution of 
enantiomers using B-cyclodextrin eluents have been investigated with the aim of facilitating 
the optimisation of both analytical and semi-preparative chiral separations.
Correlations between observed chiral discriminations in the three techniques were sought, 
with a view to using NMR or Cyclobond experiments for the rapid evaluation of whether a 
given racemate would be likely to be resolvable using B-cyclodextrin-containing HPLC 
eluents. Potentially useful empirical correlations were found, although the theoretical basis 
for these was not strong.
NMR experiments were used to investigate the stability and structure of B-cyclodextrin 
complexes. A theory was developed which allowed in some cases the determination of the 
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1.1 Chirality and pharmaceutical development
In recent years, it has become increasingly clear that chirality has important implications in 
pharmaceutical development. Hitherto, many chiral drug compounds have been developed 
and marketed as racemates. However, recent advances in chiral synthesis and chromatog­
raphic resolution of enantiomers have opened up the possibility of single enantiomer 
pharmaceutical products. Research into the pharmacokinetic and pharmacodynamic 
properties of enantiomers has shown that there may be major advantages in terms of drug 
efficacy and safety in following this course. Regulatory authorities have indicated that 
legislation may soon compel investigation of individual enantiomers in any new drug 
submission.
1.1.1 Fundamentals of optical isomerism
The phenomenon of optical isomerism was first discovered by Pasteur (Pasteur (1948)). He 
found that on crystallisation of sodium and ammonium salts of synthetic tartaric acid, two 
types of crystal were formed which were non-superimposable mirror-images of each other. 
Mechanical separation of the crystals enabled the examination of their properties. Their 
melting points, refractive indices, solubilities, etc. were found to be identical. They were 
found to rotate the plane of polarised light to the same degree, but in opposite directions. 
The starting material possessed no such optical rotation, which Pasteur correctly attributed 
to the “cancelling out” of contributions of the two forms. Natural tartaric acid was found to 
possess the same optical rotatory power as one of the two crystal forms produced from 
synthetic material. Pasteur noted that this property frequently distinguished natural from 
synthetic materials. Pasteur proposed that the asymmetry of the crystals was derived from 
asymmetry of the molecules that make them up. As ideas of chemical structure were further 
developed, this hypothesis could be placed on a firmer footing. Thus, the idea of the 
asymmetric carbon atom (or “chiral centre”), i.e. one with four different groups attached, was
8










Figure 1.1 The enantiomers of alanine, showing the four different groups attached to 
the chiral centre (from Mason (1989)).
A number of forms of nomenclature have been devised to describe optically active 
compounds. Species which rotate the plane of polarised light anti-clockwise are designated 
while those that cause clockwise rotation are designated “+”. It is not possible, however, 
to relate measured optical rotation to the spatial arrangement of atoms about the chiral 
centre. The latter may be described by the Cahn-lngold-Prelog convention, which classifies a 
chiral centre as R- or S-. In this convention, the groups attached to the chiral centre are 
classified in order of increasing atomic number, and the designation made on the basis of 
the order of the groups when the molecule is viewed from opposite the group with lowest 
atomic number. Absolute configurations may be detemined by “anomalous dispersion” in 
X-ray crystallography. This was first achieved for the sodium rubidium salt of (+)-tartaric acid 
(Bijvoet et at (1949)).
Many compounds possess more than one asymmetric carbon atom. In general, /? chiral 
centres give rise to 2n optical isomers. Thus, for a molecule with two chiral centres, four 
isomers may arise, designated as RR, SS, RS, and SR. The RR and SS forms (and similarly 
the RS and SR) are mirror images but the RR and RS forms (and all other pairs related by
inversion of just one of the chiral centres) are not enantiomeric and may differ in their 
physical properties. Such pairs of isomers are known as diastereomers.
1.1.2 Pharmacokinetic implications of chirality
As Pasteur observed (Pasteur (1901)), most biological molecules (notably sugars, peptides 
and proteins) are homochiral, i.e. only one enantiomer is present in natural systems. Their 
interactions with drug enantiomers are therefore frequently stereospecific. If a drug 
compound is administered as a racemate, differences in both the pharmacokinetics and 
pharmacodynamics of the two enantiomers may occur.
The pharmacokinetics of a drug are determined by four processes - adsorption, distribution, 
metabolism and excretion. Stereoselectivity may arise at any of these stages, and will lead to 
changes in the concentration ratio of two drug enantiomers with time and administration 
route. This in turn leads to differences in the exposure of physiological systems to the 
actions of the two enantiomers. Patient-to-patient variation will also arise, influenced by 
factors such as plasma protein concentrations, metabolic dysfunction due to disease or 
genetic factors, interactions with other drugs, and age.
In general, processes that involve passive diffusion, such as adsoption in the gut, are not 
stereoselective. Active transport processes, such as protein binding, passage across 
membranes and renal tubular secretion, are frequently stereoselective, however.
It is well established that the binding of many drugs to the main plasma proteins - serum 
albumin and ar acid glycoprotein - is enantioselective (Muller (1988)). Thus drugs such as 
ketoprofen (Rendic et a / (1980)) and warfarin (Brunner and Muller (1985)) have been shown 
to bind stereoselectively to albumin; propanolol (Brunner and Nuller (1985)) and disopyra- 
mide (Lima et al (1984)) (amongst others) bind stereoselectively to arac id  glycoprotein. The 
binding constants of the enantiomers of these drugs to proteins have been shown to differ by
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factors of up to 3 (Rendic et al (1980)). The resulting differences in free drug enantiomer 
concentrations in plasma have been widely reported (Muller (1988)).
The metabolism of two enantiomers may also differ significantly. The pharmacokinetics of 
propanolol enantiomers differ markedly, with the S-isomer exhibiting significantly higher 
bioavailability (Lindner (1989)). Walle et a l{1988) have shown that propanolol metabolism is 
significantly stereoselective. First-pass metabolic ring oxidation occurs to a greater extent 
(about 2:1) for the R-(+)- isomer, and the degree of first pass metabolism in a given patient 
largely determines the relative plasma levels of the two enantiomers (von Bahr et a / (1982)), 
with considerable inter-individual variation seen. The 2-arylpropionic acids, a widely- 
prescribed series of non-steroidal anti-inflammatory agents, provide an interesting case.
Here metabolic inversion of the inactive R isomer to the active S form has been shown to 
occur during absorption from the gastro-intestinal tract (Hutt and Caldwell (1983)). Variations 
in the rate of this metabolic route, which are particularly marked in elderly patients, lead to 
significant inter-individual differences in plasma levels of the active isomer. It has been 
suggested that this factor contributed to the toxicity problems which led to the withdrawal of 
benoxaprofen (Opren) from the market in 1982 (DeCamp (1989)).
1.1.3 Pharmacodynamic implications of chirality
Pharmacodynamic differences between drug enantiomers have been shown to arise in a 
number of cases. Such differences arise largely because of differences in binding at 
potential receptor sites. Several possibilities have been identified (Krstulovic (1989), Powell 
et al (1988)):
(1) pharmacological activity resides entirely in one enantiomer:
(2) the enantiomers have identical activity:
(3) the enantiomers have qualitatively similar activities but differ quantitatively in their intrinsic 
activities;
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(4) the enantiomers have qualitatively different activities and act independently;
(5) the enantiomers have opposite activities (possibly due to competitive antagonism of one 
for the other);
(6) one enantiomer gives rise to the desired therapeutic effect, while the other gives rise to 
unwanted (side) effects;
(7) one enantiomer inhibits the side-effects due to the other.
In cases where these can be clearly distinguished, the enantiomer giving rise to the desired 
effect is known as the eutomer, while the other enantiomer is known as the distomer. The 
ratio of the activity of the two is known as the eudismic ratio (Lehmann et a / (1976)).
Because stereoselectivity is dependent on the specificity of the drug-receptor interaction, 
high eutomer activity is frequently associated with low distomer activity, and hence a high 
eudismic ratio. This generalisation is known as “Pfeiffer’s rule”, and holds when the portion of 
the molecule interacting with a receptor contains the chiral centre (Ariens (1983)).
Propanolol (marketed as Inderal) is the most widely used 8-adrenoceptor blocking drug, and 
is administered as a racemate. It also has membrane stabilising and anaesthetic effects. As 
has already been pointed out, the two enantiomers of this compound differ in their binding to 
plasma proteins and in their metabolism. The S:R ratio in plasma after administration of the 
racemate therefore depends on the administration route (Olanoff et a / (1984)). The 
8-blocking activity of the S enantiomer is 100 times higher than that of the R isomer in 
animal studies, but the anaesthetic and other effects of the two enantiomers are the same 
(Silber et al (1982)). Therefore, in treatment of some conditions (such as angina) the S 
enantiomer is more effective than the racemate (Wilson et a / (1969)), while in others (such 
as migraine) there is little stereoselectivity in the dose-effect relationships (Stensrud and 
Sjasstad (1976))
Warfarin is used as an anti-clotting agent. In humans, S-warfarin is a five times more potent
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anti-coagulant than the R- isomer, but the S-isomer is eliminated 2-5 times more rapidly. The 
overall activities of the enantiomers on administering the racemate are therefore similar. 
However, interactions between warfarin and co-adminstered drugs such as phenylbutazone 
have also been shown to be stereoselective (O’Reilly et al (1980)). The interpretation of 
clinical data has been more problematic than would be the case if warfarin were to be 
administered as a single enantiomer.
Thalidomide represents perhaps the greatest disaster in the history of modern pharmaceuti­
cals. It was prescribed for its sedative and anti-nausea properties, often to pregnant women 
suffering from morning sickness. It rapidly became clear that thalidomide was severely 
teratogenic, and that the development of this drug had been seriously flawed. A number of 
authors have suggested that the racemic nature of marketed thalidomide had a part to play 
in the tragedy. Simonyi (1984) has noted that the teratogenicity in rabbits of racemic 
thalidomide was significantly greater than that of either enantiomer. Blaschke et al (1979) 
have reported the results of studies where teratogenicity was concentrated in one isomer 
only. DeCamp (1989) has recently reviewed all the available evidence. He concluded that 
there is strong, but not conclusive, evidence that thalidomide chirality may have an influence 
on its side-effects. When thalidomide was marketed, chiral resolution methods were much 
less well developed. The implication is that the thalidomide tragedy might have been avoided 
if its enantiomers had been available for separate investigation.
Brewster et al (presented at the 7th. Int. Conf. Prostaglandins and related cpds., Florence, 
Italy (1990)) investigated a number of 1,3-dioxane racemates possessing a pyridyl 
substituent with respect to their thromboxane TXA2  antagonism and synthase inhibition 
properties. Compounds exhibiting such activity might have therapeutic value in several 
conditions by inhibiting the vaso-constrictory and platelet-aggregatory properties of TXA2 
while enhancing the biosynthesis of the anti-aggregatory and vasodilatory species prostacyc­
lin. One compound in particular (TA5 on p.55) was found to combine strong TXA2  receptor
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antagonism and synthase inhibition. Investigation of the properties of the individual 
enantiomers of TA5 showed that almost all the TXA2 antagonism property of the racemate 
arose from the (-) isomer, while the TXA2 synthase inhibition was due mainly to the (+) 
isomer. The latter effect was attributed to enantioselective absorption of TA5 into platelets. 
Clearly, in this case the use of a drug preparation containing both isomers (although not 
necessarily in racemic mixture) might be advantageous.
1.1.4 Regulatory implications of drug stereoisomerism.
It is clear from the above examples that significant pharmacological differences between 
drug enantiomers may be the rule rather than the exception. It has been argued that 
significant advantages in terms of efficacy and safety might accrue from the development of 
single enantiomer drugs. Thus, Caldwell (presented at 2nd. Int. Symp. Chiral Sepns., 
Guildford, UK (1989)) has pointed out that single enantiomer drugs would
(1) simplify dose-response relationships
(2) reduce inter-individual variation
(3) facilitate extrapolation of animal data and
(4) reduce side-effects in many cases.
Simonyi (1984) has pointed out a number of cases where it might be particularly beneficial to 
reduce overall dose by administration of single enantiomers. These are for elderly patients, 
where metabolism may be slow and co-administration of several drugs is common; pregnant 
women, where protection of the foetus requires extra care in drug administration; and 
patients with impaired renal function, where accumulation of drug and metabolites may 
occur. Drayer (1988) has argued that single enantiomer drugs would enhance the capabili­
ties of therapeutic drug monitoring in attempting to relate dosing more closely to the 
requirements of the individual patient.
Most chiral drugs are currently marketed as racemates. Thus, in a 1982 survey of drugs
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marketed in Germany (Ariens and Wuis (1987)), nearly all synthetic chiral drugs (represen­
ting about 25% of all drugs in the survey) were marketed as racemates. Almost all the single 
enantiomer drugs (also representing about 25% of the survey) were natural or semi­
synthetic. This illustrates the extreme reluctance of the pharmaceutical industry until recently 
to invest the extra time and money required to synthesise homochiral drugs (or carry out 
resolution of racemates).
The case against the marketing of racemic drugs has been put most forcefully by Ariens 
(1984,1987). He has argued that the presence of an isomeric impurity at 50% level would 
not be deemed acceptable if the impurity was anything other than enantiomeric, and that the 
different pharmacological properties of enantiomers should mean that they are treated as 
separate chemical entities. In particular, the practice of carrying out pharmacokinetic studies 
on the racemate without differentiating the enantiomers has been strongly criticised.
The response of the pharmaceutical industry to this criticism has often been that the 
methods for synthesising or resolving optically pure pharmaceuticals are not well enough 
developed for their application on a commercial scale. In the last ten years, however, these 
techniques have advanced so far that this argument is no longer tenable.
In recent publications, it has become clear that the regulatory authorities in the UK and the 
USA will require full information on the properties of the individual isomers of a racemic new 
drug, and some justification for the marketing of the racemate as opposed to either 
enantiomer. (DeCamp (1989); Bridges, J.W., presented at 2nd. Int. Symp. Chiral Sepns., 
Guildford, UK (1989)). At the moment, drug registration legislation does not specifically cover 
the implications of chirality, but the requirements for full characterisation of the drug 
substance can be interpreted to include optical purity.
Whether the drug products of the future are marketed as single enantiomers or as
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racemates, it is clear that approaches to the production of pure enantiomers, if only in 
comparatively small quantities for pharmacological evaluation, will continue to occupy the 
minds of researchers. Analytical methodology for optical purity analysis and chiral analysis in 
biofluids, which has largely come to the fore only during the last ten years, will be needed in 
the development of all chiral drugs.
1.1.5 Approaches to the development of single enantiomer drugs
The production of pure enantiomers may be achieved either by chiral synthesis, or by 
resolution of racemic product. Both approaches have been the subject of intensive research 
in the pharmaceutical sector.
There are two main ways of synthesising homochiral products without the need for resolution 
of enantiomers (Scott (1988)). In asymmetric synthesis, chirality is introduced by reaction at 
a prochiral site (such as C=C or C=0), often using a chiral catalyst or enzyme. A typical 
reaction of this type is hydrogenation of an alkene over a chiral rhodium-phosphine catalyst, 











Figure 1.2. Industrial asymmetric synthesis of L-DOPA (from Scott (1988)).
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The use of a homochiral starting material may also lead to a homochiral product. For this 
purpose, a variety of natural products, including sugars and amino acids are frequently 
employed. This approach is exemplified by the synthetic route to phenothiazines, illustrated 
in Figure 1.3.
Figure 1.3. Trimeprazlne synthesis from chiral starting material (French Patent (1958), 
US Patent (1958))
If a synthetic route using one of the above approaches is not feasible, resolution of racemic 
target or synthetic intermediates may be possible. There a number of classical methods of 
achieving this. The method Pasteur used to initially resolve tartaric acid enantiomers, i.e. 
manual separation of enantiomeric crystals (Drayer (1988)) is both laborious and limited in 
application, since most racemates do not crystallise to form enantiomeric crystals. However, 
Pasteur also recognised that the formation of diasteromers by reaction of the racemate with 
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acid by salt formation with quinine followed by fractional crystallisation. A variation on this 
approach is kinetic resolution, where one enantiomer of a racemate reacts selectively with 
chiral reagent (often an enzyme). Pasteur himself used a similar method to resolve tartaric 
acid enantiomers, utilising the selective metabolism of the d-tartrate by yeast. Both these 
approaches have since been extended. Diastereomers may be separated either by 
crystallisation (the classical approach), or chromatographically - an approach that has 
increased in importance in recent years and is discussed in detail below.
An inherent drawback of resolution over chiral synthesis is that 50% of the material is 
wasted, if only one enantiomer is required. This problem may be overcome by the racemis- 
ation of the unwanted enantiomer and further resolution. While chiral synthesis is usually the 
method of choice for process-scale production of pure enantiomers, the complexity of 
developing such syntheses is such that resolution is often employed at earlier stages of drug 
development, where time is more critical than cost, to produce smaller quantities of 
homochiral materials. Chromatographic resolution techniques are also widely employed in 
analytical applications, where the measurement of the concentrations of two enantiomers is 
the aim, and not their isolation.
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1.2 Chromatographic chiral separations
In the last fifteen or so years, chromatographic techniques, and particularly high-performance 
liquid chromatography (HPLC) have become predominant in pharmaceutical analysis and 
separations, owing to their high speed, efficiency and ease of automation. This has been 
particularly true in the separation and analysis of enantiomers, where selectivities are often 
low, and high separation efficiencies are therefore critical. Chromatographic separation of 
enantiomers may be effected either by derivatisation and separation of the resulting 
diastereomers, or by incorporation of a chiral species into the stationary or mobile phase.
The development of chiral chromatography has been rapid in recent years, and a plethora of 
chiral derivatising reagents, stationary phases, and mobile phase additives are now in use.
1.2.1 Indirect chiral separations
Chromatographic separation of diastereomers, formed by reaction of a pair of enantiomers 
with an optically pure chiral reagent, is termed “indirect" chiral separation, since the 
chromatographic process itself is not chiral. Thus, in this approach, conventional mobile and 
stationary phases are used. It is similar in principle to the “classical" resolution methods 
involving fractional crystallisation of diastereomers discussed above, but has the advantage 
of greater efficiency. Thus, a separation that would involve many recrystallisations to achieve 
high optical purity may be achieved in one step on an efficient modern chromatographic 
column.
A wide variety of chiral derivatisation reactions have been devised. 45 reagents are listed in 
a recent review (Ahnoff and Einarsson (1989)). Typical reactions are the formation of 
amides, carbamates and ureas from amines; the formation of esters, carbonates, and 
carbamates from hydroxyl groups; and the formation of esters and amides from carboxylic 
acid groups. This approach has found wide pharmaceutical application, such as in the
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separation of enantiomers of 13-blockers (Wilson and Walle (1984)), and 2-arylpropionic acids 
(Hutt et a / (1986)). The reagents employed are often cheap and readily available, and the 
analytical methods are often more robust than those using chiral stationary phases.
As a number of reviewers have pointed out, there are distinct drawbacks to the chiral 
derivatisation approach (Lindner (1988), Karnes and Sarkar (1987), Krstulovic (1989)). The 
optical purity of the reagent is critical. For example, a 2% optical impurity in an (R)- reagent 
would lead to the formation of 98% (RR) product and 2% (RS) product on reaction with (R) 
analyte. The (RS) product would be enantiomeric with (SR), formed by reaction of the (R) 
reagent with (S) analyte. Since these isomers would be indistinguishable in an achiral 
chromatography system, erroneous results would be obtained in any optical purity assay of 
the analyte. It is therefore important to check the optical purity of a reagent before use. 
Reaction conditions must be chosen so as to avoid racemisation, and reactions should 
proceed to completion in order to avoid errors due to differential reaction rates for the two 
analyte enantiomers. In preparative applications, the reversal of the derivatisation to recover 
the separated enantiomers may be problematic. It has been suggested, therefore, that direct 
chiral chromatography, involving transient diastereomeric interactions in stationary or mobile 
phase, may be preferable where possible.
1.2.2 Principles of chromatographic chiral recognition.
The possibility of using chromatographic techniques to resolve racemates was first 
recognised by Wilstatter (1904)) who proposed enantioselective adsorption onto wool as a 
means of resolving racemic dyestuffs. Other early chiral separations used other naturally- 
occurring chiral materials such as lactose, quartz and paper.
The first attempt to rationalise such separations was made by Oalgliesh (1952). He 
investigated the resolution of various amino acid enantiomers by paper chromatography, and
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proposed what has become known as the “three-point attachment” rule to account for the 
observed variation of enantioselectivity with structure. This generalisation is derived from the 
Cahn-lngold-Prelog convention, whereby the positions of three of the four bonds around a 
tetrahedral carbon must be known in order to specify the configuration as R or S. In the case 
of chiral recognition, Dalgliesh proposed that at least one of the analyte enantiomers must be 
capable of at least three simultaneous interactions with the chiral selector, and that at least 
one of these interactions should be different for the two enantiomers, for chiral recognition to 
occur. This is illustrated in Figure 1.4, where one enantiomer is capable of three interactions 
with the selector while the other is capable of only two.
Figure 1.4. Interaction of enantiomeric analytes with a chiral selector, showing the 
“three-point” interaction required for chiral recognition (from Pirkle and Hamper 
(1987))
Pirkle has developed the three-point rule further. (Pirkle and Hamper (1987), Pirkle and 
Pochapsky (1989)). He has pointed out that the analyte-selector interactions may be 
attractive {e.g. hydrogen bonds, electrostatic interactions, dipole-dipole forces, pi-acid- 
pi-base interactions, hydrophobic effects) or repulsive {e.g. steric interactions). If the 
stereochemically-dependent interaction is attractive, i.e. free-energy lowering, the analyte- 






stereoselective interaction is repulsive {i.e. energetically unfavourable), the analyte-selector 
complex with least contribution from that interaction will be stronger.
Chromatographic retention order may thus be rationalised. If the chiral selector is bound to 
or coated on the stationary phase, the analyte enantiomer forming the strongest analyte- 
selector complex will be most retained. If the chiral selector is added to the mobile phase, 
the analyte forming the strongest analyte-selector complex will be most prevalent in the 
mobile phase, and therefore will elute most rapidly {i.e. will be least retained).
The above arguments apply only to “point” interactions. Some interactions (such as pi-pi 
interactions and dipole stacking) define an axis rather than a point. In these cases two 
interactions may be sufficient for chiral recognition. (Pirkle and Pochapsky (1989), Davankov 
(1989)). Davankov has also considered the case where diastereomeric analyte-selector 
complexes formed in the mobile phase interact with the achiral stationary phase. In such a 
case, two-point analyte-selector interaction may be sufficient, providing the diastereomeric 
complexes differ in their interactions with the stationary phase.
While an undoubted over-simplification, the three-point attachment rule has proved useful in 
rationalising many chiral separations. Indeed, considerations of this type were instrumental in 
development of several of the synthetic chiral stationary phases now widely used. For 
natural chiral resolving agents, such as proteins and celluloses, application of the three-point 
rule is more difficult, as the analyte binding site is less clearly defined. In such cases, more 
empirical development has occurred.
The relationship of enantioselectivity to the thermodynamics of chiral recognition has been 
investigated (Pirkle and Pochapsky (1989), Boehm e/a /(1988)). Equation 1.1 describes the 
dependency of chromatographic selectivity, a , on the difference in free energies of formation 
of the analyte-selector complexes, A(AG)
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A ( A G ) = - R T I n a  (eqn. 1.1).
Because of the logarithmic nature of this relationship, small free energy differences result in 
large a  values. Thus, a a ( AG) value of 0.25 kJ mol*1 gives a chromatographic selectivity of 
about 1.1. The efficiency of modern chromatographic techniques is such that this degree of 
selectivity should allow for baseline resolution of the enantiomers, under suitable conditions.
1.2.3 Chiral separations by ligand exchange
Separation of enantiomers may be achieved in chromatographic systems in which the 
analyte forms a mixed complex with a metal ion and a chiral chelating agent, either added to 
the mobile phase or immobilised on the stationary phase. This approach was first used to 
separate amino acid enantiomers on resins loaded with optically active amino acids and 
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Figure 1.5. Interaction of amino acid enantiomers with Cu2+-L-hydroxyproline bound to 
silica (from Mack and Hauck (1988))
Three points of interaction may readily be identified. Two are the dative bonds to the copper 
ion, formed by both analyte enantiomers. The third interaction is stereoselective and involves
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steric or hydrophobic interaction between the side-chain moieties of the analyte and selector 
(Gilon (1981)).
ChiraUeluents containing copper ions anq amino adds have also been employed (Gil-Av et 
al (1980)). The separation mechanism is similar to that described above.
A number of chiral HPLC ligand exchange phases are commercially available. Ligand- 
exchange TLC has also been used for separation of enantiomers (Mack and Hauck (1988)) 
and recently commercialised. The application of chiral LEC has been limited mainly to the 
resolution of amino acid enantiomers, owing to the relatively spedfic structural requirements 
of the chiral recognition mechanism.
1.2.4 Synthetic multiple interaction (“Pirkle"-type) HPLC chiral stationary phases
These stationary phases were devised with the three-point attachment rule firmly in mind 
(Pirkle and House (1979)). A typical CSP of this type is illustrated in Figure 1.6, which also 
shows the analyte-selector interactions potentially responsible for the reported resolution of 










Figure 1.6 Interaction of 3,5-dinitrobenzoylphenylglycine-silica stationary phase with 
ibuprofen-3-naphthylamide (after Nicoll-Griffith (1987))
CSP's of this type generally have at least one of each of the following types of functional 
group close to the chiral centre: (i) pi-acidic or pi-basic aromatic groups, capable of 
charge-transfer interactions (ii) polar hydrogen-bonding or dipole-dipole interaction sites and 
(iii) bulky non-polar groups to provide steric or hydrophobic interactions.
For successful resolution, the analyte should contain groups which are complementary to the 
CSP functionalities. As for ibuprofen above, this more often than not requires derivatisation, 
particularly to introduce the necessary pi-acid or pi-basic site. This requirement is one of the 
major factors limiting the applicability of these phases, although achiral derivatisation is not 
as problematic as chiral derivatisation (discussed earlier). The other practical limitation of 
Pirkle-type CSP’s is that they are usually operated in normal-phase mode. Consequently, 
they are not generally suitable for bioanalytical applications, or for very water-soluble 
compounds.
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A wide variety of multiple-interaction CSP’s are now commercially available and, despite the 
limitations mentioned above, they have been widely used and can be highly selective 
(Armstrong (1987), Oi and Kitahara (1983)).
1.2.5 Chiral separations using proteins
As has already been discussed, it is well established that the binding of many pharmaceuti­
cal agents to proteins - particularly to a  1-acid glycoprotein (AGP) and serum albumin (HSA) 
- is stereoselective. This has been exploited in the development of HPLC chiral separations 
using these and other proteins, either immobilised onto silica, or used as mobile phase 
additives.
Bovine serum albumin (BSA), immobilised onto agarose, was first used to produce a CSP of 
this type (Stewart and Doherty (1973)). A silica-based BSA phase has since been commerci­
alised as "Resolvosil” (Allenmark ef a/(1983)). Because of the nature of the BSA binding 
site, the application of this CSP is limited to neutral and anionic molecules. Racemates of 
pharmaceutical importance, including benzodiazepinones and warfarin (Allenmark (1986)), 
have been resolved on this phase.
CSP’s produced from AGP have complementary application to BSA phases, since AGP 
selectively binds cationic species (Hermansson (1983)). Thus, a large number of basic 
pharmaceuticals, including B-blockers, pheniramines and opioids, have been resolved on 
AGP phases (Hermansson, J., presented at 2nd Int Symposium Chiral Sepns., Guildford 
(1989)). Other proteins, including ovumucoid (Miwa et al (1987)) and -chymotrypsin 
(Wainer, I.W., presented at 2nd Int. Symp. Chiral Sepns., Guildford (1989)), have been used 
to produce CSP’s. These have yet to be commercialised, however.
Protein-based CSP’s have shown great potential in pharmaceutical applications. They may 
be operated in reversed-phase mode, and hence may be used for biofluid analysis. The
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mechanism of chiral recognition is not clearly defined, however. Method development can 
therefore only be conducted on something of a “trial-and-error" basis at present. AGP and 
BSA have also been used as eluent additives (Hermansson (1984)), but economic 
considerations have deterred most workers from this approach.
1.2.6 Chiral ion-pairing agents
Organic acids and bases are often chromatographed in reversed-phase systems by the 
addition of a counter-ion to the mobile phase to form “ion-pairs”. This approach has been 
extended to chiral separations, using chiral counter-ions such as (+)-10-camphorsulphonic 
acid or benzoxycarbonylglycidylproline (ZGP) (Pettersson and Schill (1981)). In order to form 
tight enough ion-pairs in the mobile phase to give chiral recognition, it is necessary to carry 
out such separations in the absence of protic solvents, i.e. in normal-phase mode. This fact 
has tended to limit the pharmaceutical applications of this method.
1.2.7 Cellulose, cyclodextrin, crown ether and other CSP’s
A wide range of chiral stationary phases based on cellulose are now commercially available. 
Cellulose is a high molecular-weight polymer of D-(+)-glucose with a helical structure, and 
can give rise to chiral recognition by means of hydrogen-bonding interactions and inclusion 
of the solute molecules. Various attempts have been made to prepare cellulose HPLC 
phases. These have either involved preparation of microcrystalline cellulose derivatives or 
coating of cellulose derivatives onto silica (Okamoto ef a / (1984)). The latter phases have 
found wider application because they are better able to withstand high-pressure operation. 
About a dozen silica-cellulose (“Chiracel") phases are now commercially available, with 
distinct selectivity according to their functionality. They are operated in normal phase mode, 
and are not very robust, with certain solvents tending to “strip off” the cellulose coating from 
the silica (Johns (1989)). Their high cost has also limited their use.
27
Cyclodextrins are also glucose oligomers, and give rise to chiral recognition via inclusion 
complexation (Hinze (1981)). Particularly with the introduction of derivatised cyclodextrin 
CSP’s for use in normal-phase mode (Astec (1991)), cyclodextrin-silica phases may 
supercede cellulosic phases in many applications, as they are chemically bonded phases 
(and hence more robust) and are considerably cheaper than Chiracel columns. Their use, 
both in CSP's and as eluent additives, will be discussed fully in subsequent chapters.
A stationary phase incorporating a chiral crown ether (Crownpak) has recently been 
commercialised. The mechanism of chiral recognition in this case is also thought to involve 
inclusion complexation.
A variety of synthetic chiral polymers have been immobilised onto silica and used as CSP’s 
(Pirkle and Pochapsky (1989)). Typical of these is poly(triphenyl methyl methacrylate), a 
helical polymer which forms the basis of the recently marketed Chiralpak OT phase 
(Okamoto et a / (1984)). The mechanism of chiral recognition on such phases may be similar 
to that on cellulose, i.e. a mixture of polar and steric interactions.
1.2.8 Preparative HPLC chiral separations
The development of chiral chromatography has so far been mainly limited to analytical scale 
separations. However, owing to the increasing demand for production of optically pure drugs, 
preparative chromatographic resolution of enantiomers, based on the methods discussed 
above, is likely to assume greater importance (Pirkle and Hamper (1987), Meyer (1987)).
Pirkle and Hamper (1987) have discussed the requirements for such separations. For high 
throughput, large samples must be introduced to the column. Under such overloaded 
conditions, both selectivity and efficiency are lower than when column loading is small. It is 
therefore critical to obtain high selectivity under analytical conditions for efficient preparative 
separations. It is also important that the loss in efficiency of the CSP with increasing sample
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size is minimised, i.e. that the phase has high loadability. A typical achiral silica or reversed 
phase packing has a loadability of the order of 1mg sample on column per gram of packing 
material (Done (1976)). Many of the currently available CSP’s have considerably lower 
capacity than this, and this limits their preparative applicability.
The separation of gram quantities of material in reasonable time usually involves the use of 
large sized stationary phase particles and high flow rates, using large columns (500x20mm 
and greater). Under such conditions, column efficiencies are lower than under analytical 
conditions, but the large particles may have greater loadability than the 5pm particles used in 
analytical columns. Milligram quantities of enantiomers, where throughput is not as critical, 
are more usually separated on semi-preparative columns of 10mm in diameter, packed with 
5-10pm particle stationary phases.
The protein-based CSP’s, where high molecular weight limits the concentration of binding 
sites on the stationary phase, show perhaps most clearly the limitations imposed by low 
loadabilities. Erlandsson et a / (1986) investigated the preparative resolution of tryptophan, 
oxazepam and benzoin enantiomers on a BSA-silica column. Very high selectivities (3.0,2.1 
and 1.7, respectively) were obtained at low column loading, giving more than baseline 
resolution in all cases. However, resolution decreased very rapidly on increasing the sample 
size up to 1 mg on a 500x22mm column, and throughputs of only 1 mg/hour at high optical 
purity could be achieved in the best case.
The cyclodextrin bonded phases are also reported to have low capacity (approximately 25%  
of that of a conventional reversed-phase packing), due to low coverage of the cyclodextrin 
on the silica (Vigh et al (1989a)). However, impressive separations have recently been 
achieved on these columns in displacement mode (Vigh e ta l{1989), (1989a), (1990)).
The CSP’s that have found greatest preparative application are the Pirkle-type phases,
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owing to their high selectivity for many pairs of enantiomers, and to their high capacity. The 
loadability of DNB-phenylglycine-silica is of the same order as a conventional silica column, 
with mass overload occurring at above 200pg sample on column per gram of packing 
material (Meyer (1987)).
The preparative resolution of chiral benzodiazepinones was demonstrated by Pirkle and 
Tsipouras (1984). Selectivities of over 4.0 on (S)-3,5-DNB-leucine-silica were achieved for 
some of the compounds studied. In such cases, 100mg racemate could be resolved into 
enantiomeric fractions at 99% optical purity on a 250x10mm column packed with 5pm 
material at a single pass.
Pirkle and Hamper (1987) studied in detail the variation in resolution of enantiomers of 
2,2,2-trifluoro-1-(9-anthrylethanol) with sample loading on an analytical (250x4.6mm) column 
packed with 3,5-DNB-phenylglycine covalently bonded to 5pm aminopropyl-silica, using a 
mobile phase consisting of 2% propan-2-ol in hexane at 1 - 2ml/min. While only moderate 
selectivity (a  = 1.44) was seen at low column loading, the capacity and efficiency of the 
phase was such that useable resolution was obtained, even at very high column loading, as 
shown in Figure 1.7.
An Rs value of 1, which theoretically corresponds to 98% purity of each fraction (Snyder
(1972)), was obtained at 5.4mg column loading. The separation was scaled-up by a factor of
4.7 by using a 250x10mm column. Under these conditions, 25mg racemate was resolved 
and the predicted 98% enantiomeric excess obtained in each enantiomer fraction. Higher 
throughputs were obtained by increasing the loading still further, and using a second pass 







0 4 8 12 16
sam ple mass (mg)
Figure 1.7. Variation in resolution of enantiomers of 2,2,2-trifluoro-1-(9-anthryl)ethanol 
on Pirkle column. Conditions as text. (After Pirkle and Hamper (1987))
Pirkle has reported that CSP’s such as that above consistently exhibit capacities of 5mg 
solute per gram of packing material. Pirkle columns are now available commercially in large 
sizes packed with large particles for preparative work. The availability of both antipodes of a 
column type enables the manipulation of elution order. Perry and Rateike (1990) have shown 
that elution of the trace component first is advantageous. The main problem with these 
phases is the need for achiral derivatisation before separation, which introduces complic­
ations in recovery of the resolved enantiomers.
Several preparative separations on Chiracel cellulosic phases have been reported. The 
enantiomers of prostaglandin precursors were resolved at a throughput of 400mg/hour of the 
required enantiomer on a 500 x 20mm Chiracel OC (cellulose triphenylcarbamate) column 
(Miller and Bush (1989), Miller and Weyker (1990)). A similar Chiracel OC column was used 
to resolve enantiomers of R-blocking drugs at 100mg scale. (Okamoto (1986)). Masurel and
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Wainer (1989) reported rapid mg-scale chiral resolution of ifosfamide on Chiracel OD. It is 
clear that the loadability of these phases is high enough for preparative applications, but at 
present the commercial cost of large columns of this type is very high.
The use of mobile phase additives to achieve preparative chiral separations is not widely 
reported. This is largely due to the difficulty of recovering the resolved enantiomers free of 
the resolving agent, and because of the high cost of the large quantities of the additive 
required (Smith, R.M., presented at 2nd. Int. Symp. Chiral Sepns., Guildford (1989)). 
Sellergren et al (1988) reported the use of ultrafiltration for the removal of BSA from D- and 
L-kynurenine following semi-preparative separation by counter-current extraction. This 
technique might be used for other macromolecular chiral additives, and allowed the recovery 
of the additive for re-use.
Preparative separation of amino acid enantiomers by ligand exchange using mobile phase 
additives has also been reported (Jeanneret-Gris et a / (1989), Keller and Niwa (1989)). 
Removal of the additives (copper ions and amino acids) from the product was achieved in 
both cases by ion-exchange.
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1.3. Cyclodextrins
1.3.1 Preparation, structure and physical properties
Cyclodextrins (CDs) are a series of glucose oligomers produced by the action of Bacillus 
macerans amylase (and certain other microbial amylases) on starch. They were first isolated 
from degraded starch by Villiers (1891), and were characterised as cyclic oligosaccharides 
by Schardinger (1904). Cyclodextrins consist of six to twelve o-D-glucopyranose units in a 
ring joined by (1 - 4) linkages. The members of the series formed in highest yield from starch 
are the alpha-, beta-, and gamma- oligomers, containing six, seven, and eight glucose 
residues, respectively. The structure of beta-cyclodextrin is shown in Figure 1.8.
Figure 1.8. Chemical structure of B-cyclodextrin, with numbering of atoms of glucose 
unit also shown. •  = oxygen atoms. $  = hydroxyl groups. (From Saenger (1980))
X-ray crystallographic studies (Takeo and Kuge (1970)) on solid cyclodextrins, and NMR and 
circular dichroism studies of their aqueous solutions (Wood et a / (1977)) have shown that the
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glucose units are in the C1 chair conformation, and that hydrogen bonds are formed 
between 2- and 3- hydroxyl groups of adjacent glucose units. These hydrogen bonds are 
thought to confer conformational rigidity on the molecule, and are maintained even in 
aqueous solution. As shown in Fig. 1.9, cyclodextrins are shaped like hollow cones , with the 
primary (6-) hydroxyls at the narrower face and the secondary (2- and 3-) hydroxyls at the 
wider end of the cavity. The cavity contains the ether-like 4- oxygen atoms and the H-5 and 
H-3 protons of the glucose units, and is therefore relatively hydrophobic compared to the 
external faces of the molecule where the hydroxyl groups are situated (Griffiths and Bender
(1973), Street (1987), Hinze (1981)).
Figure 1.9. The molecular shape of B-cyclodextrin (From Pagington (1987))
The physical properties of the common cyclodextrins are summarised in Table 1.1, overleaf.
The anhydrous forms are somewhat deliquescent, forming one of several hydrates, 
depending on temperature. Wiedenhoff and Lammers (1968) found B-cyclodextrin hydrate to 
contain 12 mole equivalents of water at 15-30°C. The aqueous solubilities of the cyclodext­
rins were investigated by Jozwiakowski and Connors (1985). They found that dissolution in 
water was enthalpically unfavourable but entropically favourable. Hence, solubility was 







less soluble in water than the other oligomers. B-cyclodextrin is even less soluble in .most 
organic solvents than in water (Saenger (1980)), but is freely soluble in dimethylsulphoxide 
and dimethylformamide.
Table 1.1. Physical properties of cyclodextrins (from Saenger (1980), Hinze (1981))
CD MW Cavity dimensions, Angstroms aq.soly.
(anhydrous) ext. diameter int. diameter depth %w/v (25°C)
alpha- 973 14.6 4.7 - 5.2 4.5 14.5
beta- 1135 15.4 6.0 - 6.4 7 1.85
gamma- 1297 17.5 7.5 - 8.3 7 23.2
Cyclodextrins are fairly stable compounds, decomposing on heating (before melting) above 
200°C (Szejtli (1982)). Like all saccharides, they are susceptible to hydrolysis by strong 
acids, but are stable in alkaline media (French and Mclntire (1950)). The hydroxyl groups 
have relatively low pKa values, between 12.1 and 12.6 (VanEtten et a / (1967)), and may be 
deprotonated at high pH, leading to increased aqueous solubility (Pharr et a / (1989)).
1.3.2. Cyclodextrin inclusion complexes
The most significant property of cyclodextrins is their ability to form inclusion complexes in 
aqueous solution. This was first reported by Freudenburg and Cramer (1948). A wide range 
of guest molecules have been shown to form such complexes, from noble gases (Saenger 
(1980)) and inorganic anions (Rohrbach et a / (1987)) through simple aromatic molecules 
(Lewis and Hansen (1973)) to large species such as steroids (Gazdag et a / (1986)).
Complex formation is frequently evidenced by changes in the physical and chemical 
properties of both guest and host, as the portion of the guest included in the cavity is moving
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from aqueous solution into a more hydrophobic environment inside the cavity. This may 
cause changes in the NMR spectra of both guest and host (Demarco and Thakkar (1970)). 
Fluorescence enhancement on complexation with cyclodextrins has been shown to occur for 
solutes such as 1-anilino-8-naphthalenesulphonate (Cramer ef a/(1967)) and dansyl amino 
acids (Kinoshita et al (1973)). Changes in guest UV absorption (Otagiri et a / (1976)) and 
circular dichroism have also been reported (Uekama et a / (1977), Kajtar et al (1981)). 
Inclusion also results in changes in the pKa values of ionisable guests, since ionised guests 
are generally less strongly included in the hydrophobic cavity (Connors and Lipari (1976)). 
Complexation often results in solubilisation of the guest in water, since the hydrophobic 
portion of the included species is less exposed to the solvent. This effect has been 
demonstrated for a number of poorly soluble pharmaceuticals, notably barbiturates (Thakkar 
et a / (1972)), non-steroidal anti-inflammatory agents (Hamada e ta l(1975)) and prostaglan­
dins (Hatachi and Inaba (1974))..
The variation in these physical properties with cydodextrinrsubstrate ratio have been widely 
used to estimate the stoichiometry and stability of cyclodextrin complexes (Connors and 
Lipari (1976), Gelb et a / (1981), Miyaji e ta l(1976), Cramer e ta l{1967), Bergeron e ta l 
(1977a), Ikeda et a / (1975)), using methods such as those of Job (1928) and Benesi and 
Hildebrand (1949). In most cases, complex stoichiometries are 1:1, but 2 :1 ,1 2  and even 
higher order stoichiometries have been reported (Szejtli (1982)). Complex formation 
(equilibrium) constants of up to 104 have been reported (Otagiri et a / (1975)).
Complexation may also cause changes in the chemical properties of a guest molecule. For 
example, the stability of phenothiazines towards oxidation is greatly increased by inclusion in 
B-cyclodextrin (Otagiri et a / (1975)). Cyclodextrins have also been shown to catalyse certain 
reactions, such as prostaglandin isomerisation (Uekama et a / (1978)) and dechlorination of 
chlorpromazine (Uekama et al (1978a))..
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1.3.3 Thermodynamics of inclusion complex formation
The thermodynamics of a number of cyclodextrin complexation reactions have been 
investigated. Free energy, enthalpy, and entropy of complex formation may be determined 
from the varation of complex stability with temperature (Cramer et a l (1967)), or by 
microcalorimetry (Lewis and Hansen (1973). Typical data from these studies are given in 
Table 1.2 (overleaf). In all cases, complexation is enihalpicaliy favourable (i.e. AH is 
negative). The entropic contribution to the free energy of complexation at 273K is generally 
small. AS is more often negative than positive.
The driving forces for formation of cyclodextrin inclusion complexes have been discussed 
widely. Tabushi et al (1978) have devised a model of the complexation process, which is 
illustrated in Figure 1.10.
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Figure 1.10. Schematic representation of the thermodynamic process of inclusion of 
an organic guest molecule by alpha-cyclodextrin in aqueous solution, (from Tabushi
et at (1978))
Tabushi argued that the overall stabilisation due to complexation can be estimated by 
summation of the free energy changes due to (i) release of “gaseous” water molecules from
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Table 1.2. Thermodynamic parameters (in KJ mol*1) for formation of cyclodextrin 
complexes at 298k
Guest Cyclodextrin Kf, M*1 AG, AH, H > CO method ref
benzene alpha -21.7 -16.7 2.1 calc Tabushi (1978)
p-iodoaniline alpha -37.6 -30.8 6.9 calc Tabushi (1978)
benzoic acid alpha -42.5 -26.5 pot Gelb (1981)
benzoate anion alpha -16.3 -10.5 pot Gelb (1981)
p-nitrophenol alpha -30.5 -17.2 spec Gelb (1981)
220 -13.4 -25.8 -12.5 me Bertrand (1989)
p-nitrophenol beta 350 -14.5 -12.0 2.4 me Bertrand (1989)
p-nitrophenolate alpha -46.9 -27.4 spec Gelb (1981)
p-cyanophanol alpha 140 -25.5 -13.0 pot Gelb (1981)
m-cyanophenol alpha 95 -25.5 -14.3 pot Gelb (1981)
phenobarbital beta 1690 -43.1 -25.1 pot Miyaji (1976)
phenobarbital sodium beta 192 -27.6 -15.1 pot Miyaji (1976)
D-norleucine alpha - 9.5 - 9.3 0.2 me Barone (1989)
L-norjeucine alpha - 9.5 - 8.9 0.6 me Barone (1989)
D-phenylalanine alpha 18 -16.3 me Cooper (1978)
L-phenylalanine alpha 15.5 -15.5 me Cooper (1978)
(+)-2-phenylethylamine alpha -15.1 ' - me Cooper (1978)
(-)-2-phenylethylamine alpha -15.5 me Cooper (1978)
D-mandelate anion alpha 7.8 -13.0 me Cooper (1978)
L-mandelate anion alpha 7.8 -14.2 me Cooper (1978)
me = microcalorimetry; pot = potentiometry; sol = solubility; spec = spectrophotometry; 
calc = energy calculation
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the cavity, (ii) return of water molecules to the bulk liquid, (iii) transfer of guest from solvated 
to “gaseous” state, with collapse of the structured water cavity it occupied, and (iv) binding of 
the guest in the cyclodextrin cavity. He calculated the enthalpy and entropy changes 
associated with each stage for the complexation of benzene, p-iodoaniline, and methyl 
orange by B-cyclodextrin. In each case, the major driving forces for complexation were found 
to be host-guest Van der Waals forces (from stage iv) and stabilisation of the water 
molecules expelled from the cavity (at stage ii). These factors were discussed by Saenger et 
al (1976). The water molecules inside the cavity in the solvated host were termed “high- 
energy" water, since they cannot form their full complement of hydrogen-bonds. On 
expulsion from the cavity and return to the bulk solvent, these water molecules are stabilised 
by being able to form additional H-bonds. The loss in host-water Van der Waals stabilisation 
may be more than compensated for by Van der Waals attraction between the host and the 
hydrophobic guest.
Water stabilisation is independent of the nature of the guest. Thus, differences in the 
stabilities of complexes formed by a given cyclodextrin reflect mainly the size of the 
host-guest Van der Waals forces, which depend on the “fit” of the guest in the cavity. Thus, 
benzene derivatives are well known to complex strongly with alpha-cyclodextrin, but larger 
aromatic molecules such as naphthalene complex more strongly with the larger beta- 
cyclodextrin. Steroidal multi-ring molecules only complex strongly with gamma-cyclodextrin 
(Szejtli (1982), Gazdag e/a/(1986)).
Mularz (1988) has demonstrated most elegantly the effect of guest size on complex stability. 
He investigated the complex stabilities of several series of halogenated benzene derivatives 
with B-cyclodextrin, and found linear relationships between the molar volume of the halogen 
substituents and the complex stabilities. The importance of steric factors is also illustrated by 
the data for meta- and para-cyanophenol (Table 1.2), where position of substituents on the 
benzene ring is seen to have a marked influence on complex stability. Table 1.2 also shows
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the effect of acid ionisation on complex stability. In general, carboxylic acids are more 
strongly complexed as their protonated forms, but the reverse is often true of phenols.
The strength of Van der Waals interactions in the cavity also depend on the hydrophobicity 
of the guest. This would account for the close correlation observed between complex 
stabilities and octanol-water partition coefficients within a structurally related series (Otagiri 
et al (1975)), and for the observation that inclusion of ionised and strongly polar groups is 
generally disfavoured (Szejtli (1982))
Szejtli (1982) has pointed out that the relative effects of water stabilisation and Van der 
Waals interactions in providing a driving force for complexation may vary with cyclodextrin 
ring size. Thus, in gamma-cyclodextrin the water molecules in the larger cavity are more like 
the bulk solvent in terms of their hydrogen-bonding capability than in the small alpha- 
cyclodextrin cavity. Expulsion of high-energy water might therefore be expected to contribute 
less to overall stabilisation of gamma-cyclodextrin complexes.
Saenger et al (1976) also suggested that relief of ring-strain is a driving force for formation of 
alpha-cyclodextrin complexes. Tabushi’s calculations, however, suggest that conformational 
changes if anything detract from complex stability. Bergeron et al (1977a) found no NMR 
evidence for significant changes in host geometry on complexation. Guest-host hydrogen- 
bonding has been suggested to account for the differences in stabilities of complexes of 
enantiomeric guests (Gelb et al (1981), Otagiri e /a /(1976)). However, Tabushi’s calculations 
do not suggest that such interactions play an important role in overall complex stabilisation. 
The evidence for such interactions in solution is sparse.
The small, and generally unfavourable, changes in entropy on complex formation were 
thought by Tabushi to arise from a near-cancelling out of reduced guest entropy due to loss 
of rotational degrees of freedom on inclusion against the increased entropy of the solvent on
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being expelled from the cavity.
1.3.4 Stereospecificity of cyclodextrin inclusion
Being oligomers of D-glucose, cyclodextrins are homochiral. B-cyclodextrin, for example, 
contains 35 chiral centres. Complexes formed with the two enantiomers of a chiral guest are 
therefore diastereomeric. Such diastereomeric complexes may differ in their physical and 
chemical properties, such as solubility, solid state structure, UV, CD, NMR and other 
spectra, chemical reactivity, and chromatographic retention.
Stereoselective inclusion by cyclodextrins was first noted by Cramer and Dietsche (1959), 
who resolved the racemates of a number of aromatic adds and their esters by fractional 
crystallisation of their beta-cyclodextrin complexes. Cramer and Dietsche (1959a) also used 
cydodextrins to catalyse enantioselective hydrolysis of chiral esters.
Cooper and MacNicol (1978) measured the enthalpy changes on complexation of a number 
of enantiomeric solutes with alpha-cyclodextrin. Some of their results are listed in Table 12 . 
In some cases (e.g. phenylalanine), significant differences in the stabilities of the diastereo­
meric complexes were seen, but the predsion of the experiments was not sufficiently great 
to allow assessment of whether chiral discrimination arose due to enthalpic or entropic 
effects. They suggested that chiral discrimination was arising due to differences in the 
binding of the exposed guest substituent groups to the cyclodextrin hydroxyls around the rim 
of the cavity, and that cavity interactions (which provide the main driving force for indusion) 
were not enantioselective. This suggestion has also been made by R.D. Armstrong (1987) to 
account for the discrimination between propanolol enantiomers induced by B-cydodextrin. 
Molecular modelling studies showed that the polar groups of one enantiomer were so 
orientated that they could form an extra hydrogen bond with the cyclodextrin primary 
hydroxyls. While in this case, the relative degree of interaction of the two enantiomers with
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the substrate were correctly predicted qualitatively, quantitative studies in this area are 
lacking at present.
The differences in solid state structures of diastereomeric cyclodextrin complexes have been 
investigated by X-ray diffraction for a number of chiral guests, including flurbiprofen (Uekama 
et a / (1983)), fenoprofen (Hamilton and Chen (1988)) and mandelic acid (Harata e ta l  
(1984)). However, it seems unlikely that these results have much relevance to the study of 
chiral discrimination in solution. Complex stoichiometries are rarely 1 :1 in the solid state. 
Cyclodextrin molecules tend to associate to form “channels" in the crystal lattice, and “guest” 
molecules are often found in the channels as well as in the cyclodextrin cavities (Saenger
(1984)). Solvation interactions in solution are likely to be very different to lattice interactions 
in the solid state.
1.3.5 Modified cyclodextrins
A wide range of derivatives of the native cyclodextrins have been produced by chemical 
synthesis (Croft and Bartsch (1983)). These have served to broaden the application of 
cyclodextrins.
Of particular note are the methylated cyclodextrins - 2,6-di-O-methyl- and 2,3,6-tri-O-methyl- 
(permethyl). In the former, the primary and half of the secondary hydroxyls are methylated.
In the latter, all the hydroxyl groups are methylated. The aqueous solubility of these 
derivatives is significantly enhanced relative to the parent cyclodextrin (Casu et a l{1979)), 
which is of particular significance for the otherwise poorly soluble B-oligomer. Methylation of 
the secondary hydroxyl groups is thought to enhance solubility by disrupting intramolecular 
hydrogen-bonding, allowing more water-cyclodextrin solubilising interactions.
The inclusion properties of methylated cyclodextrins have been shown to be different from 
those of the parent cyclodextrins. A number of authors (Szeman e ta l{1987), Uekama e ta l
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(1985), Casu et al (1979)) have shown that dimethylated cyclodextrins form more stable 
complexes than the parents with a number of pharmaceuticals. Trimethylated cyclodextrins 
appear to form weaker complexes in most cases. (Nakai e ta l{1983), Otagiri efa/(1984), 
Imai et al (1988), Uekama et al (1985)). Chiral recognition is often particularly strong in 
trimethylated cyclodextrin complexes (Imai (1988)). This has been attributed to the more 
distorted shape of the trimethyl-cyclodextrin cavity allowing more stereospecific interactions 
inside the cavity (Harata (1990), Uekama et a / (1985)).
Hydroxyalkylated cyclodextrins, particularly hydroxypropyl-, have come to the fore in recent 
years. They also are highly soluble in water, and have been widely used as solubilising 
agents for pharmaceuticals (Muller and Brauns (1985)). They do not exhibit the toxicity of 
methylated cyclodextrins, and have similar complexing ability as the parent cyclodextrins, 
particularly at low degrees of substitution (Pitha and Pitha (1986)).
3.1.6 Applications of cyclodextrins
Cyclodextrins have found wide application in chemistry, and in the pharmaceutical, food and 
other industries. The B-oligomer and its derivatives have been most widely used, partly due 
to favourable complexing properties and also to economic considerations. However, the 
prices of all cyclodextrins, and particularly the previously prohibitive gamma-cyclodextrin, 
have fallen markedly in the last few years, opening up greater possibilities for their 
application.
(a) Pharmaceutical applications
The potential use of cyclodextrins to solubilise and/or stabilise pharamaceutical agents has 
already been mentioned. The bioavailability of a number of drugs has been shown to be 
markedly increased as a result of the additional solubility of their complexes, and it seems 
likely that cyclodextrin-containing formulations may be widely used in the future. One
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commercially available formulation of this type is Prostarmon, the B-cyclodextrin-complex of 
Prostaglandin which has enhanced stability properties relative to the uncomplexed drug 
(Jones et al (1984a)).
(b) Applications in the food industry
B-cyclodextrin is approved for use as a food additive in several countries. It potentially may 
be used as a stabilising agent, such as in Vitamin D3 preparations, and may help to retain 
volatile flavour and aroma components. Cyclodextrins may also be used to extract desirable 
or undesirable components from foodstuffs, such as free fatty acids from vegetable oils 
(Pagington (1987))
(c) Enzyme models
Cyclodextrins are good, if simple, models for enzyme active sites, as they rely on steric 
recognition for complex formation. They have therefore been widely used in studies of 
enzyme kinetics and competitive binding (Bergeron (1977)).
(d) Analytical applications
The applications of cyclodextrins in analytical chemistry have recently been reviewed 
(Armstrong (1988)). The use of cyclodextrins to enhance fluorescence has already been 
mentioned, and has been utilised to increase detectability of dansyl amino acids (Kinoshita 
et al (1973)). Their effect on NMR spectra of included guests, particularly in inducing chiral 
discrimination, has led to their use as NMR shift reagents (to be discussed in Chapter 5).
Cyclodextrins have been widely used in chromatographic and related techniques (notably gel 
chromatography, HPLC, gas chromatography, super-critical fluid chromatography, isotachop- 
horesis, and electrophoresis), incorporated in stationary or mobile phase, they impart distinct 
selectivity to the chromatographic process through inclusion interactions. Of particular
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interest has been the possibility of achieving chromatographic chiral separations using 





9 1  MatPrlals
N.B. : All materials used as received, unless otherwise stated. All chiral compounds used 
were racemic, unless otherwise stated.
2.1.1 Solvents, HPLC buffer components and ion-pairing agents
HPLC grade methanol (MeOH), acetonitrile (ACN), tetrahydrofuran (THF), acetone, 
chloroform, triethylamine (TEA), trifluoroacetic acid (TFA), hexanesulphonic acid sodium salt 
(SHS) and tetra-nbutylammonium bromide (TBA) were obtained from FSA, Loughborough.
Analytical Reagent grade dimethylsulphoxide (DMSO), disodium hydrogen orthophosphate 
dihydrate (Na2H P 04), sodium dihydrogen orthophosphate (NaH2P 0 4), sodium hydroxide 
(NaOH), sodium acetate (NaAc), and orthophosphoric acid SG 1.69 (H3P 0 4) were obtained 
from FSA, Loughborough.
GPR grade anhydrous sodium carbonate (Na2C 0 3) was obtained from BDH, Poole. Sodium 
Decyl Sulphate (SDS) was obtained from Cambrian Chemicals (Croydon, Surrey). SLR 
grade glacial acetic acid (HAc), 0.880 ammonia solution (NH3) and anhydrous magnesium 
sulphate (MgS04) were obtained from FSA, Loughborough.
Ether (SLR grade) was obtained from FSA, Loughborough, and was distilled over sodium/ 
benzophenone before use. Water for HPLC was single distilled and passed through 0.45pm 
cellulose nitrate membrane filters before use.
2.1.2 Cyclodextrins
B-cyclodextrin hydrate (containing 10-13% water, w/w) was obtained from Aldrich (Gilling­
ham, Dorset), Sigma (Poole), Lancaster Synthesis (Morecambe, Lancs.), Janssen Chimica 
(Beerse, Belgium) or Wacker Chemie GMBH (Munich, Germany). Alpha and gamma
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cyclodextrins were obtained from Aldrich.
Derivatised cyclodextrins were characterised in terms of degree of substitution (DS) or 
molar substitution (MS), equivalent to the average number of substituent groups per 
glucose unit.
Methyl-B-cyclodextrin (Me-B-CD) (DS = 1.8), hydroxyethyl-B-cyclodextrin (HoEt-B-CD) (MS 
= 0.6 or 0.9), and hydroxypropyl-B-cyclodextrin (HoPr-B-CD) (MS = 0.9) were obtained from 
Aldrich, from Technicol (Stockport), or from Wacker-Chemie GMBH (Munich, Germany).
A sample of a hydroxypropyl-B-cyclodextrin was also obtained from Dr. Bemd Muller, 
Christian Albrechts University, Kiel, Germany. This was characterised by NMR, and found 
to have an MS value of about 0.5.
Cyclodextrins for thermodynamic studies were dried for 24 hours at 125°C before use. 
Otherwise, cyclodextrin hydrates were used as received.
2.1.3 Materials for NMR studies
Deuterium oxide (D20 ), 99.9atom% D, was obtained from Aldrich, from Goss (Ingatestone, 
Essex), or from MSD Isotopes (Montreal, Canada). Methyl sulphoxide-d6 (DMSO-d6) 
99.9atom% D was obtained from MSD. Acetone-d6 (99atom% D, Gold Label), methanol-d4 
(CD3OD) (99.8atom% D), acetonitrile-d3 (97% Gold Label), and ethanol^ (EtOD) 
(99.5+atom% D) were obtained from Aldrich.
Sodium 2,2-dimethyl-2-silapentane-5-sulphonate (DSS) was obtained from BOC (Croydon) 
and was used as a reference ( 8 = O.OOppm) in D20 . Maleic acid (SLR) was obtained from 
FSA, and was used as an internal standard in quantitative experiments.
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2.1.4 Preparation of ±-trimeprazine trifluoroacetate
±-Trimeprazine hemi-(+)-tartrate (0.5g) was dissolved in distilled water (20ml). Trifluoroace- 
tic acid was added dropwise until trimeprazine trifluoroacetate was produced as a 
gelatinous white precipitate. This was extracted into chloroform (2 x 10ml) and the organic 
phase was dried over MgS04, before evaporation. After drying over P20 5 at reduced 
pressure, a viscous green oil resulted which crystallised over several months. The crude 
trifluoroacetate was used for NMR comparison with chromatographically resolved material.
2.1.5 Solutes
The following solutes were obtained commercially:
d- and I- mandelic acid (Aldrich, 99% Gold Label): tropic acid (Aldrich, 97%); 3-phenyllactic 
acid (Nutritional Biochemicals, Cleveland, Ohio, USA); (S)- and (R)-2-methoxyphenylacetic 
acid (Lancaster Synthesis): (S)- and (R)-O-acetylmandelic acid (Sigma); 2-chloromandelic 
acid (Janssen Chimica); 4-chloromandelic acid (Lancaster Synthesis); 2- and 3-methoxy- 
mandelic acids (Sigma); 4-methoxymandelic acid (Lancaster); 3- and 4-hydroxymandelic 
acids (Sigma); DL-mandelic acid methyl ester (Sigma); R-(-)- and S-(+)- mandelic acid 
methyl esters (Aldrich, 99+% Gold Label); mandelic acid ethyl, benzyl and isoamyl esters 
(Sigma); a -cyclohexylphenylacetic acid (Aldrich, 96%); 2-phenylpropionic acid (Aldrich, 
98%); d-(+)-tartaric acid (Aldrich, 99+% Gold Label); hydroxyzine dihydrochloride (Sigma); 
S-(+)-benzoin (Aldrich, 99%); benzoin (BDH); (-)- and (+)- pseudoephedrine hydrochlorides, 
(+)- and DL-ephedrine hydrochlorides (Sigma); (-)-ephedrine hydrochloride (BDH); 
norephedrine hydrochloride (Sigma); L- and DL-phenylalanine (Sigma); DL-3,4-dihydroxyp- 
henylalanine (DOPA) (Aldrich, 97%); D-, L- and DL-trytophan (Sigma); meclizine dihydroch­
loride (Sigma); trimeprazine hemi-(+)-tartrate (Sigma); and meta-nitroaniline (Aldrich).
Samples of the following compounds were obtained from pharmaceutical research
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laboratories or other non-commercial sources:
Phenothiazines (trimeprazine hemi-(+)-tartrate, l-methotrimeprazine hydrochloride, 
l-methotrimeprazine tartrate, d-methotrimeprazine maleate, promethazine hydrochloride and 
dimethothiazine mesylate (fonazine)) were obtained from Rhdne-Poulenc (Dagenham, 
Essex). Isothipendyl hydrochloride was donated by Astra Pharma AG (Frankfurt, Germany). 
Tetrahydroisoquinolines (TQ1 - TQ7) were supplied by Dr. G.H. Dewar, University of Bath. 
ICI Pharmaceuticals (Macclesfield, Cheshire) supplied samples of thromboxane antagonists 
(TA1 -TA17), tetramisole hydrochloride, ICI1 and ICI2.
SmithKline Beecham (Welwyn, Herts) supplied chlorpheniramine maleate, mebrophenydra- 
mine hydrochloride, and fenoldopam. Ciba-Geigy (Horsham, Sussex) supplied methyl 
phenidate hydrochloride, chlorthalidone, and oxyphenonium bromide (antrenyl). A.H. Robins 
(Horsham, Sussex) supplied pheniramine maleate and brompheniramine maleate. Wyeth 
(High Wycombe, Bucks) supplied carbinoxamine maleate. Zyma (Alderley Edge, Cheshire) 
supplied dimethindene maleate. Pfizer (Groton, Conn., USA) supplied buclizine hydroch­
loride (vibazine). (+)- and (-)-neobenodine hydrochlorides were obtained from Dept. 
Pharmacochemistry, Vrije Universiteit, Amsterdam. Disopyramide phosphate was supplied 
by Hassle AB, Sweden. Benzhexol (trihexyphenidyl) was obtained from Cyanamid (Gosport, 
Hants.). AM5(6) was obtained from Prof. M. Stevens, Dept, of Pharmacy, Aston University. 
Riker Labs. (Loughborough) supplied nefopam hydrochloride. Schwarz Pharma AG 
(Monheim, Germany) supplied bupranolol hydrochloride and bunolol hydrochloride. 
Tropicamide was obtained from Smith and Nephew (Romford, Essex). Metoprolol tartrate, 
orciprenaline sulphate and prilocaine hydrochloride were supplied by Astra (Kings Langley, 
Herts). Salbutamol sulphate was supplied by Glaxo (Ware, Herts). Dexamisole and 
levamisole hydrochlorides were obtained from Janssen Chimica (Beerse, Belgium). 
Verapamil hydrochloride was obtained from Abbott Laboratories (Maidenhead). Telemzepine 
dihydrochloride was obtained from BYK Gulden (Konstanz, Germany).
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Roche (Welwyn, Herts) supplied benserazide hydrochloride and phenindamine tartrate 
(thephorin). The latter is a non-racemic mixture consisting of 60-65% d-phenindamine- 
d-tartrate and 35-40% l-phenindamine-d-tartrate.
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(c) Mandelic acids and related compounds
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(d) Thromboxane antagonists and related model compounds
COMPOUND R X n
TA1 3-pyridyl-CH2- -OH 2
TA2 3-pyridyl- -OH 2
TA3 3-pyridyl-C(CH3)2- -OH 2
TA4 3-pyridyl-CH=CH- -OH 2
TA5 3-pyridyl-CH2-C(CH3)2- -OH 2
TA6 3-pyridyl-CH2-CH2-C(CH3)2- -OH 2
TA7 N1 -imidazoyl-CH2- -OH 2
TA8 Phenyl-0-C(CH3)2- -OH 2
TA9 2-Chlorophenyl- -OH 2
TA10 ‘Butyl- -OH 2
TA11 CF3- -OH 2
TA12 CF3- -OH 3
TA13 3-pyridyl- -H 2
TA14 3-pyridyl-CH2- -H 3
TA15 3-pyridyl- -OMe 2
TA16 3-pyridyl-CH2- -OMe 3




(e) Other chiral pharmaceuticals
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2.1.7 HPLC packed columns and packing materials
The properties of the HPLC stationary phases employed during these studies are summari­
sed in Table 2.1.
A 150 x 4.6mm column was packed with Hypersil 5pm CPS material (obtained from 
Shandon, Runcorn, Cheshire) using a Shandon column packer, operated by air pressure at 
6000 psi, with the material slurried in acetone. A 100 x 4.6mm column was dry-packed with 
Lichrosorb Si60 12-20pm (obtained from BDH, Poole) for use as an in-line solvent saturation 
column. All other columns were obtained commercially.
Hypersil BDS C8 and Spherisorb C6 columns were packed by Capital HPLC (Edinburgh). 
Spherisorb S5CN 250 x 4.6mm and 250 x 10mm columns were obtained from Hichrom 
(Theale, Berks.). Other Spherisorb columns were obtained from Phase Separations 
(Deeside, Clwyd). Zorbax columns were obtained from Hichrom (Theale, Berkshire). SGE 
columns (packed with Spherisorb or Nucleosil materials as shown in table 2.1) were donated 
by SGE Ltd. (Milton Keynes). Semi-preparative (10mm i.d.) columns were packed by SGE 
Ltd. (Milton Keynes) using Lichroprep RP18 25-40pm (obtained from BDH, Poole) or 
Hamilton PRP-1 12-20pm (obtained from Hamilton, Reno, Nevada, USA). A Techsphere 
3pm ODS column was donated by Perkin-Elmer (Beaconsfield, Bucks). A Cyclobond 1250 x 
4.6mm column was obtained from Technicol (Stockport).
2.1.8 Other consumables
0.45pm cellulose nitrate (WCN), polyvinylenedifluoride (PVDF) and nylon (Nylaflo) 
membrane filters were obtained from FSA, Loughborough. 0.2pm Acrodisc filters were also 
obtained from FSA. Pre-cut lengths of microbore (0.02” i.d .) stainless steel tubing were 
obtained from HPLC Technology (Macclesfield, Cheshire).
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Table 2.1. Properties of stationary phases employed in chromatographic studies.
column packing description s.a. p.v. m.p.d. c.l.
m2/g cm3/g nm %
Hypersil CPS cyanopropyl-silica 170 0.7 12
Spherisorb S5CN cyanopropyl-silica 220 0.8 8 3.5
Spherisorb A5Y C1 trimethyl-alumina 12 4
Spherisorb S5C6 hexyl-silica 220 0.8 8 4.6
Zorbax CN cyanopropyl-silica 7
Zorbax TMS trimethyl-silica 7
Techsphere ODS 3pm octadecyl-silica
SGE-C8-8/5
(Spherisorb C8) octyl-silica 220 0.8 12 7
SGE-C8-30/5
(Nucleosil 300C8) octyl-silica 100 0.8 30 2
Lichrosorb60 RP18 octadecyl-silica 315 0.8 10 17
Lichroprep RP18 25-40pm octadecyl-silica
Zorbax PH phenyl-silica 7
Zorbax RX-C8 octyl-silica (base deactivated) 7
Hypersil BDS C8 octyl-silica (base deactivated) 12
Hamilton PRP-1 polystyrene-divinylbenzene (12-20pm)
Cyclobond I beta-cyclodextrin-silica
Abbreviations: s.a. = surface area
p.v. = pore volume 
m.p.d. = mean pore diameter 
c.l. = carbon loading, w/w
All packing materials listed have 5pm particle size unless otherwise stated.
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NMR tubes (type 506-P) were obtained from Goss (Ingatestone, Essex).
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2.9 Analytical HPLC studies
2.2.1 Equipment
Most of the analytical HPLC studies were carried out using a chromatographic system which 
consisted of an LDC Constametric lllG dual-piston HPLC pump, a Rheodyne 7125 manual 
sample injector fitted with a 5 ,10 , or 20|jl loop, and a Spectromonitor III variable-wavelength 
UV detector connected to a Servogor 220 chart recorder. HPLC studies of thromboxane 
antagonists were carried out on a Varian LC5500 integrated liquid chromatograph equipped 
with a variable wavelength UV detector, an autosampler fitted with a 20pl loop, and a Varian 
data processing station.
Sample injections were made using a 50pl syringe (obtained from SGE Ltd., Milton Keynes).
A 100 x 4.6mm column, packed with LiChrosorb Si60 12-20pm, was placed in-line between 
the pump and the injector in order to pre-saturate the mobile phase with silica and hence 
protect the analytical column.
2.2.2 Preparation of mobile phases
Phosphate buffers were prepared by mixing 0.05M aq. NaH2P 04 with 0.05M aq. H3P 04 or 
0.05M aq. Na2H P 04 to the required pH. Acetate buffers were prepared by a similar method, 
from aq. acetic acid and aq. sodium acetate. Triethylammonium acetate buffers were 
prepared by dissolving triethylamine at the required volume fraction in water and adding 
glacial acetic acid to the required pH. The pH of buffer solutions was checked using a Kent 
EIL 7020 pH meter, calibrated with aq. potassium hydrogen phthalate buffer at pH 4.
The aqueous portions of non-cyclodextrin-containing eluents were filtered through 0.45pm 
cellulose nitrate filters before addition of organic modifiers. Cyclodextrin-containing mobile 
phases were prepared by mixing buffer and organic modifier portions of the eluent, followed
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by addition and dissolution of the cyclodextrin. Such mobile phases were filtered through 
0.45pm polyvinylenedifluoride or nylon filters. All mobile phases were degassed by sparging 
with helium before use.
2.2.3 Operating conditions
The flow rates generally employed were 1ml/min. (through columns of 4.6mm internal 
diameter), 0.75ml/min. (through columns of 4mm internal diameter), 0.5ml/min (through 
columns of 3mm internal diameter), or 0.3ml/min (through columns of 2mm internal 
diameter).
Where practicable, column temperature was stabilised at 20-22°C, by immersion in a water 
bath containing a Grant thermostatic bath heater and BathCool cooling unit. Otherwise, 
HPLC experiments were carried out at ambient temperature.
Compounds were generally detected at their UV maxima (as reported in literature), in order 
to maximise sensitivity and selectivity. Where no literature value of UV maximum was 
available for a given compound, detection was effected at 254nm. Detector attenuation was 
adjusted as required to give reasonable peak heights in each case.
2.2.4 Solute preparation
Samples for injection at low column loading (0.1-1 mg/ml) were dissolved in buffer, water, 
mobile phase, or dimethylsuphoxide-buffer (10:90, v/v), as required by their solubility 
characteristics. Where dissolution was incomplete, samples were filtered through 0.2pm 
Acrodisc filters before injection.
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2.2.5 Determination of chromatographic parameters
(a) Capacity factor, k’
Capacity factors were determined from retention data according to equation 2.1.
k’ = (tR - to) / to (eqn. 2.1),
where tR and t0 are the retention times of retained and unretained peaks, respectively, 
to values were determined by injection of water.
(b) Selectivity, a
The chromatographic selectivity between two enantiomeric peaks was calculated from their 
capacity factors according to equation 2.2.
a  = k’i /  k’2 (eqn. 2.2).
(c) Column efficiency, Nw1/2
Column efficiency was calculated according to equation 2.3.
Nwi / 2  = 5.54 (tR /  w1/2)2 (eqn. 2.3),
where w1/2 is the peak width at half height.
For effective comparison of columns of differing lengths, L, efficiency values were often 
calculated on a “per metre” basis, where
N (nrr1) = Nw1/2 / L (eqn. 2.4)
and L = column length in metres
(d) Resolution
The resolution of two solutes is conventionally expressed as Rs, given by equation 2.5.
Rs = 2 (tR2 - tR1) / (w2 + w ,) (eqn. 2.5),
where w1 and w2 are the basal peak widths.
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Basal peak width was detemined by extrapolation of the near-straight section of the peaks, in 
order to eliminate distortions due to peak tailing.
For poorly resolved and non-Gaussian peaks, a more useful measure of resolution was 
found to be Chromatographic Response Function (C.R.F.), as used by Clark and Mama
(1989a) and defined in Figure 2.1.
Figure 2.1. Measurement of chromatograp­
hic response function (CRF). From Clark 
and Mama (1989a)
2.2.6 Definition of optical purity
Optical purity was measured in terms of enantiomeric excess (%e.e.), according to equation
2.6 (from Lindner and Pettersson (1985)).
%e.e. = ([enantiomer 1] - [enantiomer 2]) / ([enantiomer 1] + [enantiomer2]) x 100
(eqn. 2.6)
CRF = f i t
6 80 2 4
mm
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2.3. Semi-preparative resolution of trimeprazine enantlomers
2.3.1 Description of on-line recovery procedure
Trimeprazine enantiomers were separated on an SGE-100GLC4-C8-30/5 column (dimen­
sions: 100mm length x 4mm i.d.), using a mobile phase consisting of acetonitrile - aq. 
triethylammonium acetate (0.89% TEA v/v, acetic acid to pH 4) (10:90, v/v) containing 9 - 
13.5mg/ml B-cyclodextrin hydrate. 1mg injections of ±-trimeprazine hemi-(+)-tartrate were 
made onto the column using an LDC Promis 2 autosampler, at 100pl injection volume.
Following separation, the enantiomers were switched on to two “recovery” columns 
(Lichroprep RP18, 25-40pm particle size, 100 x 4.6mm dimensions) using the dual-valve 
integrated stream-switching (ISS) facility of the Promis 2 autosampler. Repeat injections (12 
-16 ) of racemate were made onto the separating column until the capacity of one of the 
recovery columns was reached. The recovery columns were then flushed with an aqueous- 
organic solvent mixture to remove cyclodextrin and buffer components. The trimeprazine 
fractions in each column were then eluted with a strong solvent (acetonitrile-TFA-water), and 
recovered as trifluoroacetate salts by evaporation of the solvent.
The switching valve arrangement is illustrated in Figure 2.2. The two Rheodyne 7000 valves 
that form the ISS facility on the Promis 2 allowed the switching of the solvent stream to 
recovery column 1 (for retention of the first enantiomer fraction), to column 2 (for retention of 
the second enantiomer fraction) or directly to waste (before and between the two peaks). A 
third Rheodyne 7000 valve, operated manually, allowed the the separation column to be 
by-passed during the flushing and elution stages of the procedure, thus reducing equilibr­
ation time prior to the next run.
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Figure 2.2. Column switching 
system used for on-line recovery of 
trimeprazine enantiomers following 
chiral separation using B-cyclodext- 
rin in the mobile phase.




















Two UV detectors were placed in-line. The first (an LDC Spectromonitor 3000, set to 340nm 
2AUFS) monitored the effluent from the separating column, and was used to determine the 
valve switching times. The second (a DuPont UV spectrophotometer with low-volume 
flow-cell, set to 302nm 1.28AUFS) monitored the effluent from the recovery system and was 
used to assess the progress of the loading, flushing and elution stages.
The eluted enantiomer fractions were assayed for recovery and optical purity as described 
below. Their chemical purity was assessed from their 270MHz 1H-NMR spectra in D20 .
2.3.2 Chiral assay of trimeprazine fractions from semi-preparative system.
The resolved trimeprazine enantiomers were assayed for recovery by re-injection into the 
chromatograph under similar conditions to those used for the semi-preparative resolution.
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Calibration standards of ±-trimeprazine tartrate at 5, 50, and 500pg/ml in mobile phase were 
prepared, and assayed in duplicate to produce a calibration curve for each enantiomer. 
Levo-methotrimeprazine was used as internal standard. Peak height ratio calibration was 
carried out using a Spectra-Physics SP4270 computing integrator. Samples were prepared . 
for analysis by mixing 500pl of standard solution or semi-preparative fraction with 500pl 
internal standard solution (50pg/ml), and 20pl injections were made in to the chromatograph 
using the Promis 2 autosamples.
The optical purity of each trimeprazine fraction was estimated by comparison of the levels of 
the two enantiomers measured by the above procedure. The eluates from the recovery 
columns collected during the “flushing” stage of the recovery procedure were also assayed 
by this method, to assess the loss of recovery sustained during this stage. Samples found to 
contain trimeprazine levels above the calibration range were diluted appropriately and 
re-assayed.
2.3.3 Optimisation of recovery procedure.
The capacity of recovery columns was estimated by experiments in which racemic 
trimeprazine was loaded onto the columns until “breakthrough” of UV-absorbing material was 
observed. The chromatograph employed in these studies consisted of an LDC constametric 
lllG pump, LDC Spectromonitor III UV recorder (set at 302nm, 0.2 AUFS to provide selective 
monitoring of trimeprazine), and a Servogor 220 chart recorder. The column was placed in a 
thermostatted water bath for studies into the effect of temperature on column capacity; 
ambient temperature was used in all other studies.
The recovery column under test was loaded with trimeprazine by pumping through it a 
solution consisting of acetonitrile - aq. triethylammonium acetate (0.88% TEA v/v, acetic add 
to pH 4) (10:90 v/v) containing 13.5mg/ml B-cyclodextrin hydrate and 0.1 - 0.2mg/ml
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±-trimeprazine hemi-(+)-tartrate. The trimeprazine concentration was chosen so as to 
approximately simulate the trimeprazine concentration in the eluate from the semi­
preparative separation described above. Column loading was ended when breakthrough of 
UV-absorbing material occurred, and the capacity estimated from the volume of solution 
passed up to this point.
Optimisation studies into the “flushing” procedure were carried out in a similar fashion to the 
above. In these studies the column was not necessarily loaded to its capacity. The flush 
solvent was passed though the column after loading, and the eluate collected for analysis. 
Eluates were assayed for trimeprazine in an achiral assay. This utilised an SGE-100GL4- 
C8-8/5 column, with a mobile phase consisting of acetonitrile- aq. triethylammonium acetate 
(1.3% TEA v/v, acetic acid to pH 4) (40:60, v/v) at a flow rate of 1ml/min. Standard solutions 
of trimeprazine tartrate at 5, 50 and 500pg/ml in mobile phase were prepared, and a 
calibration graph constructed using peak height ratios of trimeprazine to chlorpromazine 
(internal standard). Peak heights were measured using a Spectra-Physics SP4270 
computing integrator. Samples and standards were prepared for analysis by adding 50pl of 
internal standard solution (500pg/ml) to a 500pl aliquot of the standard or unknown solution.
The flushing of triethylamine from a Hamilton PRP1 column (150x4.6mm) after equilibration 
of the phase with acetonitrile - aq. triethylammonium acetate (0.89% TEA v/v, acetic acid to 
pH4) containing 9mg/ml B-cyclodextrin hydrate was investigated, using post-column ion-pair 
extraction detection to assay samples of the flush eluate (Roy and Jefferies (1990)). This 
assay utilised a chromatograph consisting of an SSI 220B pump, a Hypersil CPS 
(100x2.1 mm) column, with injections made manually using a Rheodyne 7125 injector fitted 
with a 20pl loop. The mobile phase employed consisted of acetonitrile - 2-propanol - aq. 
NaH2P 04 (0.025M, adjusted to pH 4 with H3P 0 4) (7.5:7.5:85, v/v) at a flow rate of 0.2ml/min. 
Under these conditions, the triethylamine was unretained. On elution from the column, the 
eluate was mixed on-line with an aqueous solution containing 9,10-dimethoxyanthracene-
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sulphonate (DAS) (1 x K H M ) at a flow rate of 0.4 ml/min, and subsequently with 1,2- 
dichloroethane at a flow rate of 0.5 ml/min. After passing through a stainless steel extraction 
coil (0.8mm i.d., 1.05m length, 50mm coil diameter), the organic and aqueous layers were 
separated using a dual channel sandwich-type phase separator (manufactured by SSI, State 
College, Penn., USA). The organic layer was then passed into an LDC Fluoromonitor 
detector (excitation filter 340-380nm, emmision filter 418-700nm, range 200), where the 
DAS-triethylamine ion-pairs were detected spectrofluorimetrically. Triethylamine concentr­
ations were estimated by comparison of peak heights with previously injected standard 
solutions at 0, 0.008, and 0.0008% TEA, v/v.
2.3.4 Solvent extraction procedure for recovery of trimeprazine
The feasability of using solvent extraction to recover trimeprazine after semi-preparative 
resolution was investigated in an off-line experiment. A solution consisting of acetonitrile - 
aq. triethylammonium acetate (0.89% TEA v/v, acetic acid to pH 4) containing 10mg/ml 
B-cyclodextrin hydrate and 0.2mg/ml ±-trimeprazine hemi-(+)-tartrate was prepared. A 20ml 
portion of this solution was taken, and TFA was added to pH 1. The resulting precipitate was 
extracted into 4 x 5ml ether, and the organic phase dried over M gS04, before being 
evaporated to dryness, yielding non-crystalline trimeprazine trifluoroacetate.
A similar experiment was carried out on ±-trimeprazine, eluted from an RP18 recovery 
column in methanol after loading (6mg) as described above (2.3.3) and flushing the recovery 
column with 10ml of acetonitrile - water (10:90, v/v). The methanol was removed by 
evaporation, and the recovered trimeprazine reconstituted in water (10ml), and converted to 
the trifluoroacetate as described.
Trifluoroacetate salts prepared as above were converted to hydrochlorides by adding dry 
ethereal HCI to the trifluoroacetate in dry ether, causing precipitation of the hydrochloride.
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2.4. Semi-preparative resolution of thromboxane antagonist enantiom ers
2.4.1 Description of on-line recovery procedure
The procedure employed for resolution of the enantiomers of TA1 and TA12 was similar to 
that used for trimeprazine, with some differences in the instrumentation employed, as shown 
in Figure 2.3.
Figure 2.3. Instrumentation 
used to effect semi­
preparative resolution of 
thromboxane antagonist 
























Racemates were resolved on an SGE-100GLC4-C8-30/5 column (as before) using a mobile 
phase consisting of acetonitrile - aq. phosphate buffer (0.05M, pH 7) containing 20mg/ml 
B-cyclodextrin hydrate. 1mg racemate injections were made manually onto the column, using 
a Rheodyne 7125 injector fitted with a 10Opil injection loop. On-line recovery of the
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enantiomers following separation was achieved using two Lichroprep RP18 columns as 
before. In this case, column switching was carried out using a purpose-built device, using 
timer control triggered by the injector (via an event marker output on the Varian LC5500 
system). The Varian detector (detector 1) was set to 320nm, while the Pye-Unicam LC-UV 
detector (detector 2) was set to 280nm 1.28AUFS for more sensitive detection of the solutes,
Following elution from the recovery columns in methanol, a sample of each fraction was 
taken for optical purity analysis. The remainder of each fraction was evaporated to dryness 
under nitrogen and chemical purity determined from its 400MHz 1H-NMR spectrum in 
CD3OD.
2 A 2  Chiral assay of TA1 fractions after semi-preparative separation.
Resolved TA1 enantiomers were assayed for recovery by re-injection into the chromatograph 
under similar conditions to those employed for the semi-preparative resolution. Calibration 
standards of ±-TAl at 50, 250 and 1250pg/ml in mobile phase were prepared, and injected 
in triplicate to produce a calibration graph for each enantiomer. Meta-nitroaniline was used 
as internal standard. Peak-height calibration was carried out by the Varian data system. 
Samples were prepared for analysis by mixing 200pl of standard solution or semi-preparative 
fraction with 50pl internal standard solution (0.1 mg/ml) and 1ml mobile phase. 20pl injections 
were made using the Varian autosampler. Optical purity values were estimated as before, by 
comparison of the levels of each enantiomer found by the above procedure.
2.4.3 Chiral assay of TA12 fractions after semi-preparative separation.
Resolved TA12 enantiomers were assayed for recovery and optical purity on a Cyclobond I 
(250 x 4.6mm) column, using a mobile phase consisting of acetonitrile - aq. phosphate buffer 
(0.05M, pH 7) (10:90, v/v) at a flow rate of 1 ml/min. Calibration standards of ±-TA12 at 0.02, 
0.06, 0.18, 0.54, and 1.62mg/ml in mobile phase were prepared, and injected in duplicate to
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produce a calibration graph for each enantiomer. Meta-nitroaniline was used as internal 
standard. Peak-height ratio calibration was carried out by the Varian data system, except 
where the data system failed to recognise small peaks, in which case peak heights were 
measured manually and linear regression was carried out using a Casio FX-570c calculator. 
Samples were prepared for analysis by mixing 150pl standard solution or semi-prep fraction 
with 150pl internal standard solution (0.2mg/ml) and making up to 1.5ml with aq. phosphate 
buffer (0.05M, pH 7). 20pl injections were made using the Varian autosampler. The detection 
wavelength employed was 270nm, for maximum sensitivity. The quality of the assay was 
checked by assaying the injection solution from the semi-prep run (nominally 10mg/ml 
±-TA12), diluted 1 in 20 to bring its concentration into the calibration range.
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2.5. Semi-preparative resolution of brompheniramine enantlomers
2.5.1 Description of procedure
Brompheniramine enantiomers were separated on a Spherisorb S5CN column (dimensions: 
250mm length x 10mm i.d.), using a mobile phase consisting of methanol - aq. triethylam- 
monium acetate (0.85% TEA v/v, acetic acid to pH 4) (5:95, v/v) containing 12mg/ml 
R-cyclodextrin hydrate. The instrumentation employed was similar to that shown in Figure
2.3, except that an LDC Constametric lllG pump and Spectromonitor III UV detector 
connected to a Servogor 220 chart recorder were used in place of the Varian LC5500 
system. The detection conditions employed were 285nm 2AUFS (detector 1), 290nm 
1.28AUFS (detector 2).
5mg injections of ±-brompheniramine maleate were made onto the column using a 
Rheodyne 7125 injector equipped with a 10Opil loop. Following separation, the enantiomers 
were switched onto Hamilton PRP1 recovery columns (12-20pm particle size; 100 x 10mm 
dimensions) using the ICI REL valve switching system. 22-24 repeat injections of racemate 
were made, giving a total recovery column loading of about 60mg per enantiomer. The 
recovery columns were then flushed with 180ml of methanol - water (5:95, v/v); and the 
brompheniramine fractions were eluted with methanol.
A sample of each fraction was taken for subsequent analysis. The remainder of each fraction 
was evaporated to dryness, re-dissolved in mobile phase, and further purified by a second 
pass though the recovery system, under the conditions described above.
The eluted enantiomer fractions from each stage were assayed for recovery and optical 
purity by HPLC as described below. Their chemical purity was assessed from their 270MHz 
1H-NMR spectra in D20 . Recovery was also checked by NMR, by addition of one mole 
equivalent of maleic acid as internal standard, and comparison of the resulting proton signal
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integrals.
A sample of each fraction was converted to brompheniramine free base by solution in water, 
addition of excess conc. NaOH and extraction into ether. The ether extracts were evaporated 
to dryness, and the brompheniramine taken up in dimethylformamide. The optical rotation of 
the resulting solution was measured using an Optical Activity Ltd. AA-10 Polarimeter.
2.5.2 Chiral assay of brompheniramine fractions from semi-preparative system.
The resolved brompheniramine enantiomers were assayed for recovery and optical purity on 
a Spherisorb C6 column (150 x 3mm), using a mobile phase consisting of acetonitrile - aq. 
triethylammonium acetate (0.89% TEA v/v, acetic acid to pH 4) containing 21 mg/ml 
B-cyclodextrin hydrate, at a flow rate of 1 ml/min.
Calibration standards of ±-brompheniramine maleate at 0.01, 0.05 and 0.25mg/ml in mobile 
phase were prepared, and injected in triplicate to produce a calibration graph for each 
enantiomer. ±-pheniramine maleate was used as internal standard. Peak-height ratio 
calibration was carried out using a Spectra-Physics SP4270 computing integrator.
Samples were prepared for analysis by mixing 50pl standard solution or semi-prep fraction 
with 50pl internal standard solution (0.1 mg/ml) and making up to 500pl with mobile phase.
10|jl injections were made in partial loop-fill mode using a Rheodyne 7125 injector fitted with 
a 20pl loop, and a SGE 50pl guided plunger syringe. The detection wavelength employed 
was 254nm.
2.5.3. Optimisation of recovery procedure
Experiments were conducted in a similar manner to that described for trimeprazine in section
2.3.3. Brompheniramine was loaded onto the recovery column in a solution consisting of 
methanol - aq. triethylammonium acetate (0.85% TEA v/v, acetic acid to pH 4) (5:95, v/v)
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containing 12mg/ml f3-cyclodextrin hydrate and 1 mg/ml ±-brompheniramine maleate. The 
recovery column was flushed with methanol - water (5:95, v/v), and the brompheniramine 
eluted with methanol. Chemical purity and recovery were assessed by NMR, as described 
above. Comparison of the performances of Lichroprep RP18 and Hamilton PRP-1 as 
recovery column packings were made.
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2.6. Determination of the solubility of B-cyclodextrln in some aqueous-organic solvent
mixtures
The solubility of B-cyclodextrin in aqueous-organic solvent mixtures was determined by the 
gravimetric method of Jozwiakowski and Connors (1985). 350mg portions of 6-cyclodextrin 
hydrate were placed in 14ml screw-top vials containing 11 ml of the solvent under test. The 
vials were sealed with PTFE tape. The vials were agitated in a thermostatted water bath at 
20°C  for 7 days, and extra portions of cyclodextrin added if neccessary during that time. The 
resulting saturated solutions were filtered through 0.2pm Acrodisc filters and a 10ml portion 
of each sample was evaporated to dryness overnight in at 60°C  and < 10mbar pressure (in 
a vacuum oven). The concentration of the saturated solution was then determined by 




270 MHz 1H-NMR spectra were recorded on a Jeol JNM-GX-270 instrument. 32K data 
points were used in acquiring spectra with widths of 3001.2 Hz at ambient temperature. A 
5ps pulse corresponding to a tilt angle of 30° was employed with an aquisition time of 4.918 
seconds and a 0.541 second pulse delay. Digital resolution was 0.18 Hz per point.
400 MHz 1H-NMR spectra were recorded on a Jeol GX-400 instrument at the Department of 
Chemistry, University of Bristol. 32K data points were used in acquiring spectra with widths 
of 4000Hz. A pulse angle of 45° was employed with an aquisition time of 4.1 seconds and a 
pulse delay of 0.5 seconds.
400 MHz 1H-NMR spectra of ±-TA1 were also recorded on a Bruker WM400 spectrometer.
16K data points were used in aquiring spectra with widths of 5000Hz. A 7ps pulse corres­
ponding to a tilt angle of 45° was employed, with an aquisition time of 1.6 seconds. The 
probe temperature was 25°C. Digital resolution was 0.3Hz per point.
Solvent suppression was employed in recording spectra at 270MHz in H20 , and in some 
400MHz studies in D20 . The method employed was homogated decoupling with the H20  or 
HDO resonance irradiated using an irradation attenuation (IRATN) value of 120.
Spectra in D20  were referenced internally to HDO (4.9ppm) or externally to DSS (sodium 
2,2-dimethyl-2-silapentane-5-sulphonate, O.OOppm). Samples were prepared in 5mm o.d. 
tubes.
The deuterium of the solvent was used to provide a lock signal in all experiments. 5% D20  
was added to H20  in experiments involving solvent suppression for this purpose. The 
number of accumulations per spectrum was typically 32, but was increased to give additional
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sensitivity where necessary.
2.7.2 Assignment of spectra
Assignments were made on the basis of expected chemical shifts and signal multiplicity, 
and/or by comparison with published data. Spin decoupling experiments were carried out 
where necessary. The 400MHz 1H-1H COSY spectrum of TA1 in CD3OD was produced by 
Mr. D.F. Wood, School of Pharmacy and Pharmacology, University of Bath. nOe difference 
spectra were produced by irradiation of the signal of interest (at IRATN = 320) and 
subtraction of the resulting nOe spectrum from a control spectrum, produced by irradiation of 
a blank region of the spectrum.
2.7.3 Chiral discrimination trials
For chiral discrimination trials, a racemate concentration of 1.33 x 10*5M was employed, with 
one mole equivalent of cyclodextrin added. Sodium salts of thromboxane antagonists and 
other acids were prepared in situ by addition of one mole equivalent of sodium carbonate.
2.7.4 Formation constant determination
Determination of cyclodextrin complex formation constants was carried out by addition of 
varying amounts of B-cyclodextrin to a fixed amount of substrate, and measurement of the 
resulting changes in substrate chemical shift. Such experiments on single compounds were 
carried out according to the method of Smith et a / (1989). Non-linear least-squares 
regression analysis of the data was carried out using MINSQ (MicroMath Software, Salt Lake 
City, Utah, USA) run in MS-DOS using an Acorn PC Emulator on an Archimedes 3Q00 
micro-computer. Experiments to determine formation constants for both enantiomers of a 
substrate simultaneously were carried out by a similar method, and the system of equations 
outlined in Appendix 1 used to analyse the resulting data. Non-linear regression was again
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carried out using MINSQ.
2.7.5 Job plot for ±-TA1 sodium salt /  B-cyclodextrin
A continuous variation (Job) plot for ±-TA1 sodium salt with B-cyclodextrin was constructed 
according to the method of Greatbanks and Pickford (1987). The quantities (mg) of ±TA1, 
sodium carbonate and B-cyclodextrin dissolved in D20  (1ml) were 0/0/22.1,1.81/0.50/16.98, 
2.49/0.68/15.01, 3.88/1.07/11.44, 5.29/1.47/7.49, and 5.61/1.55/5.73.
2.7.6 ROESY experiment on ±-TA1/B-cyclodextrin
A ROESY experiment was carried out on ±TA1 (3.88mg/ml, sodium salt) with B-cyclodextrin 
(11.44mg/ml) in D20 . A Bruker WM400 spectrometer was used, and the Z-Filter CAMEL 
method of Ranee (1987) employed. This uses the decoupler to supply the spin-lock field.
The problem of transmitter and decoupler being out-of-phase is overcome by the use of 
phase-cycled 90° decoupler pulses before and after the spin-lock field. A spin-lock (mixing) 
time of 0.8 seconds was employed, with a 90° (13.5ps) observe pulse and a relaxation delay 
of 5 seconds. 256 ^ increments were used, with 64 accumulations per ^ increment. 




Results: Analytical HPLC studies
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3.1. Introduction
Cyclodextrins have found wide application as bonded phases and/or as eluent additives in 
HPLC, TLC and GC. Improved chromatographic separations for many species of interest 
have been achieved, particularly of positional, geometric and optical isomers which often 
provide difficult chromatographic problems. The separation mechanism in cyclodextrin 
chromatography has been shown to depend on the strength of interaction of the analytes 
with the cyclodextrin.
B-cyclodextrin has found greater chromatographic use than the other native oligomers, due 
partly to its lower cost, but also its cavity size is optimal for inclusion of many solutes of 
interest.
3.1.1 Cyclodextrin stationary phases for liquid chromatography
Stable chromatographic stationary phases have been produced by modification or immobilis­
ation of cyclodextrins. On such phases, solutes elute in order of increasing strength of 
interaction with the cyclodextrin.
The first cyclodextrin stationary phases to be reported were B-cyclodextrin polymer gels, with 
mechanical rigidity conferred by cross-linking with epichlorohydrin. Wiedenhoff e ta l (1969) 
achieved column chromatographic separation of some benzoic acids by this approach. 
Harada et al (1978) reported resolution of ±-methyl mandelate into its enantiomers and 
partial resolution of ±-mandelic acid, ±-ethyl mandelate and ±-0-methyl mandelic acid using 
B-cyclodextrin-epichlorohydrin (B-CDE) as stationary phase. A B-cyclodextrin polymer with 
poly-ether cross-links was used by Zsadon et al (1986) to resolve several indole alkaloid 
racemates.
HPLC stationary phases have been prepared by bonding cyclodextrins to microparticulate
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silica. Kawaguchi et a / (1983) produced such a phase by treating succinamidopropyl-silica 
with ethylenediamine-substituted B-cyclodextrin. Fujimura efa /(1983) produced similar 
stationary phases by bonding cyclodextrins to aminopropyl-silica. The chiral separations 
reported on these phases include those of cyclohexylphenylacetic and mandelic acids 
(Feitsma et al (1984)) and several mandelic acid esters (Fujimura et a / (1986)).
An alternative cyclodextrin stationary phase has been produced and patented by Armstrong. 
In this phase, the cyclodextrin is linked to silica by a six to ten atom spacer containing no 
nitrogen (Ward and Armstrong (1986)). This linkage method overcomes the problems 
associated with previous phases, i.e. hydrolytic instability, low cyclodextrin loading, 
competing ion-exchange interactions due to the amine functionality in the spacer, and 
synthetic difficulties (Seeman et a / (1988)). Armstrong’s phases have been commercialised 
as the Cyclobond® range, and have been very widely used. Some of the chiral separations 
achieved on Cyclobond I (the B-cyclodextrin phase) are illustrated in Table 3.1. Other chiral 
separations on this phase that have been reported include peptides (Florance e /a /(1987)), 
amino acid derivatives (Han and Armstrong (1987)), barbiturates and hydantoins (Berthod et 
al (1990), Maguire (1987)) metallocenes (Armstrong et al (1985)) and nicotine analogues 
(Seeman e/a /(1988)). Pharmaceutical applications, both in optical purity analysis and 
bio-fluid analysis have also been reported (Krstulovic e ta l{1988), Lee and Webb (1988), 
Walhagen e ta l{1989), McClanahan and Maguire (1986), Edholm e /a /(1988), Matsui and 
Sekiya (1989)).
More recently, a number of HPLC stationary phases incorporating derivatised cyclodextrins 
have been produced by Armstrong and his co-workers, using the same bonding chemistry as 
before (Astec (1991)). Hydroxypropyl, acetyl, toluyl, napthylisocyanate, and dimethyliso- 
cyanate derivatives of the three native cyclodextrins have been used to produce phases 
which dramatically extend the range of racemates resolvable by this approach. Several of 
these phases are used in normal-phase mode, with non-polar organic solvents as eluents. In
84
Table 3.1. Chiral separations reported using Cyclobond I (beta-cyclodextrin) HPLC 
columns
Solute a R, ref.
ibuprofen 8.2 1.07 1.5 Geisslinger (1989)
ketoprofen 7.7 1.06 1.2 Berthod (1990)
mephobarbita! 14.8 1.14 0.6 Ward (1986)
benzoin 3.2 1.08 1.0 Han (1988)
chlorthalidone 0.5 1.44 1.9 Berthod (1990)
benzyl mandelate 3.0 1.02 0.6 Han (1988)
mephenytoin 0.5 1.33 1.8 Armstrong (1986)
brompheniramine 7.8 1.14 1.5 Mercer (1989)
chlorpheniramine 5.9 1.07 1.5 Berthod (1990)
pheniramine 2.2 1.03 0.4 Mercer (1989)
carbinoxamine 3.0 1.07 0.8 Mercer (1989)
propanolol 2.8 1.04 1.4 Berthod (1990)
methyl phenidate 1.2 1.14 1.6 Berthod (1990)
nomifensine 2.0 1.35 3.0 Aboul-Enein (1988)
scopolamine 1.7 1.10 1.8 Armstrong (1987a)
cocaine 6.3 1.04 0.9 Armstrong (1987a)
atropine 6.8 1.04 0.6 Armstrong (1987a)
tropine mandelate 2.0 1.07 1.4 Armstrong (1987a)
nisoldipene 4.1 1.04 0.9 Armstrong (1986)
norgestrel 0.5 1.24 1.1 Armstrong (1986)
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these cases, solute inclusion is hindered by preferential inclusion of eluent molecules. 
Retention and selectivity are thought to arise via interactions with the outside of the 
cyclodextrin molecule.
3.1.2. Factors affecting HPLC resolution on cyclodextrin stationary phases
Cyclodextrin stationary phases exhibit differing selectivity to conventional reversed phase 
materials, owing to the predominant retention mechanism being inclusion in the cyclodextrin 
cavity. Phases prepared from native cyclodextrins are always used with aqueous eluents 
containing organic modifiers (typically acetonitrile, methanol, ethanol, isopropanol). As in 
conventional RP-HPLC, an increase in the organic modifier concentration leads to a 
decrease in retention times and selectivity (Armstrong et al (1985a)). In cyclodextrin 
chromatography, this reflects the ability of the organic modifier to include in the cavity, 
reducing the binding of the solutes. Methanol forms a much less stable complex with 
B-cyclodextrin than either ethanol or acetonitrile, and therefore causes less reduction in 
retention and selectivity at a given level in the mobile phase.
It is known from measurement of complex stability constants that an increase in temperature 
decreases the extent of complexation of a substrate (Hinze (1981)). Thus, selectivity on 
cyclodextrin bonded phases is generally reduced by increasing temperature. However, band 
spreading may be reduced at higher temperature due to improved retention kinetics. The 
overall effect of temperature on resolution is therefore not entirely predictable, with increases 
in resolution with temperature reported in some cases (Armstrong et al (1985a), but 
decreases in others (Isaaq et a / (1987)).
Buffer components have also been shown to have an effect on resolution using cyclodextrin 
bonded phases. The use of triethylammonium acetate buffer is particularly beneficial, 
producing marked improvements in peak shapes (Ward and Armstrong (1986)). This is
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thought to result from interactions between the triethylamine and cyclodextrin hydroxyls, 
reducing the incidence of strong interactions between solute amine groups and cyclodextrin 
hydroxyls, and thus improving the kinetics of the retention process
As might be expected, eluent pH has a marked effect on resolution of enantiomeric and 
other solutes using cyclodextrin phases. Thus, Feitsma et a / (1985) reported a decrease in 
retention and enantioselectivity for mandelic acid on a B-cyclodextrin phase on increasing pH 
from 4.2 to 6.5, reflecting weaker binding of the dissociated acid. For other acids, opposite 
effects were noted, indicating that the effect of dissociation on enantioselective binding to 
B-cyclodextrin is not entirely predictable.
3.1.3 Cyclodextrin phases for GC and TLC
Smolkova-Keulemansova et a / (1988) have prepared packed GC columns containing a 
phase consisting of B-cyclodextrin and formamide deposited from aqueous solution onto an 
inert support. These columns were used to improve separations of positional isomers. A 
similar appproach has been taken by Sybilska and Jurczak (1989), who produced phases 
containing all three native cyclodextrins. The alpha-cyclodextrin phase was used to separate 
optically active hydrocarbons. Other workers (KOnig (1989), Li et al (1990)) have prepared 
phases using mixtures of various alkylated and acetylated cyclodextrin derivatives, which are 
hydrophobic liquids, to coat capillary columns. A wide variety of racemic analytes have been 
resolved on these phases, which are more efficient than the earlier packed columns.
The preparation of a B-cyclodextrin bonded RP-TLC phase has also been reported (Alak and 
Armstrong (1986)). This was found to resolve the enantiomers of several analytes, giving 
analogous results to those obtained using the Cyclobond I phase in HPLC.
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3.1.4 Cyclodextrins as mobile phase additives in liquid chromatography
Cyclodextrins may also be used as additives to chromatographic eluents. As described 
above for cyclodextrin stationary phases, separations are obtained due to the selectivity of 
the cyclodextrin's complexing ability, which is dependent on the size, shape and functionality 
of the solute molecules, in most cases, the addition of cyclodextrin causes a reduction in 
solute retention, by solubilising the solute in the mobile phase. The greatest reduction in 
retention will occur for the most highly complexed solute in a mixture. The elution order may 
therefore be reversed in a cyclodextrin mobile phase compared to that obtained using the 
analogous cyclodextrin stationary phase.
The first applications of cyclodextrins as eluent additives were in gel chromatography. Thus, 
Uekama eta ! (1977a) found that the addition of B-cyclodextrin to an aqueous eluent caused 
reductions in the retention times of isomeric prostaglandins on an anion-exchange resin, and 
facilitated their separation. The first chiral separation by this approach was reported by Sato 
and Suzuki (1985), who separated the enantiomers of warfarin and of mandelic acid by 
chromatographing aqueous solutions of the racemates containing B-cyclodextrin on 
Sephadex g e l.
Sybilska and his co-workers have reported separations of a large range of positional, 
geometric and optical isomers using B-cyclodextrin as an HPLC eluent additive. Some of the 
chiral separations reported are listed in Table 3.2. Many other groups have reported chiral 
separations using native cyclodextrins as eluent additives. Some of these are also listed in 
Table 3.2. Industrial applications of this approach have arisen, both in optical purity analysis 
(Berger e ta l (1989)) and in bio-analysis (Yoshikawa e ta l{1986)).
88


































































3.1.5 Cyclodextrins as eluent additives in TLC and ITP.
The use of cyclodextrin mobile phases in TLC has been explored. Hinze and Armstrong 
(1980) reported improved resolution of substituted benzoic acids on a polyamide stationary 
phase using an aqueous eluent containing B-cyclodextrin. Debowski et a / (1985) used a 
similar approach with C18-silica reversed-phase TLC plates, and found strong correlations 
with results obtained using similar mobile phases in HPLC. Chiral separations of racemates 
such as labetalol, mephenytoin, metallocenes, nicotine derivatives, and amino acid 
derivatives were achieved under similar conditions by Armstrong et al (1988a). Improve­
ments in separations could be achieved by the use of urea in the eluent to increase the 
solubility of B-cyclodextrin (Hinze et a / (1989)). B-cyclodextrin has also been used as a 
leading electrolyte additive in isotachophoresis (ITP). By this means, separations of isomeric 
and enantiomeric compounds (including ±-pseudoephedrine and ±-promethazine) have been 
achieved (Jelinek et a / (1989), Smolkova-Keulemansova (1988a)).
3.1.6 Theoretical aspects of cyclodextrin eluent HPLC
The theoretical basis of chromatographic separations using cyclodextrins as eluent additives 
has been widely discussed. Chromatographic data has been used to determine thermodyna­
mic parameters for the cyclodextrin-solute complexes. The important equilibria thought to 
account for the retention properties of guest molecules in chromatographic systems using 
cyclodextrin-containing mobile phases are illustrated in Figure 3.1, as described by Uekama 
eta! (1978b, 1978c).
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stationary phase I mobile phase
Figure 3.1. Equilibria 
responsible for effects of 
cyclodextrin in mobile phase 













The distribution ratios Ds, Ds CD, and the 1 :1 complex stability constant K f are given by
Ds = [S]st/[S]m [eqn. 3.1],
Ds.cd = [S.CD]st/[S.CD]m [eqn. 3.2],
and Kf = [S.CD]m/([S]m.[CD]m) [eqn. 3.3],
where [S], [CD] and [S.CD] are the equilibrium concentrations of substrate (guest), 
cyclodextrin (host) and complex respectively, and the suffixes st and m refer to the stationary 
and mobile phases respectively.
The observed distribution ratio for the system, Dobs, is given by
Dobs = ([S]s,+[S.CD]st)/([S]m+[S.CD]m) [eqn. 3.4].
Combination of these equations yields
D obs = (Ds + D s . c D * K f . [ C D ] m ) / ( 1  +  K f . [ C D ] m )  [eqn. 3.5].
The distribution ratios are related to retention times by
Ds = k’s. Vm/Vst = (ts-Vto) (Vm/Vst) [eqn. 3.6],
Ds.cd = k’s.cD • Vm/Vst = (ts.cD'V^o)  ^(Vm/Vst) [eqn. 3.7],
aRd Dobs = k obs . Vm/Vst = (tobs"W^o)• (^m^st) [eqn. 3.8],
where to, ts, ts.cD and tobs are the retention times of an unretained solute, uncomplexed
91
substrate {i.e. at zero cyclodextrin concentration), complexed substrate {i.e. at infinite 
cyclodextrin concentration), and observed substrate peak at equilibrium, respectively. 
is the phase volume ratio of the column.
Substitution then yields
tobs ■ Os + ts.CD-Kf.ICDJn,)/ (1 + Kf^CD],,,) [eqn. 3.9J,
which rearranges to
[CDL^ts-tobs) "  0*As"ts.CD)*[CD]m + (1/(Kf.(ts-ts,co)) [eqn.3.10].
A plot of [CD]m/(ts-t0bS) against [CD]m thus gives a straight line of slope 1/(ts-ts.co) and 
intercept 1/(Kf.(ts-ts.co)). from which the stability constant and retention time of the complex 
can be determined.
A similar expression (equation 3.11) has been derived by Sybilska (1987).
k’obs = ((k’s-k’obs)/(Kf.[CD]m)) + k’s co [eqn. 3.11].
In this case, a plot of k’^  versus (k's-k'obJ/JCDJm gives a straight line of slope 1/Kf and 
intercept k’s CD.
These equations have been found to adequately describe the chromatographic process in 
most cases, and have given good agreement with Kf values determined by other means. A 
number of assumptions are inherent in the above treatment:
(1) that only one form of the guest is present,
(2) that the complex stoichiometry is 1:1,
(3) that the cyclodextrin does not change the properties of the stationary 
phase, i.e. k’CD = 0, and
(4) that the equilibrium cyclodextrin concentration is the same as the initial 
concentration.
Modifications of Uekama’s treatment have been proposed to deal with cases where the 
assumptions inherent therein may not be valid.
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Sybilska et al (1982) have derived equation 3.12 for cases where ionised and unionised 
forms of an acid are present.
*obs =  O h A +  ( t A - K a/[H + ] )  +  (tHA .C D -K f,H A '[C D ]m)
+ (tA,CD.Kf,A-.[CD]m.Ka/[H+])) /  (1 + Ka/[H+] + Kf HA-[CD]m + (KfiA_.[CD]m.Ka/[H+]))
[eqn. 3.12],
where the subscripts HA and A- refer to the unionised and ionised forms of the guest, 
respectively, and Ka is the acid dissociation constant.
Deviations from assumption (2) above have been considered by Debowski e /a /(1986), who 
derived equation 3.13 to include the possibility of 2:1 complexation.
k'obs = (k’s + (k*s.co.Kf1.[CD]m) + ( k ’s ( C D ) 2  Kf1.Kf2.[CD]m2)) / (1 + Kf1.[CD]m + Kf1.Kf2.[CD]m2)
[eqn. 3.13],
where S(CD)2 refers to the 2:1 complex, Kf1 applies to the first complexation step, and Kk  
applies to the second.
They found that this treatment helped to explain certain anomalies in values obtained by 
equation 3.11 (particularly negative values of k’s Cd)> but that the Kf1 values calculated from 
equation 3:13 did not differ by more than 10% from Kf values calculated using equation 3.11 
for the cases studied.
Assumption (3) appears to be justified for the native cyclodextrins on reversed-phase silicas, 
since their capacity factors are reported to be very low (Fujimura et al (1986a)) owing to the 
hydrophilic nature of the outside of their cavities. Some authors have further simplified the 
equations by the additional assumption that complexes are also unretained (Fujimura et at 
(1986a), Cline Love and Arunyanart (1986), Mohseni and Hurtubise (1990)). Equations such 
as 3.14 have thus been derived.
1/k’obs = 1/k’s + Kf.[CD]m/k’s [eqn. 3.14]
from which Kf is determined directly from the slope of a plot of k ^ *  against [CD]m.
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Assumption (3) has been shown not to be valid for modified cyclodextrins and on highly 
hydrophobic phases (Zukowski et a / (1988), Clark and Mama (1989a))t where retention of 
the cyclodextrin is greater.
Assumption (4) is valid in the absence of organic modifiers, because the cyclodextrin is 
usually in large excess relative to the substrate, and so its concentration is not significantly 
reduced by substrate inclusion. However, the equilibrium cyclodextrin concentration may be 
reduced by inclusion of organic modifiers such as methanol or acetonitrile. This situation has 
been treated by Zukowski et al (1985), who proposed that the equilibrium cyclodextrin 
concentration in such a case might be given by
[CD]m = [CDLnO/tKso^solvlnO + 1) [eqn. 3.15],
where [CD]m° and [solv]m° are the initial molar concentrations of the cyclodextrin and the 
organic modifier, respectively, and K ^  is the formation constant of the 1:1 cyclodextrin- 
modifier complex.
The effect of organic modifiers on selectivity has been widely investigated. All authors have 
taken the view that low concentrations of organic modifiers are necessary for optimum 
selectivity when using cyclodextrin-containing eluents. This is illustrated in Figure 3.2, which 
shows the dramatic reduction in selectivity between dansyl-serine enantiomers with 
acetonitrile content of 6-cyclodextrin-containing eluents.
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Figure 3.2. Effect of the mobile phase 
acetonitrile content on separation factor for 
dansyl-D,L-serine. Column: Hypersii ODS-3 
(100x0.26mm); Mobile phase: acetonitrile- 
phosphate buffer (pH 5.0) containing 10mM 
B-cyclodextrin. Flow rate: 2.1pl/min. From 
Takeuchi et a / (1986).
It is also generally agreed that, of the commonly used organic modifiers, methanol has the 
lowest tendency to complex with B-cyclodextrin. Matsui and Mochida (1979) estimated 
values for (3-cyclodextrin-alcohol systems from spectrophotometric measurements. They 
found values of 0.32 M-1 for methanol, 0.82 M-1 for ethanol, and higher values for higher 
alcohols. Fujimura et al (1986a) found that B-cyclodextrin caused a larger change in 
retention of 1 - and 2-naphthylamine isomers in methanol-containing mobile phases than in 
acetonitrile-containing eluents, and that tetrahydrofuran appeared to almost completely 
eliminate the effect of cyclodextrin on retention.
Equation 3.16 predicts that the apparent Kf value, Kf\  determined from equation 3.11 will be 
related to the value determined from equation 3.15, Kf°, by
Kf’ = Kf°/(KSO|V.[solv]m° + 1) [eqn. 3.16],
i.e. that apparent Kf should decrease with increasing organic modifier concentration. Whilst 
this is generally the case, Cline-Love and Arunyanart (1986) have reported anomalies. They 
found that apparent Kf values for a number of benzene derivatives increased on addition of 
10% methanol (v/v) to aqueous mobile phases containing B-cyclodextrin. They postulated 
that this effect was due to methanol inclusion aiding the substrate inclusion process, and 
their results indicate that Zukowski’s treatment may be over-simplistic.
10 15
CHSCN (%) in eluents.
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Another factor affecting choice of organic modifier is its influence on cyclodextrin solubility. 
Here, there is considerable disagreement in the literature, due to the lack of any detailed 
data regarding B-cyclodextrin solubility in aqueous-organic solvent mixtures. Thus some 
authors (Sybilska (1987), Nobuhara et a / (1983)) have preferred ethanol-buffer eluents; 
others have preferred acetonitrile (Mularz (1988), Takeuchi et a / (1986)) or methanol 
(Gazdag et al (1986)) as organic modifier.
3.1.7 Modified cyclodextrins
A number of reports have appeared concerning the use of chemically modified cyclodextrins 
as mobile phase additives in TLC and HPLC. Tanaka et a / (1985) reported the use of 
2,6-di-O-methyl and 2,3,6-tri-O-methyl derivatives of alpha- and B-cyclodextrin as mobile 
phase additives in RP-HPLC on a C18 column. Improved separations of some disubstituted 
benzenes compared to those achievable using unmodified cyclodextrins were obtained, 
particularly with the tri-methylated derivatives. There was strong evidence to suggest that 
significant interaction between the ODS stationary phase and the modified cyclodextrins was 
occurring. Thus, deviations from eqn. 3.14 were found for all solutes. Indeed, at low 
concentrations of the cyclodextrins, retention was found to increase relative to that seen in 
mobile phases containing no cyclodextrin. This was attributed to adsorption of the derivatives 
on the stationary phase, and was confirmed in RP-TLC experiments in which the derivatives 
were found to have significant retention on RP18 plates.
A number of other authors have reported results in accordance with the above. Thus, 
Zukowski et al (1986) reported reversal of elution order of enantiomers of some barbiturates 
on C18-silica on increasing the eluent concentration of dimethyl-B-cyclodextrin. This was 
attributed to a change in retention mechanism from predominant interaction of the solutes 
with cyclodextrin adsorbed on the stationary phase (at low eluent additive concentrations) to 
predominant interaction of the solutes with cyclodextrin in the mobile phase (at high eluent
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additive concentrations). The adsorption of trimethyl-B-cyclodextrin on the ODS phase was 
such that interaction with adsorbed cyclodextrin on the stationary phase was found to be the 
dominant mechanism of selectivity at all additive concentrations (Zukowski et a / (1988)).. In 
this case, the inherent enantioselectivity of the additive towards the enantiomers of the 
barbiturates studied was found to be opposite to that observed with underivatised 0- 
cydodextrin. The generation of ‘dynamic chiral stationary phases” by adsorption of such 
derivatised cyclodextrins onto C18-silica has been studied in more detail (Zukowski and 
Nowakowski (1989)). Improved chiral recognition and higher column efficiendes were found 
for a number of racemates, compared to those observed using underivatised cydodextrin in 
mobile phase.
Clark (1989 ,1989a) has described resolution of enantiomers on porous graphitic carbon 
(PGC) stationary phase using dimethyl-B-cyclodextrin as a mobile phase additive. On this 
material, dynamic CSP generation was found to be the mechanism responsible for resolution 
at all additive concentrations. Thus, the retention and selectivity for chlorpheniramine 
enantiomers increased on increasing the additive concentration from 15 to 25mM. The other 
principal advantage of the use of derivatised cyclodextrins identified by Clark was their 
increased solubility in aqueous-organic solvent mixtures, allowing the use of a much wider 
range of solvent compositions.
Partially substituted hydroxyalkyl-cydodextrins have also been used as chromatographic 
eluent additives. These have even greater solubility than the methylated derivatives, 
although the fact that the steric bulk of the substituents is thought to interfere with chiral 
recognition, and this has limited their utility. Armstrong et a l (1988b) reported improved TLC 
separation of enantiomers using hydroxypropyl- and hydroxyethyl-8-cyclodextrins with 
various degrees of substitution. While the derivatives with high degrees of substitution were 
found to have highest solubility in the eluents, chiral recognition was less with these 
derivatives. This was attributed to the loss of hydroxyl binding sites around the rim of the
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cyclodextrin cavity. The high viscosity of eluents containing high additive levels was found to 
lead to increased development times. Clark and Mama (1989a) found that derivatised 
cyclodextrins of this type did not give improved separations of the solutes studied on PGC.
The addition of dimethyl- and trimethyl-cyclodextrins to electrolytes in isotachophoresis 
(Snopek et al (1988)) and capillary zone electrophoresis (Fanali and Sinibaldi (1989)) has 
been reported. Resolution of ephedrine enantiomers, which was unachievable using 
unmodified B-cyclodextrin, was achieved using dimethyl-B-cyclodextrin in both techniques.
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3.2 TetrahydrolsoqulnoHnes
3.2.1 B-cyclodextrin mobile phases
A series of tetrahydroisoquinolines was selected for study with cydodextrin-containing 
eluents because several of them exhibited chiral discrimination in NMR experiments with 
cyclodextrins. None of the seven tetrahydroisoquinolines investigated could be resolved into 
their enantiomers using B-cyclodextrin-containing mobile phases, although complexation was 
evidenced by reduction in retention on addition of the cyclodextrin, as illustrated in Table 3.3. 
Table 3.4 gives typical data obtained for these solutes with a B-cyclodextrin containing 
eluent. Increasing pH from 4 to 7.4 was seen to increase retention (due to partial suppres­
sion of amine protonation increasing the hydrophobic character of the solutes) but did not 
lead to resolution of enantiomers.
Table 3.3. Effect of beta-cyclodextrin in the mobile phase on retention of tetrahydroi­
soquinolines
Solute Mobile phase k’
TQ1 A (no CD) 8.6
B (+ CD) 6.9
TQ2 A (no CD) 4.9
B (+ CD) 4.5
Column: Hypersil CPS 100 x 4.6mm
Mobile phase A: Ethanol - aqueous diethylammonium acetate (0.5% DEA v/v, acetic add to 
pH 4.7) (12:88 v/v)
Mobile phase B: As mobile phase A with the addition of 20mg/ml beta-cyclodextrin hydrate.
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Table 3.4. Retention of racemic tetrahydroisoquinolines using (a) beta-cyclodextrin 
mobile phase and (b) beta-cyclodextrin stationary phase 
Solute Retention (k')








Conditions: (a) Column: Spherisorb S5CN (250 x 4.6mm); Mobile phase: acetonitrile - 
aqueous triethylammonium acetate (0.8% TEA v/vpacetic acid to pH 4.0) (10:90 v/v) 
containing 20mg/ml beta-cyclodextrin hydrate.
(b) Column; Cyclobond I (250 x 4.6mm); Mobile phase; methanol - aqueous 
triethylammonium acetate (0.8% TEA v/v, acetic acid to pH 4.0) (5:95 v/v)
3.2.2 Cyclobond I data
The tetrahydroisoquinolines were also unresolved on a Cyclobond I column. Typical data is 
shown in Table 3.4. The solutes were not strongly retained, even with only 5% methanol in 
the mobile phase, indicating that inclusion interactions were weak. Increasing pH from 4 to 7 
increased retention but did not lead to chiral resolution.
3.2.3 Comparison of Cyclobond I and 8-cyclodextrin eluent data.
Comparison of the capacity factor (k’) values for the two systems given in Table 3.4 was
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carried out, and a statistically significant positive correlation obtained indicating that, 
hydrophobic interactions with the stationary phase probably determine the retention order in 
both systems, and that inclusion interactions in the mobile phase do not substantially 
influence retention order.
3.3 Phenothlazines
3.3.1 B-cyclodextrin mobile phases
Resolution of trimeprazine, promethazine and methotrimeprazine enantiomers could be 
achieved using B-cyclodextrin mobile phases. Resolution of isothipendyl and dimethothiazine 
enantiomers could not be achieved. Typical data is shown in Table 3.5.
Table 3.5. Resolution of racemic phenothlazines using (a) beta-cyclodextrin mobile 
phase and (b) beta-cyclodextrin stationary phase
Solute (a) BetaCD eluent (b) BetaCD bonded phase
k’i a  Rs k’i a. Rs
isothipendyl 3.6 not resolved 2.3 not resolved
promethazine 1.3 1.06 0.5 3.8 not resolved
dimethothiazine 4.7 not resolved 3.3 not resolved
trimeprazine 0.5 1.22 0.8 10.0 1.11 1.0
methotrimeprazine 0.3 1.2 0.6 27.1 1.13 1.5
Conditions: (a) Column: Spherisorb S5CN (250 x 4.6mm); Mobile phase: acetonitrile - 
aqueous triethylammonium acetate (0.8% TEA v/v, acetic acid to pH 4.0) (10:90 v/v) 
containing 20mg/ml beta-cyclodextrin hydrate
(b) Column: Cyclobond I (250 x 4.6mm); Mobile phase: acetonitrile - aqueous 
triethylammonium acetate (0.8% TEA v/v, acetic acid to pH 4.0) (10:90 v/v)
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Addition of B-cyclodextrin to mobile phases caused a significant decrease in retention for the 
racemates that were resolved, but had little effect on the retention of isothipendyl and 
dimethothiazine, indicating that these substrates may interact with B-cyclodextrin weakly or 
not at all. Increasing mobile phase pH from 4 to 7.4 was found to increase retention times by 
a factor of about 2 in all cases, but did not have any apparent effect on chromatographic 
enantioselectivity.
3.3.2 Cyclobond I data
As shown in Table 3.5, only trimeprazine and methotrimeprazine of the five chiral phenothia- 
zines studied could be resolved on a Cyclobond I column. Retention times were much longer 
for these solutes than for the unresolved cases, indicating stronger inclusion interactions.
3.3.3 Comparison of Cyclobond I and B-cyclodextrin eluent data
The elution order of the phenothiazines investigated was seen to be reversed using the 
Cyclobond I column compared to that seen using B-cyclodextrin eluents. The elution order 
obtained using B-cyclodextrin eluents was also opposite to that observed on the same 
(achiral) stationary phase in the absence of the cyclodextrin. Inclusion interactions are 
therefore prominent in determining the retention order in both the cyclodextrin eluent and 
cyclodextrin stationary phase systems.
Since the retention order on Cyclobond I was the same as that in the achiral reversed-phase 
system, it seems that hydrophobicity largely determines the strength of interaction with the 
cyclodextrin. This observation is in accordance with that of Otagiri et a / (1975), who found a 
positive correlation between hydrophobicity (log P values) and complex stability (Kf) for a 
series of phenothiazines.
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3.3.4 Correlation of enantioselectivity with structure
In this series, there appears to be a strong correlation between hydrophobicity,• strength of 
complexation and chromatographic enantioselectivity. Thus, methotrimeprazine, which is 
most retained in the absence of B-cyclodextrin, exhibits the largest change in retention on 
addition of B-cyclodextrin and also the largest enantioselectivity. Isothipendyl is the most 
polar of the solutes, due to partial ionisation of its pyridyl group at pH 4, and showed no 
evidence here of interaction with B-cyclodextrin. Dimethothiazine, however, was an 
anomalous case, being more retained than promethazine in the absence of B-cyclodextrin 
but not interacting strongly with the cyclodextrin. In this case, complexation may be sterically 
hindered by the sulphonamide group on the phenothiazine nucleus.
3.4 Mandelic acids and related compounds
3.4.1 B-cyclodextrin mobile phases
A series of compounds related to mandelic acid were investigated. These were mandelic 
acid itself; 2- and 4-chloromandelic acids; 2-, 3-, and 4-methoxymandelic acids; 3- and 4- 
hydroxymandelic acids; tropic, 3-phenyllactic, 2-methoxyphenylacetic, and O-acetylmandelic 
acids. The solutes were largely unretained and unresolved at pH 7, even on an ODS 
column. In several cases, samples of the two enantiomers were available. Replicate 
injections were made, and an accurate assessment of chromatographic enantioselectivity 
made. In all these cases, selectivity was not significantly different from unity.
Mandelic acid itself was found to exhibit some resolution under similar conditions to those 
employed by Sybilska (1987), i.e. using an eluent consisting of aq. phosphate buffer (0.05M, 
pH 2.1) containing 17mg/ml beta-cyclodextrin hydrate on a Hypersil ODS column (250 x 
4.6mm). Other compounds in the series were not resolved under these conditions, in 
contrast to Sybilska's results.
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Of particular note is the failure to resolve the enantiomers of 2-chloromandelic acid. Sybilska 
(1987)) reported that this racemate was well resolved ( a  = 1.8) under similar conditions to 
those used in this study.
The methyl, ethyl, benzyl and isoamyl esters of mandelic add were also investigated. 
Retention was higher than for the ionised adds, due to greater hydrophobicity, but no 
resolution was observed.
3.4.2 Cyclobond I data
All the mandelic acids studied were found to be unresolved on a Cyclobond I column, both at 
pH 7 and at pH 2.5. At pH 7, all 12 compounds were unretained using an eluent containing 
10% methanol (v/v) in phosphate buffer, indicating that indusion interactions with the ionised 
soluted were weak. At pH 2.5, higher retention was observed in some cases, but no 
resolution.
3.5 Thromboxane antagonists
3.5.1 6-cyclodextrin mobile phases
The enantiomers of fourteen of the seventeen thromboxane antagonists investigated were 
resolved by 6-cyclodextrin-containing mobile phases, as shown in Table 3.6. (The structures 
of these compunds are shown on p.55). in some cases, chromatographic selectivity was 
very high. Baseline resolution of enantiomers was achieved in eight cases. In two cases 
(TA6 and TA17), resolution was only observed when mobile phases containing urea were 
employed. In such eluents, a higher concentration of B-cydodextrin than is normally possible 
could be employed.
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Table 3.6. Resolution of racemic thromboxane antagonists using (a) beta-cyclodextrin 
in mobile phase (b) a beta-cyclodextrin stationary phase.
Solute (a) BetaCD eluent (b) BetaCD bonded ph
k'i a Rs conditions k*i a Rs
TA1 7.4 1.62 5.2 Oi) 7.0 1.35 3.1
TA2 6.0 1.13 1.0 (a2) 7.3 1.10 1.2
TA3 33.5 1.58 5.7 (ai) 9.6 1.24 2.2
TA4 28.9 1.21 2.1 (at) 10.6 1.11 1.4
TA5 56.0 not resolved (3!) 11.8 1.06 0.6
TA6 96.0 not resolved (ai) 33.7 1.08 0.8
58.3 1.11 0.8 (32)
TA7 5.6 1.21 0.9 (ai) 4.1 1.10 1.1
TA8 >100 not eluted (a-i) 11.8 1.06 0.6
0.8 not resolved (a3)
TA9 18.6 1.19 1.5 (3i) 10.0 1.11 0.8
TA10 11.4 1.06 0.7 (3i) 18.0 1.06 0.8
15.8 1.11 1.0 (34)
TA11 9.1 1.22 2.3 (3i) 4.0 1.23 2.4
TA12 20.2 1.22 2.3 (3i) 5.9 1.16 1.7
TA13 5.7 1.28 2.1 (3l) 14.2 1.25 2.5
TA14 10.5 1.66 4.8 (3i) 30.1 1.34 4.8
TA15 45.9 not resolved (3i) 8.4 not resolved
TA16 >100 not eluted (3i) 11.4 1.07 0.7
1.6 not resolved (33)
TA17 >100 not eluted (3i) 15.9 1.11 1.0
35.1 1.06 0.6 (3z)
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Table 3.6 (contd.)
Conditions: (a^ Column: SGE100GL4-C8-30/5; Mobile phase: acetonitrile - aq. phosphate 
buffer (0.05M, pH 7.0) (10:90 v/v) containing 20mg/ml beta-cyclodextrin hydrate.
(a2) Column: SGE100GL4-C8-30/5; Mobile phase: acetonitrile - aq. phosphate 
buffer (0.05M, pH 7.0) (10:90, v/v) containing 120mg/ml urea and 40mg/ml beta-cyclodextrin 
hydrate.
(a3) Column: Spherisorb S5CN (250 x 4.6mm); Mobile phase: as a-j.
(a4) Column: SGE100GLC4-C8-8/5; Mobile phase: acetonitrile - aq. 
phosphate buffer (0.05M, pH 7) (10:90, v/v) containing 240mg/ml urea and 100mg/ml 
beta-cyclodextrin hydrate.
(b) Column: Cyclobond I (250 x 4.6mm); Mobile phase: acetonitrile - aq. 
phosphate buffer (0.05M, pH 7.0) (10:90, v/v)
The effect of pH on retention and selectivity was investigated, with TA1 (R=CH2-pyr) and 
TA12 (R=CF3) used as examples. The variation in retention with pH in the absence of 
B-cyclodextrin for these two compounds is illustrated in Figure 3.3. A decrease in retention 
with increasing pH was observed for TA12, reflecting an increase in carboxyl group 
ionisation. The pH-retention relationship for TA1 was more complex, reflecting deprotonation 
of the pyridyl group (pKa about 5) and carboxyl group ionisation (pKa about 4) as pH was 
increased.
The pH-retention relationships of these compounds proved to be very similar to Figure 3.3 
when using B-cyclodextrin-containing eluents. This indicates that hydrophobic effects are still 
important in determining retention, even in the presence of inclusion interactions in the 
mobile phase. The variation of chromatographic enantioselectivity with pH for these 
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Figure 3.3. Variation of k’ with pH for thromboxane antagonists in the absence of 
B-cyclodextrin. Column: SGE-100GL4-C8-30/5; Mobile phase: acetonitrile - aq. 
phosphate buffer (0.05M) (22:78, v/v).
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Figure 3.4. Variation of enantioselectivity with pH for thromboxane antagonists. 
Column: SGE-100GL4-C8-30/5. Mobile phase: acetonitrile - aq. phosphate buffer 
(0.05M) (10:90, v/v) containing 20mg/ml B-cyclodextrin hydrate.
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For TA12, a slight increase in selectivity was observed as pH was decreased, reflecting 
stronger complexation of the non-ionised solute at low pH. That this change is small 
probably reflects the length of the alkyl chain between the ionisable carboxyl group and the 
chiral centres and/or the the included portion of the molecule. The pH-selectivity relationship 
for TA1 was very different from that of TA12. In this case, a marked decrease in selectivity 
was observed as pH was decreased. This suggests that the ionisation of the pyridyl group of 
TA1 at low pH markedly disfavours enantioselective inclusion. This group is therefore seen 
to have a large effect on the inclusion of this solute, and its presence may account for the 
fact that at pH 7 TA1 is resolved much more effectively than TA12 by B-cyclodextrin.
Other pyridine-containing compounds in the series were seen to exhibit similar behaviour to 
TA1 on changing eluent pH.
3.5.2 Cyclobond I data
Using a Cyclobond I column, all but one of the thromboxane antagonists studied were 
resolved into their enantiomers, using the conditions shown in Table 3.6. Six of the 
seventeen racemates were baseline resolved under the conditions employed.
3.5.3 Comparison between Cyclobond I and B-cyclodextrin eluent data
Direct comparison was made between the two systems by employing the same mobile 
phase (acetonitrile: 0.05M aqueous phosphate buffer (pH 7), 10:90 v/v) in both cases, with 
the addition of 20mg/ml B-cyclodextrin to the mobile phase used with the achiral stationary 
phase.
A significant positive correlation, though far from linear, was found between the selectivities 
obtained using the two systems, indicative of similarities between the resolution-producing 
interactions. In general, higher selectivity was obtained using the B-cyclodextrin eluent.
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3.5.4 Correlation of enantioselectivity with structure
It has already been noted that ionisation of the pyridyl group in compounds such as TA1 has 
a marked effect on the chromatographic enantioselectivity induced by 13-cyclodextrin. 
However, the presence of this group perse  is not necessary for enantioselective inclusion 
(viz. the selectivity observed for compounds TA7 to TA12). At least one other group in these 
structures must therefore be able to include in the cyclodextrin cavity. It seems that the 
length of the alkyl chain between the pyridyl group and the dioxan ring also has an effect on 
enantioselective complexation. Thus, TA5 and TA6 were poorly resolved. This may be 
because the site of inclusion is too far removed from the chiral centres in the molecule in 
these cases for enantioselective interactions to be significant.
The group X also has a noticeable effect on enantioselectivity. Highest selectivity was 
observed when X = H. Slightly lower selectivity arose when X = OH. Very low selectivity was 
observed in those cases (TA15, TA16, TA17) where X = OMe. This is indicative perhaps of a 
steric effect, whereby the inclusion of the aryl ring is hindered by the presence of a 
comparatively bulky methoxyl group.
The length of the alkyl chain, as given by the value of n, appeared to have very little effect 
on chromatographic properties. Thus, the selectivities observed for TA11 and TA12 were 
very similar, with the larger retention of TA12 in both chromatographic systems being 
attributable to its slightly higher hydrophobicity.
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3.6. Other compounds
A number of other racemates were resolved using B-cyclodextrin mobile phases, as shown 
in Table 3.7.
No resolution could be achieved for ephedrine, norephedrine, phenylalanine, pheniramine, 
normetanephrine, mebrophenhydramine, buclizine, ICI1, ICI2, fenoldopam, hydroxyzine, 
neobenodine, meclizine, telemzepine, tryptophan, metoprolol, prilocaine, AM5(6), bupranolol, 
bunolol, disopyramide or verapamil. Attempts were also made to separate the enantiomers 
of orciprenaline, salbutamol, benserazide and 3,4-dihydroxyphenylalanine. These solutes 
were unretained under all the conditions employed.
Table 3.8 summarises the resolution of other racemates achieved on a Cyclobond I column. 
In this system, no resolution could be achieved for trihexyphenidyl, bunolol, mebrophenhyd­
ramine, bupranolol, oxyphenonium bromide, tetramisole, verapamil, metoprolol, disopyra­
mide, AM5(6), phenindamine, methyl phenidate, tropicamide, and neobenodine. These 
solutes were retained on the Cyclobond I column, indicating that some inclusion interactions 
were occurring. Other solutes - pseudo-ephedrine, tryptophan, benserazide, prilocaine, 
salbutamol and orciprenaline - were unretained on Cyclobond I, using a mobile phase 
consisting of acetonitrile - aq. triethylammonium acetate (0.89% TEA v/v, acetic acid to pH 4) 
(6:94, v/v). These solutes clearly interact weakly, if at all, with B-cyclodextrin.
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Table 3.7. Resolution of various racemates using beta-cyclodextrin-containlng mobile 
phases
Solute k’i « Rs conditi
pseudo-ephedrine 0.29 1.17 0.8 A
brompheniramine 2.9 1.15 1.0- A
carbinoxamine 3.9 1.07 0.8 A
chlorpheniramine 4.8 1.12 1.1 A
benzoin 1.3 1.14 1.0 B
dimethindene 24.4 1.06 0.6 A
chlorthalidone 0.9 1.46 2.6 C
nomifensine 0.9 1.37 1.8 D
methyl phenidate 13.1 1.07 1.4 E
nefopam 3.6 1.11 2.9 E
tetramisole 3.0 1.04 0.7 E
oxyphenonium bromide 6.3 1.07 0.9 E
tropicamide 23.2 1.20 2.9 E
phenindamine 41.0 1.10 1.4 F
Conditions: (A): Column: Zorbax CN (250 x 4.6mm); Mobile phase: acetonitrile - triethylam­
monium acetate (0.8% TEA, v/v; acetic acid to pH 5.0) (4:96, v/v) containing 18mg/ml 
beta-cyclodextrin hydrate
(B): Column: Spherisorb S5CN (250 x 4.6mm); Mobile phase: dimethyl 
sulphoxide - water (5:95, v/v) containing 12mg/ml beta-cyclodextrin hydrate
(C): Column: Spherisorb S5CN (250 x 4.6mm); Mobile phase: methanol - water 
(5:95 v/v) containing 12mg/ml beta-cyclodextrin hydrate
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Table 3.7 (contd.)
(D); Column: Spherisorb S5CN (250 x 4.6mm); Mobile phase: methanol - aq. triethylam­
monium acetate (0.85% TEA v/v, acetic acid to pH 4) (5:95, v/v) containing 11 mg/ml 
beta-cyclodextrin hydrate
(E): Column: Zorbax RX C8 (250 x 4.6mm); Mobile phase: acetonitrile - aq. triethylam­
monium acetate (0.89% TEA v/v, acetic acid to pH 4) (10:90, v/v) containing 20mg/ml 
beta-cyclodextrin hydrate
(F): Column: SGE-100GLC4-C8-8/5 (100 x 4mm); Mobile phase: as D.
Table 3.8 Resolution of racemates on a Cyclobond I (250 x 4.6mm) column.
Solute k \  a  Rs mobile phase
chlorthalidone 0.6 1.18 1.0 A
benzoin 1.9 1.07 0.7 A
nomifensine 0.2 1.5 1.0 A
nefopam 3.8 1.14 1.2 B
Mobile phases: A: methanol - aq. triethylammonium acetate (0.5% TEA v/v, acetic add to 
pH 4) (40:60 v/v)
B: acetonitrile - aq. triethylammonium acetate (0.8% TEA v/v, acetic acid to 
pH 4) (12.5:87.5, v/v)
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3.7. Determination of B-cyclodextrln complex formation constants by HPLC
Kf and complex retention values for the enantiomers of chlorthalidone, benzoin, and 
brompheniramine were determined from the variation of k' with eluent B-cyclodextrin 
concentration. The data was fitted to equation 3.11 using MINSQ. The data are illustrated in 
Figures 3.5, 3.6 and 3.7, and the resulting thermodynamic parameters are shown in Tables
3.9 and 3.10. Good fit of the data to the model was achieved in these cases, as shown by 
the high values of correlation coefficient obtained.
The complexes of benzoin and chlorthalidone were seen to be unretained under the 
conditions employed. The high enantioselectivity seen for chlorthalidone was seen to result 
from a large difference in the Kf values for its enantiomers. Benzoin was more strongly 
complexed, but there was less difference between the Kf values calculated.
Brompheniramine complexes were seen to be significantly retained under the conditions 
employed. The Kf values obtained (793 and 750 M*1) were similar to those reported by 
Mularz (1988) - 741 and 668 M'1.
In similar experiments - methyl mandelate and nomifensine with B-cyclodextrin - very poor fit 
of data to equation 3.11 was obtained. This could be due to the breakdown of one or more of 
the assumptions inherent in equation 3.11 or (more likely) due to failure to adequately control 
experimental conditions. In particular, variation in stationary phase retentivity during the 
course of the experiment might be expected to cause difficulties in obtaining meaningful 
results. It is also important to note that Kf values obtained from these experiments are 
“apparent” Kf values, and will be different from the true thermodynamic parameters because 
the experiments were conducted in the presence of acetonitrile and buffer components.
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Figure 3.5. Variation of k’ with B-cyclodextrin concentration for chlorthalidone 
enantiomers. Column: Zorbax CN 250 x 4.6mm; Mobile phase: acetonitrile - water 
(10:90, v/v) containing B-cyclodextrin. Data fitted to eqn. 3.11 using MINSQ.
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Figure 3.6. Variation of k’ with B-cyclodextrin concetration for benzoin enantiomers. 
Conditions as figure 3.5.
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Table 3.9. Stability and chromatographic properties of the complexes of benzoin and 
chlorthalidone enantiomers with beta-cyclodextrin on Zorbax CN stationary phase, In 
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Figure 3.7. Variation of k’ with B-cyclodextrin concentration for brompheniramine 
enantiomers. Column: SGE-100GL2-C8-30/5. Mobile phase: acetonitrile - aq. triethy­
lammonium acetate (0.89% TEA v/v, acetic acid to pH 4) (10:90 v/v) containing 
B-cyclodextrin. Data fitted to eqn. 3.11 using MINSQ.
Table 3.10. Stability and chromatographic properties of the complexes of bromp­
heniramine enantiomers with beta-cyclodextrin. Column: SGE-100GL2-C8-30/5. Mobile 
phases: acetonitrile - aq. triethylammonium acetate (0.89% TEA v/v, acetic acid to pH 
4) (10:90, v/v) containing beta-cyclodextrin. Data fitted to eqn. 3.11 using MINSQ.
Solute Parameter Value Std. Dev.
brompheniramine (peak 1) k'complex 1.8 0.2
apparent Kfl M*1 793 23
brompheniramine (peak 2) k’complex 2 3  °-2
apparent K(, M-1 750 22
correlation coefficient, r 0.9997
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3.8. Application of advanced detection techniques to chromatographic studies using
cyclodextrin eluents.
3.1Q.1 Photodiode-array detection
The potential utility of diode-array detection as a confirmatory method for chiral separations 
is illustrated by Figure 3.8, which shows the output obtained from analysis of the separation 
of trimeprazine enantiomers.
(a)
R  U  N - 0  Sb r-j m  ©  . 3 f t  IJ
3 , 2 9  231niri lj
I *? 7 Q K*, rft f 1
5 . 7 ?  2binni £1 . 0 .
11 9 . 1 3  232nm Cl
(b)
O U E R L r t Y  S P E C T R A  8 s  




P U R I T Y  : . E X  =  1 . 3
Figure 3.8. Diode-array detector (Perkin-Elmer LC-135) output for separation of 
trimeprazine enantiomers. (a) real-time chromatogram (b) overlay of apex spectra of 
peaks for the two enantiomers. Conditions: Column: Zorbax TMS (250 x 4.6mm); 
Mobile phase: acetonitrile - aq. triethylammonium acetate (0.89% TEA v/v, acetic acid 
to pH 5) (4:96, v/v) containing 20mg/ml B-cyclodextrin hydrate.
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Overlaying the spectra obtained at the apex of each peak confirmed that the two peaks 
arose from species with the same UV absorbance spectrum, thus considerably reducing the 
possibility of an erroneous “chiral" separation based on the resolution of the desired 
compound and an impurity. However, since the diastereomeric complexes of two enantio­
mers with B-cyclodextrin may have different UV spectra, it is possible that a “false negative” 
result may be obtained using this approach, which must therefore be used with caution.
3.10.2 Polarimetric detection
The utility of an optical activity detector with B-cyclodextrin mobile phases was evaluated. As 
might be expected, the chiral cyclodextrin mobile phase gave rise to high background optical 
rotation. Whilst the detector “auto-zero” function was able to back-off this background signal 
to zero, baseline noise and drift was a significant problem and it was rarely possible to 
reduce the attenuation below the highest level. Sensitivity (never high with such detectors) 
was therefore considerably reduced compared with what might be achievable using achiral 
eluents.
A variety of racemates and enantiomers, with varying degrees of resolution under the 
conditions employed, were chromatographed. For some (e.g. promethazine) no signal was 
detected, even at high column loading (up to 100pg on column.) The best results were 
achieved for polar solutes such as benzoin and methyl mandelate with relatively high specific 
rotations. Thus S- benzoin was readily detected at only 6pg on column.
Perhaps the most striking results were obtained for methyl mandelate, where a racemate 
that showed no resolution by UV detection was clearly seen to be partially resolved using 











Figure 3.9. Chromatograms obtained using the ACS ChiraMonitor detector (a)
S-(+)-methyi mandelate (138pg on col.) (b) R-(-)-methyl mandelate (174pg on col.) (c) 
RS-methyi mandelate (100pg on col.) UV detector output is shown for comparison.
Conditions: Column: SGE-100GL4-C8-30/5; Mobile phase: acetonitrile - aq. triethylam­
monium acetate (0.8% TEA v/v, acetic acid to pH 4) containing 13.5mg/ml B-cyclodext­
rin hydrate; ChiraMonitor attenuation: 64; UV detection a! 254nm, 2.0 AUFS.
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It was noticeable in certain cases that the peaks shown by polarimetric detection for a 
resolved racemate were by no means of equal and opposite area, as would be the case for a 
racemate resolved using an achiral mobile phase and a chiral stationary phase. This is 
clearly seen in the traces obtained for trimeprazine (Figure 3.10).
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Figure 3.10. Chromatogram obtained using the ACS ChiraMonitor detector, showing 
resolution of trimeprazine enantiomers (1mg trimeprazine hemi-(+)-tartrate on col.). UV 
detector output also shown. Conditions as Figure 3.9, except UV detection at 315nm, 
2.0AUFS.
This phenomenon may arise due to the fact that the complexes of two enantiomers with
6-cyclodextrin in the mobile phase are diastereomeric, and therefore may not have equal 
and opposite optical rotations. This factor may limit the quantitative application of polarimetric 
detection when using chiral mobile phases. It thus seems that the main application of this 
detection method will be in semi-preparative separations, where sensitivity is not limiting, and 
in qualitative confirmation of chiral separations.
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3.9 Use of derivatised cyclodextrlns as mobile phase additives
A number of experiments were conducted in which derivatised B-cyclodextrins (dimethyl, and 
various hydroxy alky I derivatives) were used as mobile phase additives. In contrast to 
previously reported studies (Zukowski et a / (1988), Clark and Mama (1989a)), stationary 
phases of moderate hydrophobicity and mobile phases with low organic modifier contents 
were employed, in order to compare more directly the influence of these additives with 
B-cyclodextrin itself.
3.9.1. Comparison of selectivity and retention obtained under identical conditions using 
various additives.
The retention, selectivity and resolution observed for a number of racemic solutes on an 
SGE-100GL2-C8-30/5 column with mobile phases consisting of acetonitrile-aq. triethylam­
monium acetate (0.89% TEA v/v, acetic acid to pH 4) (10:90 v/v) containing 7.2 mmol I'1 of 
B-cyclodextrin, methyl-B-cyclodextrin (DS=1.8), hydroxyethyl-B-cyclodextrin (MS=1.0), or 
hydroxypropyl-B-cyclodextrin (MS=0.9) are shown in Table 3.11
In all cases, resolution of enantiomers was much poorer using the derivatised cyclodextrins, 
due to lower selectivity. The hydroxyethyl derivative gave highest resolution of the three 
derivatives. No resolution at all was obtained with the methylated cyclodextrin.
The retention times of the solutes investigated were shorter with the methyl-B-cyclodextrin- 
containing eluent than with the equivalent mobile phase containing B-cyclodextrin itself. This 
indicates that the methyl-B-cyclodextrin is more effective at eluting solutes than the parent 
compound, which is most likely to be due to stronger complex formation in the mobile phase. 
However, it is clear that this stronger complexation is not accompanied by an increase in 
enantioselectivity. Thus, the modes of inclusion of the solutes in the two cyclodextrin cavities 
must be different.
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Table 3.11. Resolution of enantiomers using mobile phases containing beta-cyclodext­
rin and derivatives. Conditions as text.
solute betaCD OH-Et-betaCD
k’i a  Rs k'i o Rs
trimeprazine 9.8 1.2 1.7 10.8 1.18 1.3
brompheniramine 7.0 1.10 0.75 9.0 1.06 0.6
chlorpheniramine 10.0 1.05 0.6 9.5 not resolved
benzoin 10.8 1.08 1.0 14.9 1.05 0.8
chlorthalidone 6.1 1.10 1.1
solute OH-Pr-betaCD Me-betaCD
k'i a  Rs k'i >
trimeprazine 10.2 1.14 0.75 5.5 not resolved
brompheniramine 7.9 not resolved 6.3 not resolved
chlorpheniramine 7.6 not resolved 5.5 not resolved
benzoin 10.3 1.05 <0.5 7.1 not resolved
chlorthalidone 3.5 1.09 0.6 4.0 not resolved
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3.9.2. Effect of degree of substitution on performance of derivatised cyclodextrins.
A hydroxyethyl- substituted B-cyclodextrin with a lower degree of average molar substitution 
(MS = 0.6) was found to give improved resolution of all the racemates investigated, as 
shown in Table 3.12. In some cases, higher selectivity than that given by underivatised 
B-cyclodextrin under similar conditions was observed. In these cases, the lower degree of 
substitution may be providing optimum number of hydrogen-bonding sites and steric bulk 
around the cavity rim for enantioselectivity.
3.9.3. Use of high additive levels
Tables 3.12, 3.13 and 3.14 summarise data obtained using much higher additive concentr­
ations than would be possible with underivatised B-cyclodextrin, on a more hydrophobic 
column than used previously (Spherisorb C6).
Table 3.12. Resolution of enantiomers using hydroxyethyl-beta-cyclodextrin (MS = 
0.6). Column: Spherisorb C6 (150 x 3mm); Mobile phase: acetonitrile: aq. triethylam­
monium acetate (0.8% TEA v/v, acetic acid to pH 4) (10:90 v/v)
Solute 20mg/ml CD in eluent 100mg/ml CD In eluent
k’i a Rs k’i a Rs
nomifensine 7.3 1.39 2.1 1.8 1.35 1.4
chlorthaiidone 16.8 1.17 1.5 6.4 1.33 1.4
brompheniramine 18.3 1.08 1.1 5.9 1.13 0.8
benzoin 29.9 1.09 1.3 8.4 1.13 1.1
chlorpheniramine 20.2 1.06 1.0 6.5 1.10 0.8
trimeprazine 29.1 1.17 1.5 4.9 1.18 1.3
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Table 3.13. Resolution of enantiomers using hydroxypropyl-beta-cyclodextrin (MS =
0.9) on Spherisorb C6. Conditions as Table 3.13
Solute 20mg/ml CD in eluent 100mg/ml CD in eluent
a Rs k'i a Rs
nomifensine 7.4 1.15 1.5 2.1 1.19 1.1
chlorthalidone 13.7 1.10 1.5 7.1 1.28 1.3
brompheniramine 16.0 1.06 0.9 4.5 1.06
trimeprazine 25.6 1.18 1.8
methyl-beta-cyclodextrin (DS = 1.8) on 









Table 3.14. Resolution of enantiomers using 
Spherisorb C6. Conditions as Table 3.13
solute
With hydroxyethyl-(3-cyclodextrin (DS = 0.6), some increases in selectivity were obtained 
using high additive levels, but resolution was in general lower owing to sub-optimal retention 
and a marked drop in column efficiency. This deterioration in column performance probably 
reflects the increased viscosity of eluents containing high additive levels, as discussed by . 
Armstrong et al (1988b), resulting in poorer mobile phase mass transfer.
With the other derivatives, improved resolution was obtained at high additive levels. 
However, this was still lower than obtained using the underivatised cyclodextrin. Compari­
son of the results obtained for hydroxypropyl-6-cyclodextrin (MS = 0.9) at the two additive 
levels employed leads to similar conclusions to those above. In this case, even at 100mg/ml 
in the eluent, selectivity was lower than has been observed using much lower concentrations 
of underivatised B-cyclodextrin. This suggests that the inherent enantioselectivity of the 
inclusion process has been lessened by derivatisation. For methyl-B-cyclodextrin, some 
resolution was observed at high additive levels where none had been using lower levels of 








Cyclodextrins have long been applied to the preparative resolution of complexed solutes, 
including enantiomers. Techniques involved include precipitation, differential reactivity, gel 
chromatography and, most recently, HPLC.
4.1.1. Resolution of enantiomers by stereoselective precipitation using cyclodextrins.
The diastereomeric complexes formed between a cyclodextrin and a racemic substrate may 
differ in their solubilities, as well as their formation constants. Therefore, if cyclodextrin is 
added to increase the solubility of a poorly soluble racemic mixture, the resulting solution 
may be enriched in one enantiomer. This was first exploited to effect chiral resolution by 
Cramer and Dietsche (1959). They used B-cyclodextrin to resolve carboxylic acid esters by 
this approach, and achieved optical purities of 3 to 10% after one separation step, which 
could be increased by repeated precipitation or recrystallisation steps. Other racemates, 
including phosphinates (Benschop and Van den Berg (1970)) and sulphinates (Mikolajczyk 
and Drabowitz (1978)) have subsequently been resolved by this method, with one-step 
optical purities of up to 80% achieved in some cases.
The chief drawback of this approach is that, like the classical resolution method of fractional 
crystallisation of diastereomeric derivatives, many steps are usually required to achieve high 
optical purities. However, recovery of the resolved enantiomers from their cyclodextrin 
complexes is somewhat easier than the reversal of derivatisation required in the classical 
approach.
4.1.2 Enantioselective catalysis by cyclodextrins.
Cyclodextrins are known to catalyse effectively certain reactions, particularly hydrolyses and 
trans-acylations (Hinze (1981)). Such catalysis may be enantioselective, i.e. the cyclodextrin
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may catalyse the reaction of one enantiomer of a racemate faster than the other, leading to 
partial resolution of the racemic product. This principle has been applied effectively to the 
resolution of racemic organophosphates and other substrates. In the best case, ±- 
isopropyl-2-dimethylaminoethylmethylphosphonthioate, a rate differential of 110 in 
alpha-cyclodextrin-catalysed base hydrolysis was reported (Van Hooidonk (1972)). In a 
recent report (Coates et al (1991)), a potentially effective method for the resolution of 
ibuprofen enantiomers has been outlined. This involves enantioselective hydrolysis of a 
cyclodextrin-ibuprofen ester, with the diastereomer derived from (R)-ibuprofen being more 
than 10 times more susceptible to hydrolysis than that derived from (S)-ibuprofen.
The application of this technique has proved to be limited to certain substrates. A major 
drawback is that chemical change in the substrate may be inherent in the method.
4.1.3 Preparative separations on cyclodextrin polymer gels.
Cyclodextrin polymer gels, produced by cross-linking with epichlorohydrin, have been used 
for preparative chromatographic separations, both achiral and chiral. Zsadon e ta l (1983) 
resolved the enantiomers of a number of indole alkaloids by this approach, using a 
50x900mm column packed with B-cyclodextrin polymer. ±-Vincadifformine was resolved at 
optical purities of 98.3% and 92.5% for the two enantiomers in 92.5% yield at a rate of 
17mg/hour. Increasing throughput to 25 mg racemate per hour reduced optical purity to 
87.5% and 81.6% for the two enantiomers.
The chief drawback of this technique, when compared to preparative HPLC, is the large 
particle size of such cyclodextrin gels, resulting in poor mass transfer and hence low 
efficiency. Other gels, where the cyclodextrin is immobilised on the surface of a non- 
complexing polymer such as polyacrylamide (Tanaka e ta l{  1981)), exhibit higher efficiency 
but much lower capacity, and so have not been applied to preparative separations.
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4.1.4 Semi-preparative HPLC on cyclodextrin silicas
Cyclodextrin-silica HPLC phases generally have lower loading capacities than conventional 
reversed-phase materials (Vigh et a / (1989)). Consequently, reports of preparative HPLC 
separations in the conventional (elution) mode are few and far between. Florance et al 
(1987) reported the attempted semi-preparative resolution of enantiomers of a cyclic peptide 
at hundred milligram scale on a 1 inch i.d. Cyclobond I column. Resolution was reported to 
be poor, however.
In a recent series of publications, Vigh et al (1989,1989a, 1990) have described the 
effective application of Cyclobond I columns to preparative separations in displacement 
mode.
Displacement chromatography has recently been re-discovered as a potentially useful 
technique for achieving large-scale separations. In reversed-phase elution chromatography, 
which is the mode most applicable to small-scale analytical separations, solutes are 
partitioned between mobile and stationary phases and are eluted due to the presence of 
organic modifiers in the mobile phase. In the past, overloaded elution chromtatography has 
been much used for preparative separations, owing to its close relationship to analytical 
HPLC, allowing facile method development. In displacement chromatography, solutes are 
introduced to the column in a mobile phase which does not effect their rapid elution. A 
displacer solution, containing a high concentration of a substance which has a stronger 
affinity for the stationary phase than the solutes, is then pumped through the column. This 
displaces the solutes from the stationary phase in order of their adsorption strengths. If 
these are sufficiently different, and the column is efficient, then solutes will be fully resolved 
and will emerge from the column in turn. Horvath (1985) has argued that throughput can be 
increased by an order of magnitude in displacement mode compared to overloaded elution 
mode.
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Vigh has used displacement HPLC on Cyclobond I to achieve impressive preparative 
separations of positional, geometric and optical isomers, using normal or reversed-phase 
solvents (Vigh et a / (1989 ,1989a, 1990). Using two 250x4.6mm Cyclobond I columns in 
series, up to 6mg of various racemates (mephobarbital, hexobarbital, dansylleucine, 
dansylvaline) were resolved in high yield and optical purity in run times of 3-6 hours. In all 
these cases, the elution mode selectivities at low loading were less than 1.1 under the 
conditions used, indicating that preparative separations in elution mode would not have 
been realistic.
4.1.5 Preparative chromatographic separations using cyclodextrin-containing eluents
As with all chiral separation methods using mobile phase additives, application of cyclodext­
rin eluents to preparative separations has been limited by the problem of recovering the 
resolved enantiomers free from the chiral additive (Pirkle and Sikkenga (1976)). Sato and 
Suzuki (1985) separated the enantiomers of warfarin and mandelic acid as their 6- 
cyclodextrin complexes on Sephadex gel. Optical purities of around 30% were achieved, 
with throughputs of up to 2mg per hour on a 400 x 25mm column. The enantiomers were 
recovered by freeze-drying followed by addition of acetone to break up the complexes and 
precipitate out the cyclodextrin.
The most significant report in this area has come from Harada et al (1989), who used 
alpha-cyclodextrin as a mobile phase additive to achieve the medium-pressure liquid 
chromatographic resolution of the enantiomers of some chiral ferrocenes on a polyamide 
gel stationary phase. High selectivities (aup to 1.64) were obtained and throughputs of up 
to 20mg racemate per hour were achieved on a 500 x 8mm column. The resolved 
enantiomers were recovered by solvent extraction (although no experimental detail on this 
point was given), and it was reported that the alpha-cyclodextrin could also be recovered 
and re-used (which was economically advantageous).
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Only brief mention of the use of cydodextrins as eluent additives in preparative RP-HPLC 
has appeared in the literature. Thus, Sybilska et al (1986) have reported the use of 
B-cyclodextrin in the mobile phase to achieve the preparative separation of enantiomers of 
mephenytoin and hexobarbital on a 250 x 8mm Lichroprep RP18 column. However, no data 
for these separations were given , and there was no indication that attempts had been 
made to recover the enantiomers from the mobile, phase after resolution. It is clear that the 
good resolutions obtained in analytical-scale HPLC using cydodextrins have yet to be 
exploited to their full potential on a larger scale.
4.1.6 Enantiomer separations using cyclodextrin-containing liquid membranes. •
The potential utility of liquid membranes containing chiral additives to achieve very large 
scale enantiomer separations has recently been demonstrated (Pirkle, W.H., reported at 
2nd. Int. Symp. Chiral Sepns, Guildford (1989)). The principle of this technique is that the 
the chiral additive acts to solubilise the solutes in a liquid membrane separating two portions 
of a solvent with which the liquid is immiscible. Solutes are thereby transported across the 
membrane. The selectivity induced by the chiral additive may result in enrichment of one 
enantiomer from a racemate. Preparative resolutions at high optical purity may therefore be 
achieved by the use of a number of such liquid membrane systems in series.
Armstrong and Jin (1987c) have described the application of this approach using cydodext­
rins to selectively transport solutes across an aqueous liquid membrane separating two 
portions of ether. By this means, the potential for preparative resolution of a number of 
racemates (derivatives of ferrocene and nicotine, a crown ether, mephenytoin and 
disopyramide) was demonstrated. The initial rates of transport of two enantiomers across 
the membrane were found to differ by factors of up to 17.
This technique has enormous potential for process-scale separations, since it can be
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operated on a continuous-flow basis and the chiral additive is not consumed. However, no 




4.2.1 Effect of trimeprazine loading on resolution.
The variation in resolution of trimeprazine enantiomers on a wide-pore C8 column 
(100x4mm) with concentration of injected solution (at constant injection volume) using a 
8-cyclodextrin-containing eluent is illustrated in Figure 4.1, and quantified in Table 4.1.
Table 4.1. Effect of trimeprazine loading on resolution. Conditions as Figure 4.1. 
Recovery and optical purities of collected fractions (assayed by reinjection into the 
system) are also shown.
Column loading resolution Peak 1 Peak 2
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Figure 4.1. Resolution of trimeprazine enantiomers on SGE-100GLC4-C8-30/5 column 
(containing 0.77g packing material). Mobile phase: acetonitrile - aq. triethylam- 
monium acetate (0.89% TEA v/v, acetic acid to pH 4) (10:90, v/v) containing 13.5mg/ 
mi B-cyclodextrin hydrate. Flow rate: 0.75ml/min. Temperature: 20°C. Injection 
volume: 100pl. Sample solution.: ±-Trimeprazine hemi-(+)-tartrate in water. Column 
loading: (a) 0.018mg (b) 0.16mg (c) 0.4mg (d) 1.98mg. UV detection: (a) 300nm 
0.2AUFS (b) and (c) 300nm 2.0AUFS (d) 340nm 2.0AUFS.
134
Figure 4.1 shows that the trimeprazine enantiomers were baseline resolved at low column 
loadings. As the loading was increased, retention fell and resolution was reduced. Such 
behaviour is consistent with that generally reported in overloaded elution chromatography 
(McDonald and Bidlingmeyer (1987)). This indicates that saturation of stationary phase 
sites is the primary factor operative on overloading, rather than saturation of the complexing 
ability of the cyclodextrin in the mobile phase, which might be expected to lead to increases 
in retention on column overloading. Some resolution was observed at very high column 
loadings, up to 2mg on this small column.
Table 4.1 also shows the recovery and optical purity of collected fractions, determined by 
re-injection into the system and comparison of peak areas of the two enantiomers. The high 
optical purities obtained indicated the possibility of achieving mg-scale separations of 
trimeprazine enantiomers using this system.
The effects of injection volume and sample concentration on resolution were investigated. 
The results obtained are illustrated in Figure 4,2.
Peak shapes were significantly poorer on injecting a 40mg/ml sample concentration. Little 
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Figure 4.2. Variation in resolution of trimeprazine enantiomers with injection volume 
and sample concentration. Column: SGE-100GLC4-C8-30/5. Mobile phase: acetonit- 
rile - triethylammonium acetate buffer (0.89% TEA v/v, acetic acid to pH 4) (10:90, v/v) 
containing 9mg/m! B-cyclodextrin hydrate. Flow rate: 0.75mg/ml. Sample solution: 
±-Trimeprazine hemi-(+)-tartrate in mobile phase. Injection conditions: (a) 25pl x 
40mg/ml (b) 50pl x 20mg/ml (c) 1 OOjjI x 10mg/ml.
4.2.2 Effect of mobile phase composition and stationary phase type on resolution of 
trimeprazine enantiomers.
The effect of varying the acetonitrile content of the eluent on resolution of trimeprazine 
enantiomers at low column loadings was investigated. The results obtained are shown in 
Table 4.2.
In the absence of cyclodextrin, an increase in eluent organic modifier content in RP-HPLC 
causes a decrease in retention. In this case the opposite trend was observed. This may be 
attributed to the competitive inclusion of the organic modifier reducing the eluting ability of 
the cyclodextrin in the mobile phase as the organic content was increased.
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Table 4.2. Effect of eluent acetonitrile content on resolution of trimeprazine enantio­
mers. Column: SGE-100GLC4-C8-30/5. Mobile phase: ACN - aq. triethylammonium  
acetate (0.89% TEA v/v, acetic acid to pH 4) containing 13.5mg/ml beta-cyclodextrin 
hydrate. Flow rate: 0.75ml/min. Solute: Trimeprazine tartrate (2pg on column)
[ACN] in eluent, k*i a Rs Nwi / 2  m-
% v/v (peak 2)
0 5.8 1.30 1.29 5943
5 6.1 1.28 1.91 15283
10 7.0 1.24 2.35 32355
While selectivity was reduced as acetonitrile content was increased, resolution was 
improved due to a substantial increase in column efficiency (as measured by the number of 
theoretical plates, N). This is attributable to the “wetting” of the hydrophobic stationary 
phase by the organic modifier, improving mass transfer.
The effect of G-cyclodextrin content of the mobile phase on resolution is illustrated in Table
4.3 (at low column loading) and Figure 4.3 (at high column loading).
Table 4.3. Effect of beta-cyclodextrin hydrate concentration in eluent on resolution of 
trimeprazine enantiomers. Conditions as Figure 4.3, except column loading: 2pg.
eluent [BetaCD], k’i a Rs Nwi / 2  nr'
mg/ml (peak 2)
6.8 12.4 1.23 2.06 24533
9.0 9.3 1.24 2.10 22945
13.5 7.0 1.24 2.35 32355
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Figure 4.3. Effect of B-cyclodextrin concentration in eluent on resolution of trimepra­
zine enantiomers on SGE-100GLC4-C8-30/5 column. Mobile phase: acetonitrile - aq. 
triethylammonium acetate buffer (0.89% TEA v/v, acetic acid to pH 4) (10:90, v/v) 
containing (a) 6.75mg/ml (b) 9.0mg/ml (c) 13.5mg/ml B-cyclodextrin hydrate. Flow 
rate: 0.75ml/min. Loading: 1mg ±-trimeprazine hemi-(+)-tartrate on column.
Selectivity and resolution were increased, and retention time reduced, on increasing the 
cyclodextrin concentration, due to increasing degree of complexation. However, 9mg/ml 
was deemed to be the most appropriate concentration for semi-preparative separations 
using this system, since the slightly increased run time would allow greater margin for error 
in fraction collection times.
Triethylamine was incorporated in all the eluents employed. It was found to significantly 
reduce peak tailing, and improve resolution. An eluent concentration of 0.8% v/v was found 
to be optimal. There was little improvement in resolution on increasing the triethylamine 
content above this level.
The separation of trimeprazine enantiomers on a column with higher carbon loading was 
investigated. This gave much longer retention times without improvement in resolution, as 
shown in Figure 4.4.
Figure 4.4 Resolution of trimeprazine enantiomers on a SGE-100GL4-C8-8/5 column. 
Mobile phase: acetonitrile - aq. triethylammonium acetate (0.8% TEA v/v, acetic acid 
to pH 4) (10:90 v/v) containing 13.5mg/ml B-cyclodextrin hydrate. Flow rate: 
0.75ml/min. Loading: (a) 5pg; (b) 2mg ±-trimeprazine hemi-(+)-tartrate on column.
It was clear that throughput would be reduced under these conditions. Retention time could 
have been reduced by using a higher acetonitrile content in the mobile phase, but this 
would have resulted in lower selectivity. The wide-pore C8 material, with low carbon 
loading, was therefore the most appropriate choice for this separation. The differences in 
retentivity of the two materials made it impossible to assess whether the differing pore sizes 
of the two stationary phases had any effect.
(a) (b)
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The use of a “base-deactivated” reversed-phase stationary phase was investigated as a 
means of reducing peak tailing without the use of amine modifiers. As shown in Figure 
4.5a, resolution on this column was quite poor, and its retentivity rather too high (necessit­
ating the use of higher organic content in the mobile phase than optimal).
(a) (b)








Figure 4.5. Resolution of trimeprazine enantiomers on Hypersii BDS (150x2.1 mm). 
Column loading: 2pg ±-trimeprazine tartrate, (a) Mobile phase: acetonitrile - aq. 
NaH2P 0 4 (0.05M, H3P 0 4 to pH 4) (20:80, v/v) containing 25mg/ml B-cyclodextrin 
hydrate, (b) Mobile phase: acetonitrile - aq. triethylammonium acetate (0.4% TEA v/v, 
acetic acid to pH 4) (20:80, v/v) containing 20mg/ml B-cyclodextrin hydrate.
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Figure 4.5b shows that an improvement in resolution was obtained by the use of a 
triethylamine-containing mobile phase on this column, indicating that silanol effects are still 
operative on this material (i.e. that the base-deactivation is far from complete). Retention 
was still high, and so little advantage was seen in the use of this phase.
Sodium hexanesulphonate was investigated as a possible alternative to the use of 
triethylamine-containing mobile phases. The ion-pairing agent increased retention, 
necessitating the use of an increased acetonitrile content in the eluent. This factor, coupled 
with poor peak shapes in the absence of triethylamine, led to poor resolution. The 
ion-pairing agent had no apparent effect on selectivity. This was probably because, in an 
eluent containing only 20% v/v acetonitrile, adsorption of ion-pairing agent onto the 
stationary phase {i.e. ‘dynamic ion-exchange”) was probably the predominant retention 
mechanism rather than ion-pair formation in the mobile phase.
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4.2.3 Effect of temperature on capacity of Lichrosorb RP18 stationary phase for trimepra­
zine
The potential utility of Lichrosorb RP18, a very hydrophobic stationary phase (carbon 
loading 17% w/w) for the recovery of trimeprazine enantiomers following chiral separation 
using a B-cyclodextrin-containing eluent was investigated in a series of “breakthough” 
experiments. The effect of temperature on capacity was also investigated, with a view to 
disrupting complexation of the trimeprazine by the cyclodextrin at high temperature, thereby 
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Figure 4.6. Variation in capacity of Lichrospher RP18 for ±-trimeprazine with 
temperature. Column dimensions: 100x4.6mm. (containing 1.0g packing material). 
Loading solution: acetonitrile - aq. triethyiammonium acetate (0.89% TEA v/v, acetic 
acid to pH 4) (10:90, v/v) containing 13.5mg/ml B-cyclodextrin hydrate and 0.1 mg/ml 
±-trimeprazine hemi-(+)-tartrate. Flow rate: 1ml/min.
At all temperatures across the range studied, the capacity of the column was found to be
142
about 6mg per gram of packing material, which indicated that this phase was likely to be 
suitable for the intended purpose. Significant variation in capacity with temperature was not 
observed, indicating that any effects due to the disruption of cyclodextrin concentration at 
high temperature were cancelled out by the change in inherent capacity of the stationary 
phase.
4.2.4 Application of the Promis 2 autosampler with integrated stream switching (ISS) facility 
to the on-line recovery of trimeprazine enantiomers following chromatographic separation.
The ISS facility of the LDC Promis 2 autosampler, consisting of two Rheodyne 7000 six-port 
switching valves with pneumatic actuators controlled by the autosampler, allowed the 
possibility of on-line recovery of trimeprazine enantiomers following their separation. Two 
Lichroprep RP18 columns were used to recover the enantiomers free from B-cyclodextrin. 
The high capacity of this phase allowed the resolution of 12-14 1mg injections of racemate 
on the separating column, before the recovery columns were flushed free of cyclodextrin 
and the resolved enantiomers eluted.
Several semi-preparative runs were carried out, using differing procedures for flushing the 
recovery columns free of mobile phase components and eluting the trimeprazine from the 
recovery columns, as outlined in Table 4.4 The optical purities of the recovered trimepra­
zine fractions were assayed by re-injection into the system. Typical calibration data from 
this assay is shown in Table 4.5.
The results of the semi-prep runs listed in Table 4.4 are summarised in Table 4.6. The 
capacity of recovery column 2 was invariably reached first, presumably because of the 
greater width and hence longer fraction collection time of peak 2. Consequently, losses of 
trimeprazine from recovery column 2 on flushing off the cyclodextrin were greater, and 
recoveries of peak 2 generally lower.
143
Table 4.4. Summary of semi-preparative procedures employed.
Run eluent-[BetaCD], flush elution
mg/ml procedure procedure
1 13.5 1 1
2 13.5 2 2
3 13.5 2 2
4 13.5 - 2 3
5 13.5 3 4









Flush procedures: 1. 20ml x acetonitrile - water (20:80, v/v)
2. 5ml x acetonitrile - water (20:80, v/v)
3. 5ml x tetrahydrofuran - water (20:80, v/v)
4. 2.5ml x water + 5ml x acetonitrile - water (10:90, v/v)
Elution procedures: 1. 20ml x acetonitrile - TFA - water (50:0.1:49.9, v/v)
2. 30ml x acetonitrile - TFA - water (50:0.1:49.9, v/v)
3. 25ml x acetonitrile - TFA - water (50:0.1:49.9, v/v)
4. 25ml x acetonitrile - TFA - water (70:0.1:29.9, v/v)
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Table 4.5. Calibration data for chiral trimeprazine assay.
Conditions: Column: SGE-100GLC4-C8-30/5. Mobile phase: acetonitrile - aq. 
triethyiammonium acetate (0.89% TEA v/v, acetic acid to pH 4) (10:90, v/v) containing 
9mg/ml beta-cyclodextrin hydrate. Internal standard: levomepromazine (50pg/ml). 
Detection: UV 300nm. integration: Spectra-Physics SP4270.
[trimep. tart.], peak heights
pg/ml/'enantiomer trimeprazine int.std.










number of measurements, n 
correlation coefficient, r 




peak 1 peak 2
0.0305 0.0296
0.0373 0.0344
42722 39765 135646 0.315 0.293
42035 38960 134705 0.312 0.289
445739 408755 134276 3.32 3.04












Table 4.6. Summary of results: semi-preparative resolution of trimeprazine enantio­
mers with on-line recovery.
fraction 1
run recovery %e.e. loss in throughput
% flushing, % mg/hour
1 80 98 10 1.1
2 65 >98* 1 1.5
3 46 >98* <1** 0.8
4 83 >98* 1 1.2
5 89 >98* 11 1.9
fraction 2
run recovery %e.e. loss in throughput
% flushing, % mg/hour
1 35 92 25 0.5
2 38 90 24 0.7
3 37 92 16 0.6
4 62 92 28 0.9
5 54 92 60 1.2
6 85 92 <1** 1.5
* = optical impurity not detected
**= no loss detected
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The optical purities of the peak 2 fractions were also generally lower (90 - 92% e.e. as 
opposed to 98% e.e. or higher for the peak 1 fractions), owing to the “tail” of the first eluting 
peak co-eluting with the second peak fraction. Considerable losses at the “flushing" stage of 
the procedure were observed in several cases. The mildest flushing procedure, (iv), using 
small amounts of water, followed by acetonitrile-water (10:90, v/v) was found to be effective 
at selectively removing the cyclodextrin from the. recovery column. Very high recoveries 
were obtained when this procedure was employed.
o 16 min4 128
Figure 4.7. Semi-preparative resolution of trimeprazine enantiomers (1mg racemate 
on column). Column: SGE-100GLC4-C8-30/5. Mobile phase: acetonitrile - aq. 
triethylammonium acetate (0.8% TEA v/v, acetic acid to pH 4) (10:90, v/v) containing 
9mg/ml B-cyclodextrin hydrate. Flow rate: 0.75ml/min. ISS valve switching points for 
recovery of enantiomers are also shown (dotted lines).
The resolution obtained in run 6 is illustrated in Figure 4.7, which also shows the valve
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switching times employed for recovery of the enantiomer fractions. The optical purity of the 
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Figure 4.8. Analytical resolution of trimeprazine enantiomers, Conditions as Figure 
4.7. Peak identities: (1) levomepromazine (internal standard), 0.25pg on col.; (2) and 
(3) trimeprazine enantiomers. Sample identities: (a) ±-trimeprazine tartrate 0.25pg on 
col. (calibration standard) (b) recovered trimeprazine peak 1 fraction (e.e. >98%) (c) 
recovered trimeprazine peak 2 fraction (e.e. 92%)
NMR analysis of the collected fractions from all six semi-preparative runs showed them to 
contain significant quantities of triethylamine, as shown by characteristic signals at 1.1 ppm
148
(triplet) and 3.2ppm (quartet). Some of the fractions, particularly those from runs 2 to 5, 
showed the presence of B-cyclodextrin, as evidenced by characteristic signals at 5.1 ppm 
(doublet) and 3-4ppm (multiplets), indicating that the flush procedures used in these cases 
were not fully effective. The fractions from run 6, where a larger volume of weaker flush 
solvent had been employed, showed the presence of only trace quantities of B-cyclodextrin, 
as illustrated in Figure 4.9.
The procedure was found to be robust and reproducible. Over the 4 hours of a 16-injection 
run, no significant changes in retention were observed, despite slight variation in laboratory 
temperature. No adjustment of valve switching times during the course of a run were 
therefore necessary, and the system could therefore be left to run unattended during the 
loading of the recovery columns. In principle, with the use of a suitable ternary gradient 
system to control the necessary solvent changes, a fraction collector to recover the 
enantiomers on elution from the recovery columns, and with microcomputer control, the 
whole system could be automated. This possibility was not explored, however, as the 
required equipment was not available.
While the optimised flushing procedure proved capable of producing the resolved 
enantiomers free from cyclodextrin, the problem of triethylamine contamination required 
further study. The use of a TFA-containing eluting solvent, while making for easy recovery 
of product from the eluting solvent, produced trimeprazine trifluoroacetate as product, which 
proved to be largely insoluble in water. The production of water-soluble salts (typically 
maleates, tartrates, or hydrochlorides) would be advantageous in analysis and for the 
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Figure 4.9. 270MHz 1H-NMR spectra of trimeprazine trifluoroacetate. (a) racemate 
(prepared from racemic tartrate as described in 2.1.4.) (b) recovered peak 1 fraction 
from semi-preparative run 6.
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4.2.5 Solvent extraction recovery procedure.
The use of a liquid-liquid extraction procedure to recover enantiomers from the chiral mobile 
phase following separation was investigated. The procedure involved adding TFA to the 
HPLC fraction, followed by extraction of the trifluoroacetate into ether, and evaporation of 
the ether layer to reclaim the crude trifluoroacetate. NMR analysis of the resulting product 
showed that the procedure was effective at removing B-cyclodextrin from the product 
(owing to the very low solubility of B-cyclodextrin in ether), but that substantial triethylamine 
contamination was still present. Presumably, the triethylamine trifluoroacetate was 
significantly extracted into ether.
A similar experiment with tri ethyl amine-contaminated fractions from the on-line recovery 
procedure showed that solvent extraction was unable to significantly reduce the amount of 
triethylamine present. While this procedure might be employed as an alternative to the 
on-line approach for resolved enantiomers where no triethylamine in mobile phase was 
employed, it was not seen to offer any advantages in this particular case.
4.2.6 Use of polymeric recovery column.
The use of a polystyrene-divinylbenzene (Hamilton PRP-1) stationary phase for the 
recovery of trimeprazine was investigated. This material was found to have a higher 
capacity for trimeprazine than the Lichroprep RP18 material. 10.0mg per gram ±- 
trimeprazine tartrate could be loaded onto this material without significant breakthrough 
loss, compared to about 6mg per gram on Lichroprep RP18 under the same conditions.
The PRP-1 column was flushed with 10ml of acetonitrile - water (10:90, v/v), followed by 
10ml acetonitrile - TFA- water (10:0.1:89.9, v/v); and the trimeprazine could be eluted at 
high recovery in 20ml acetonitrile - TFA - water (70:0.1:29.9, v/v). NMR analysis of the 
reclaimed trimeprazine showed that the procedure had been effective as before at removing
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B-cyclodextrin, but that triethylamine was present. This was somewhat surprising, since the 
lack of silanol groups on the polymeric material might be expected to lead to much lower 
affinity for triethylamine than on the silica-based RP18.
The flushing of triethylamine from the PRP-1 phase was further investigated in an 
experiment in which the column was equilibrated with the chiral mobile phase, and flushed 
with acetonitrile - water (10:90, v/v). Samples of the eluate were taken and analysed for 
triethylamine content by HPLC using on-line post-column ion-pair formation with 9,10- 
dimethoxyanthracenesulphonate (DAS), extraction into organic solvent, and fluorescence 
detection of ion-pairs in then organic phase. Figure 4.10 shows the variation in triethylamine 
content in the eluate with volume of flushing solvent passed through the column.
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Figure 4.10. Triethylamine content of eluate from Hamilton PRP-1 (150x4.6mm) 
column (dead volume = 2.49ml). Column pre-equilibrated with acetonitrile - aq. 
triethylammonium acetate (0.8% TEA v/v, acetic acid to pH 4) (10:90, v/v) containing 
13.5mg/ml beta-cyclodextrin hydrate and flushed with (a) acetonitrile - water (10:90, 
v/v) (b) acetonitrile - aq. H3P04 (0.001 M) (10:90, v/v)
ACN:H20 (10:90 v/v)
ACN:0.001M aq.H3P04 (10:90 v/v)
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It can be seen that substantial quantities of flush solvent were necessary to remove all the 
triethylamine from the column. The situation was slightly improved by using an acidified 
flushing solvent, indicating that the phase has lower retentivity for triethylamine in 
protonated form.
The higher capacity of the PRP-1 phase would provide advantages in its use as a recovery 
column material for on-line recovery of trimeprazine enantiomers, but the recovery 
procedure using this column was unable to produce recovered material free from
triethylamine.
4.2.7 Modification of recovery column loading
More thorough flushing of the PRP-1 phase was made possible by reducing the loading to
4.1 mg per gram. A 100x10mm column could then be flushed with 360ml of acetonitrile- 
water (10:90, v/v) (about 65 column volumes), and the trimeprazine eluted with 50ml of 
methanol. The NMR spectrum of the product is shown in Figure 4.11. This shows that the 
product under these conditions was almost completely free from triethylamine and 
6-cyclodextrin. Comparison with a trimeprazine sample “spiked” with triethylamine and 
6-cyclodextrin suggested that the product contained considerably less than 0.2 mol% 
B-cyclodextrin and 2 mol% triethylamine. No loss of trimeprazine recovery occurred during 
the flushing procedure. This was checked by addition of tartaric acid as internal standard to 
the product before NMR analysis.
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Figure 4.11 1H-NMR spectrum  of trim eprazine recovered from  PRP-1. Recovery 
procedure as text. 2 mol. equiv. (+)-tartaric acid added as int. std. Solvent: CD3OD.
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4.3 Thromboxane antagonists
4.3.1 Effect of loading on resolution of ±-TA1
The effect of column loading on resolution of TA1 enantiomers is illustrated in Table 4.7. 
Near-baseline resolution was observed up to 1 mg racemate on column, due to the high 
selectivity (a  = 1.6 at low column loading) induced by the eluent B-cyclodextrin for this 
racemate. It was therefore anticipated that semi-preparative resolution of enantiomers of 
TA1 could easily be achieved by this approach.
4.3.2 On-line recovery of TA1 enantiomers following chiral separation.
On-line recovery of TA1 enantiomers was accomplished by the same principle as used for 
trimeprazine, using somewhat different instrumentation. Four complete semi-preparative 
runs were carried out for TA1, under conditions described in table 4 .8 .1mg of racemate 
was introduced to the column at each injection.
The low solubility of ±-TA1 (about 4mg/ml) in the mobile phases used presented difficulties. 
To overcome these, samples for injection were dissolved in 50% DMSO/ 50% mobile 
phase, in which a concentration of 10mg/ml could be achieved. DMSO was used in 
preference to other solvents as it did not cause precipitation of B-cyclodextrin from the 
eluent.
A typical chromatogram obtained at 1mg loading is shown in Figure 4.12, which also shows 
the recovery system valve switching times used.
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Table 4.7. Effect of column loading and beta-cyclodextrin concentration on resolution 
of TA1 enantiomers. Column: SGE-100GLC4-C8-30/5 (100 x 4mm), containing 0.77g 
packing material. Mobile Phase: acetonitrile - aq. phosphate buffer (0.05M, pH 7) 
(10:90, v/v). Injection volume: 100pl.
eluent [beta-CD] racemate loading k’i a Rs %CRF
mg/ml mg on coi
15 0.015 14.5 1.56 3.8 100
0.045 13.5 1.57 2.5 100
0.140 12.4 1.56 2.8 100
0.420 9.7 1.9 100
0.69 9.0 1.5 100
1.03 8.0 95
18 0.015 11.8 1.58 3.0 100
0.045 10.9 1.56 2.2 100
0.14 9.5 1.58 1.8 100
0.42 7.8 1.7 99
0.69 7.0 94
1.03 6.3 89
21 0.015 10.4 1.61 3.1 100
0.045 9.8 1.62 2.3 100































(1): 5ml x acetonitrile - water (10:90, v/v)
(2): 5ml x TFA- water (0.2:99.8, v/v) followed by 
5ml x acetonitrile -TFA - water (10:0.2:89.8, v/v)
(3): 10ml x acetonitrile - TFA - water (10:0.2:89.8, v/v)











Figure 4.12. Resolution of TA1 enantiomers on SGE-100GLC4-C8-30/5 column.
Eluent: ACN - aq. phosphate buffer (0.05M, pH7) (10:90 v/v) containing 21mg/ml 
B-cyclodextrin hydrate. Sample: ±-TA1 (10mg/ml in DMSO - eluent (50:50 v/v)). 
Injection volume: 100pl. Detection: UV 290nm. Dotted lines show recovery system  
valve switching times, shown by dotted lines.
10-12 racemate injections were made per run before the recovery columns were flushed 
and the resolved enantiomers eluted and recovered. Eluates from the recovery columns 
were collected at both the “flushing” and elution stages, so that any loss of recovery could 
be accounted for. The “loading” part of the procedure could, in principle, be carried out 
unattended (as it had been for trimeprazine). In practice, however, manual injections were 
made, as the Varian autosampler tended to waste large amounts of sample in purging the 
loop at each injection.
The fractions were assayed for recovery and optical purity by re-injection into the 
chromatograph under the same conditions as above. m-Nitroaniline was used as an internal 
standard, and a calibration graph was constructed using peak height ratios. Typical 
calibration data is shown in Table 4.9. The semi-preparative results obtained are summari­
sed in Table 4.10, and typical optical purities illustrated in Figure 4.13.
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Table 4.9. Calibration data from chiral TA1 assay. Column: SGE100GLC4-C8-30/5. 
Mobile phase: acetonitrile - phosphate buffer (0.05M, pH 7) (10:90, v/v) containing 
18mg/ml beta-cyclodextrin hydrate. Internal standard: m-nitroaniline. Injection 






peak 1 peak 2 peak 1 peak 2
26 349 233 8502 0.041 0.027
337 238 8776 0.038 0.027
356 239 8721 0.041 0.027
128 2047 1410 8798 0.233 0.160
2036 1389 8734 0.233 0.159
2035 1392 8750 0.233 0.159
638 10326 6902 8522 1.212 0.810
10644 7091 8776 1.213 0.808
10610 7079 8688 1.221 0.815
number of measurements, n 9 9
correlation coefficient, r >0.9999 >0.9999
slope 0.00192 0.00127
intercept (y-axis) -0.0087 -0.0019
intercept (x-axis), pg/ml 4.5 1.5
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Table 4.10. Summary of results: semi-preparative resolution of TA1 enantiomers with 
on-line recovery
run fraction recovery e.e., %
%
loss in throughput
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Figure 4.13. Analytica l reso lu tion of TA1 enantiomers on SGE-100GLC4-C8-30/5. 
Mobile phase: aceton itrile  - aq. phosphate buffer (0.05M, pH 7) (10:90, v/v) conta in ing 
21 mg/ml B -cyclodextrin hydrate. Flow rate: 0.75ml/min. In jection volum e: 20pl. 
Detection: UV 254nm. Peak identities: (1) m -nitroaniline (internal standard, 0.1mg/ml). 
(2) and (3): TA1 enantiomers. (a) ±TA1 standard, 0.256mg/ml, ATTEN 8  ( b )  peak 2  
sem i-prep fraction , ATTEN 1 (c) peak 1  semi-prep fraction, ATTEN 1.
The throughputs obtained here (1 - 1 .5mg of each enantiomer per hour) are comparable to 
those obtained for trimeprazine. In general, however, higher optical purities (>99% for both 
peaks) were obtained in this case, reflecting the higher enantioselectivity. Throughput could 
be increased further by increasing the column loading, at the expense of optical purity. In 
general, increasing the cyclodextrin concentration in the eluent increased throughput, 
although not markedly, owing to shorter run time.
The flush procedure was not effective in all cases. In run 1, loss of TA1 from the recovery 
columns occurred during the flushing stage. In subsequent runs, TFA was incorporated into 
the flush solvent in order to suppress carboxy lic acid ionisation and hence improve
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retentivity of TA1 on the recovery column. This was effective, as shown by the much 
smaller losses on flushing sustained. NMR analysis of the recovered enantiomers from runs 
2 and 3 revealed them to contain significant quantities of B-cyclodextrin, as exemplified in 
Figure 4.14b. The eluting strength of the flush solvent was increased in run 4. Recovered 
enantiomers from this run showed less cyclodextrin contamination, as shown in Figure 
4.14c. This was quantified from NMR integrals to be up to 3 mol% in fraction 1, and 2 moi% 
in fraction 2. It is clear that more prolonged flushing should be carried out to reduce this 
contamination.
8 6 2 0i
Figure 4 .1 4 .1H-NMR spectra of TA1 in CD3OD. (a) racemate (400MHz spectrum) (b) 






Methanol was used as the eluting solvent in this case owing to the higher solubility of TA1 
in methanol compared to acetonitrile. The higher volatility of methanol compared to 
acetonitrile and acetonitrile - water mixtures facilitated recovery of the enantiomers from the 
elution solvent without heating.
4.3.3 Semi-preparative resolution of TA12 enantiomers
TA12 was resolved somewhat less easily than TA1, with an a  value of around 1.2, and 
near-baseline resolution on an SGE-100GLC4-C8-30/5 column with an eluent consisting of 
acetonitrile - aq. phosphate buffer (0.05M, pH 7) (10:90,v/v) containing 20mg/ml 6- 
cyclodextrin hydrate. Under these conditions, the resolution shown in Figure 4.15 was 
achieved at 1mg column loading, This degree of resolution was deemed adequate.
18 20 2212 14 16106 82 40
mins.
Figure 4.15. Semi-preparative resolution of TA12 enantiomers. Conditions as text. 
Detection UV 290nm. Valve switching points for recovery system are also indicated.
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The semi-preparative procedure employed was very similar to that used for TA1. Eleven 
1mg injections of racemate (1 OOpI x 10mg/ml in 50% DMSO / 50% mobile phase) were 
made, before the recovery columns were flushed and the fractions eluted.
The recovered fractions were assayed for recovery and optical purity using a Cyclobond I 
column, as better resolution per unit time could be achieved by this approach than by using 
(3-cyclodextrin-containing eluents with the columns available. A calibration graph was 
constructed using peak height ratios, with m-nitroaniiine as internal standard. Calibration 
data is given in Table 4.11, and chromatograms illustrating the optical purities obtained are 
shown in Figure 4.16. Recovery and optical purity data is summarised in Table 4.12. The 
NMR spectra of the fractions are shown in Figure 4.17.
(a)
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Figure 4.16. Analytical resolution of TA12 enantiomers on Cyclobond I (250 x 4.6mm). 
Mobile phase: acetonitrile - aq. phosphate buffer (0.05M, pH 7) (10:90, v/v). Detection 
UV 270nm. Peak identities: (1): Internal standard (m-nitroaniline), 40ng on col. (2) and 
(3): TA12 enantiomers. (a) standard ±TA12, 1.08pg on col. (b) semi-prep peak 1 
fraction (c) semi-prep peak 2 fraction. Note that elution order of enantiomers Is 
reversed relative to cyclodextrin mobile phase system.
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Table 4.11. Calibration data for chiral TA12 assay. Column: Cyclobond I (250 x 
4.6mm). Mobile phase: acetonitrile - aq. phosphate buffer (0.05M, pH 7) (10:90, v/v). 
Internal standard: m-nitroaniline (0.1 mg/ml). Injection volume: 20pl. Detection: UV 
270nm. Integration: Varian data station.
peak heights[TA12],
pg/ml/enantiomer TA12



































number of measurements, n 





































* = peak heights measured manually
1 6 6
Table 4.12. Summary of results: semi-preparative resolution of TA12 enantiomers
with on-line recovery, (n.d. = not detected).
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Figure 4 .1 7 .1H-NMR spectra of TA12. (a) 270 MHz spectrum of ±TA12 in D20 . (b) 
400MHz spectrum of semi-prep peak 1 fraction in CD3OD. (c) 400MHz spectrum of 







Throughput for TA12 was somehat lower than that achieved for TA1 or trimeprazine, owing 
to low recovery and longer run time. The optical purities achived were also lower, and a 
“second pass” through the system might be required in this case to yield the degree of 
optical purity required for pharmacological testing of the enantiomers.
The recovery procedure was seen to be satisfactory. The “flushing” stage resulted in no 
loss of TA12 recovery, while only trace amounts of B-cyclodextrin appeared in the product. 




4.4.1 Optimisation of brompheniramine enantiomer separation.
The effect of on-column loading on resolution of brompheniramine enantiomers on a 
Spherisorb S5CN column (250 x 4.6mm) using various B-cyclodextrin-containing mobile 
phases is shown in Table 4.13. This column was chosen on the basis of its relatively low 
retentivity (allowing the use of low concentrations of organic modifiers in mobile phases), 
and also because a 10mm i.d. column packed with this material was available, allowing 
larger-scale separations.
Highest selectivity was observed when using a mobile phase containing 5% DMSO v/v, and 
20mg/ml B-cyclodextrin hydrate. Highest resolution at low column loading was observed 
using a similar eluent with a lower cyclodextrin content, the reduced cyclodextrin content 
causing increased retention and hence improved resolution. However, at 1mg column 
loading, highest resolution was obtained using an eluent containing 5% methanol (v/v) and 
11 mg/ml B-cyclodextrin hydrate. The resolution obtained under these conditions was 
deemed adequate for semi-preparative separation of the enantiomers.
Increasing pH from 4 to 7.4 was found to increase retention, but had little effect on 
selectivity or resolution. Triethylamine was added to all eluents in order to reduce peak 
tailing. Variation in injection volume, over the range 20 to 200pl (at constant 1mg loading) 
was found to have no observable effect on resolution.
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Table 4.13. Effect of mobile phase composition and column loading on resolution of 
brompheniramine enantiomers on a Spherisorb S5CN (250 x 4.6mm) column 
(containing 2.5g packing material). All mobile phases contain 0.8% triethylamine, v/v 
and acetic acid to pH 4. In], vol. 20pl
organic modifier, [BetaCD], 2pg on col. 1mg on col.
v/v mg/ml k’i a %CRF %CR
5% CH3CN 16 0.9 1.14 55 42
10%CH3CN 20 0.8 1.12 39 low
3% CH3OH 11 1.5 1.14 48 36
5% CH3OH 11 1.7 1.14 43 50
5% DMSO 11 1.6 1.12 57 18
5% DMSO 20 1.1 1.15 49 30
5% EtOH 20 0.9 1.12 42 low
In order to increase throughput, further studies were carried out on a 250mm x 10mm i.d. 
column packed with the same material. This column contained 4.7 times more packing 
material than the 4.6mm column above. However, the flow rate employed was limited to 
3.5ml/min., due to high back-pressure. The effect of loading on resolution on this 10mm i.d. 
column is illustrated in Figure 4.18.
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Figure 4.18. Resolution of brompheniramine enantiomers on an S5CN 250 x 10mm 
i.d. column, containing 11.8g packing material. Mobile phase: methanol - aq. 
triethylammonium acetate (0.85% TEA v/v, acetic acid to pH 4) (5:95 v/v) containing 
12mg/ml B-cyclodextrin hydrate. Flow rate: 3.5ml/min. Injection solution: ±-bromp- 
heniramine maleate in mobile phase. Loading: (a) 10pg on col. (10pl x 1mg/ml) (b) 
2.5mg on col. (50pl x 50mg/ml) (c) 5mg on col. (100pl x 50mg/ml). Detection: UV (a) 
254nm 0.1AUFS (b) 280nm 2.0AUFS (c) 285nm 2.0AUFS. Fraction collection switching 
points are shown (dotted lines).
The change in peak shapes as column loading was increased is of interest. Initially, 
increases in column loading caused marked increases in the tailing of peak 2, resulting in 
peak 1 being taller than peak 2. However, above 2.5mg on column, the tailing of peak 1 
became more severe, so that peak 2 appeared taller. The second situation is clearly 
disadvantageous with respect to the collection of peak 2 at high optical purity. However, 
overall throughput might be maximised by using a high column loading, with a second pass 
through the system used to further purify the initial fractions. Thus 5mg on column was the 
loading used in semi-prep runs.
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4.4.2. Optimisation of recovery procedure
The capacities of Hamilton PRP1 (12-20pm) and Lichroprep RP18 (25-40pm) materials for 
±-brompheniramine maleate, loaded at 1 mg/ml in methanol - aqueous triethylammonium 
acetate (0.84% TEA v/v, acetic acid to pH 4) (5:95, v/v) containing 12mg/ml B-cyclodextrin 
hydrate were measured in off-line “breakthrough” experiments. The capacities of columns 
packed with the two material were found to be 3.8mg per gram packing material (PRP1) 
and 2.8mg per gram packing material (RP18).
In a subsequent experiment, 2.4mg per gram packing material ±-brompheniramine maleate 
was loaded onto PRP-1. The column was flushed with 30 column volumes (164ml) of 
methanol-water (5:95 v/v), and the brompheniramine eluted in 5 column volumes of 
methanol (25ml). The brompheniramine was recovered at more than 90% yield containing 
less than 0.1 mol% B-cyclodextrin or 1 mol% triethylamine (as determined by NMR using 
maleic acid as internal standard.) When Lichroprep RP18 was loaded with bromphenira­
mine under the same conditions, 46% of the brompheniramine was lost during the flushing 
of the column. The remaining brompheniramine was free from cyclodextrin or buffer 
components.
It was clear from these experiments that Hamilton PRP-1 was the more appropriate choice 
of material for on-line recovery of brompheniramine following chiral separation, owing to its 
higher capacity.
4.4.3 Semi-preparative resolution of brompheniramine enantiomers with on-line recovery
Semi-preparative resolution of brompheniramine enantiomers was accomplished under the 
optimised conditions described above, with on-line recovery achieved using Hamilton 
PRP-1. Repeat injections of racemate (22 x 5mg) were made into the 250 x 10mm S5CN 
column, giving a loading of 55mg onto each of the recovery columns. These were then
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each flushed with 140ml (25 column volumes) of methanol - water (5:95 v/v) before the 
brompheniramine fractions were eluted in methanol. The fractions were introduced to the 
system a second time, under identical conditions, to increase their optical purity.
The optical purities and recoveries obtained by HPLC chiral analysis of the fractions at each 
stage are shown in table 4.14, and illustrated in figure 4.19. The more efficient and retentive 
C6 column gave near-baseline resolution of the enantiomers under analytical conditions. 
Overall recoveries were also checked by NMR, using maleic acid as internal standard.
Good agreement was obtained between the two techniques.
Table 4.14. Summary of results: semi-preparative resolution of brompheniramine 
enantiomers with on-line recovery. Recovery and optical purity determined by HPLC. 
Recovery and chemical purity determined by NMR. Throughput values derived from 
recoveries determined by HPLC.
Peak Recovery, % e.e., % throughput, beta-CD TEA
mg/hour content, mol% content, mol%
After 1st pass:
1 68 82.2 11.9
2 72 75.8 12.8
After 2nd pass:
49.7 (HPLC) 95.4 4.5
48.3 (NMR)
35.1 (HPLC) 88.0 3.2
39.2 (NMR)
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Figure 4.19. Analytical resolution of brompheniramine enantiom ers on S5C6 (150 x 
3mm) column. Eluent: acetonitrile - aq. triethylamm onium acetate (0.89% TEA v/v, 
acetic acid to pH 4) (10:90, v/v) containing 20mg/ml B-cyclodextrin hydrate. Flow rate: 
im l/m in . Inj. vol.: 10pl. Detection: UV 254nm. Peak identities: (1) ±-pheniramine (Int. 
std., 1pg on col.) (2) and (3) brompheniramine enantiomers. (a) ±-brompheniramine 
maleate standard, 3.5pg on col. (b) peak 1 fraction after 1st pass (c) peak 1 fraction 
after 2nd pass (d) peak 2 fraction after 1st pass (e) peak 2 fraction after 2nd pass.
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Figure 4.20 illustrates the chemical purity of the fractions. They were found to contain up to 
0.4 mol% 6-cyclodextrin, but no triethylamine was detected by NMR.
No brompheniramine was detected in the eluate from the columns on flushing, suggesting 
that less than 1% of the brompheniramine was lost during the flushing stages of the 
recovery procedure. The overall recoveries obtained therefore reflect the diversion of 
optically impure material to waste between the two collected fractions. The greater loss of 
peak 2 reflects the difficulty in collecting this peak pure due to the tailing of peak 1. If 
recovery was critical, less material could be diverted to waste. More passes through the 
system would then be needed to produce a given degree of optical purity. For this reason, 
recovery must be “traded off” against throughput or purity.
(a)
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Figure 4.20. 270MHz 1H-NMR spectra of brompheniramine maleate in D20 . (a) 
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The optical rotation of the fractions (as free base) in DMF was determined. The peak 1 
fraction gave a positive optical rotation (+0.18° from an approx. 8mg/ml solution). The peak 
2 fraction gave a negative optical rotation (-0.17° from an approx. 6mg/ml solution). These 
results are consistent with those of Mercer (1989), who found that (-)-brompheniramine 
eluted before the (+)-enantiomer on a Cyclobond I column, which might be expected to give 
reversed elution order compared to the 8-cyclodextrin mobile phase employed here.
Further confirmation of chiral separation was provided by the NMR spectra of the fractions 
in the presence of beta-cyclodextrin. As reported by Casy and Mercer (1988), the addition 
of beta-cyclodextrin to racemic brompheniramine causes duplication of NMR signals. On 
addition of beta-cyclodextrin to the fractions resolved as described above, no duplication of 
signals was observed. On mixing the fractions to re-form a racemate, duplication of some 
signals in the presence of beta-cyclodextrin was observed.
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Chapter 5
Results: 1H-NMR studies on the interaction of racemic substrates with cyclodextrins
179
5.1 introduction
5.1.1 1H-NMR spectra of cyclodextrins
The 270MHz 1H-NMR spectrum of alpha-cyclodextrin in D20  is shown in Figure 5.1a. The 
proton chemical shifts for the three common native cyclodextrins are listed in Table 5.1.
CHjOH
5 0  4.6 4 .0 1 5  3.0
P-pjn-
Figure 5.1. 270MHz 1H-NMR spectra of (a) alpha-cyclodextrin (0.01 M) and (b) 
alpha-cyclodextrin - para-nitrophenol (pNP) (0.05M) in phosphate buffer solution at 
pH 6.0. Reference (external): tetramethylsilane (O.OOppm). From Inoue (1987).
Assignments were made initially at 100MHz by Demarco and Thakkar (1970), and 
confirmed in subsequent studies at220MHz (Wood et a l (1977)) and 500MHz (Inoue et al
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(1984)). All the glucose units in an underivatised cyclodextrin are equivalent, owing to the 
symmetrical nature of the molecule. This considerably simplifies the spectra. The spectra of 
the three native cyclodextrins are very similar, as Table 5.1. shows.
Table 5.1. 400MHz NMR characteristics of cyclodextrins in D20  (from Casy and 
Mercer (1988). External reference: acetone (2.1 ppm). Multiplet separations (Hz) in 
parentheses. Abbrevations: s = singlet; d = doublet; t = triplet; m = multiplet; b = 
broad; u = unresolved.
Cyclodextrin H-1 H-2 H-3 H-4 H-5 6-CH2
alpha- 5.03d 3.61dd 3.96t 3.59t u u
(3.5) (3.4,10) (9.5) (9)
beta- 5.05d 3.62dd 3.94t 3.56bt u u
(4) (3.5, 9.8) (9.5) (9)
gamma- 5.08d 3.63dd 3.911 3.59t u u
(3.7) (3.4, 9.8) (9.5) (9.5)
Cyclodextrin conformations have been confirmed from coupling constants. These are 
consistent with conformations where each glucose unit is in the C1 chair conformation 
(Wood et al (1977)). In DMSO-d6 solution, the hydroxyl proton resonances of cyclodextrins 
are observed. The temperature-dependance of the chemical shifts of these signals has
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been used to confirm the presence of interglucosidic hydrogen bonds between C-2 and C-3 
hydroxyls (St.-Jacques efa/(1976)).
5.1.2. NMR spectra of cyclodextrin complexes
When a cyclodextrin complex is formed, changes may be induced in the NMR spectra of 
both the cyclodextrin and the substrate. This is exemplified in Figure 5.1b, which shows the 
changes induced in the 1H-NMR spectrum of alpha-cyclodextrin on addition of para- 
nitrophenol (pNP) as guest. The changes shown in Figure 5.1b are typical of those caused 
by inclusion of an aromatic guest, i.e. shielding of the cyclodextrin cavity protons H-3 and 
H-5. This effect is due to the high pi-electron density above and below the plane of an 
aromatic ring. The changes in chemical shifts of the cyclodextrin protons on the outside of 
the cavity (H-1, H-2 and H-4) on complex formation are generally very small and less 
predictable.
Changes in substrate chemical shifts are also somewhat unpredictable. In the case of the 
alphaCD-pNP system, the substrate aromatic proton resonances move to lower field on 
complexation (Inoue et al (1984)). This is by no means always the case, however.
The complexation equilibrium is almost always fast on the NMR time-scale (Demarco and 
Thakkar (1970)). Thus, in most cases, only one signal is recorded for a given substrate 
proton, reflecting a weighted average of the signals due to the free and bound form of the 
substrate. Rapid spinning of the substrate within the cavity accounts for the NMR 
equivalence of the glucose residues of the cyclodextrin being preserved on addition of 
substrate. In recent reports, it has been shown that complexes with slow exchange on the 
NMR time-scale can be prepared (Saito et al (1990), Yoshida et a / (1990)). Thus, in the 
NMR spectra of some polymethylene bis-(1-pyridinium) substrates with alpha-cyclodextrin, 
distinct NMR signals for the free and complexed forms of the substrate can be observed at
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5°C, with coalesence occurring as temperature is increased. Line-broadening in the proton 
NMR spectrum of G-cyclodextrin with anthraquinone sulphonate at low temperature has 
been attributed to “intermediate" exchange, although in this case full resolution of signals 
due to free and complexed forms was not seen (DjedaTni and Perly (1990)).
Spin-spin coupling constants also change on complex formation. Inoue et a / (1981) have 
shown by analysis of coupling constants that the side-chain conformations of some 
aromatic amino acids are altered by complex formation with beta-cyclodextrin. Changes in 
coupling constants of underivatised cyclodextrins on complexation are generally small, 
consistent with the view that the cyclodextrin conformation is largely unaltered on inclusion 
of a guest (Wood et al{ 1977)).
5.1.3 Determination of complex stoichiometry from NMR data
The method of continuous variation, as originally described by Job (1928) has been widely 
used to determine the stoichiometry of cyclodextrin complexes. In this method, the total 
molar concentration of two complexing species is kept constant, and complex stoichiometry 
determined from the variation in some quantity reflecting the equilibrium mole fraction of 
complex with the initial mole fraction of one of the species.
In an NMR spectrum of a cyclodextrin CD complexed with a substrate S, assuming fast 
exchange on the NMR time-scale, observed cyclodextrin chemical shifts, 6obs» are 9iven by 
the weighted mean of the chemical shifts of the free (6 free) and bound ( 6compi.) cyclodext­
rin, i.e. <50bs= (( ^compi.[S.CDn]) + ( <5free.([CD]-[S.CDn])))/[CD] (eqn. 5.1),
where [S.CDn] is the equilibrium concentration of the complex (of unknown stoichiometry), 
[CD] and [S] are the initial concentrations of cyclodextrin and substrate.
The change in chemical shift on addition of substrate to cyclodextrin, AS, is given by 
A  5  =  Sobs - <5free. and hence
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A 8 .[CD] = ( 8 compL - 8 free)-[S.CDn] = constant. [S.CDn]. (eqn. 5.2) 
The equilibrium mole fraction of complex is therefore proportional to a 8 [CD]/([S]+[CD]).
The equilibrium constant for the complexation is given by
Kf=[S.CDn]/([Sfree] . [CDfree]n) (eqn. 5.3),
where [Sfree] and [CDfree] are the equilibrium concentrations of free cyclodextrin and 
substrate. The total initial concentration of cyclodextrin and substrate is given by
[S]+[CD]=M. (eqn. 5.4)
The initial mole fraction of substrate, x, is given by
x = [S]/([CD]+[S]). (eqn. 5.5).
The concentration of free substrate and cyclodextrin are then given by
[ S f r e e ]  = x M - [S.CDn] (eqn. 5.6)
and [CDfree] = (1-x).M - n.[S.CDn]. (eqn. 5.7).
The mole fraction of complex will be maximised when d[S.CD]/dx = 0. Differentiation of 
equations 5.3, 5.6, and 5.7 with respect to x, incorporating the above condition, gives
[CDfree] d[Sfree]/dx + n.[Sfree].d[CDfree]/dx = 0 (eqn. 5.8),
d[Sfree]/dx = M (eqn. 5.9)
and d[CDfree]/dx = -M (eqn. 5.10).
Combination of equations 5.4, 5.5, 5.8, 5.9, and 5.10 yields the condition
x=1/(1+n) (eqn.5.11)
for maximisation of [S.CDn]. Hence a plot of A5.[CD]/([S]+[CDj) against x is maximised 
when equation 5.11 is satisfied, n may therefore be determined from such a plot.
Continuous variation plots have been used to determine the stoichiometry of complexes of 
6-cyclodextrin with propanolol hydrochloride (Greatbanks and Pickford (1987)), dimethin- 
dene maleate (Mercer (1989)), anthraquinone sulphonate (Djedai'ni and Perly (1990)), 
indomethacin (Djedai'ni et al (1990a)), 5-fluorouracil and ftorafur (Wen and Cui (1990)) from 
NMR data. In all these cases, 1:1 complex stoichiometry was deduced, and complex
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stability was high. A recent report has pointed out disadvantages of Job’s method, most 
notably that the maximum in a Job plot may be poorly defined for weak complexes and that 
complications arise when competing equilibria occur, such as in a case where 2:1 
complexes are also present (Gil. and Oliveira (1990)).
5.1.4 Determination of complex formation constants
The variation of substrate chemical shifts with the mole ratio of substrate to cyclodextrin 
provides a useful method for the determination of cylodextrin complex stability constants. 
The procedure was originally described by Bergeron et a l (1977a), and was a modification 
of that developed by Benesi and Hildebrand (1949).
For the equilibrium S + CD ^  S.CD, the complex stability constant Kf is given by
Kf = [S.CDJ/([Sfree].[CDfree] -  [S.CD]/(([S]-[S.CD])([CD]-[S.CD]))(eqn. 5.12). 
Assuming fast exchange on the NMR time-scale, the observed substrate chemical shift will 
be given by 8 obsd = ([S]-[S.CD]/[S]). 8 free + ([S.CD]/[S]). 8 ^ p , .  (eqn. 5.13).
The change in chemical sh iftA ^, is given by
A a  = 8 obsd freo (eqn. 5.14).
Combining equations 5.13 and 5.14 gives, on rearrangement,
A  5 = «S.CDJ/[S]).D (eqn. 5.15),
where D is the limiting chemical shift change at infinite degree of complexation and is given
by D -  ^ compl. - 8 free (eqn. 5.16).
Equation 5.12 may be rearranged to
[S.CDJ/K, = [S.CDHCD].[S.CD]-[S].[S.CD]+[CD].[S] (eqn.5.17).
At this point, it is assumed that [S.CDp«[CD].[S], which is true for small degrees of
complexation. With this approximation, and combined with equation 5.15, equation 5.17 
becomes
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[CD]/ A5 = ([CD]+[S])/D + 1/(Kf.D) (eqn. 5.18).
The parameters D and Kf could therefore be determined from a linear plot of [CD]/ A 6 vs. 
[CD]+[S].
Equation 5.18, and similar modifications of the Benesi-Hildebrand equation have been 
widely used for the determination of stability constants of cyclodextrin complexes (Vecchi et 
a /( 1988), Inoue efa/(1984), Bergeron e ta l{1978), Inoue efa /(1985 ), Djedai'ni and Perly 
(1990), Djedai'ni et al (1990a), Wen and Cui (1990)).
An alternative and more rigourous approach to the solution of the above equations has 
recently been provided by Wenz and von der Bey (1988) and by Smith et a / (1989). 
Equation 5.12 is transformed to
k=(x-y)(1 -y)/y (eqn. 5.19),
where y = [S.CD]/[S] = A5 /D (eqn. 5.20),
x = [CD]/[S] (eqn. 5.21),
and k = 1 /(K f.[S]) (eqn. 5.22).
Rearrangement of equation 5.19 and solution of the resulting quadratic gives
y = (x+k+1 )/2 - ((x+k+1 )2/4 - x)1/2 (eqn. 5.23).
Resubstitution of x, y and k then gives
A 5/D = ([CD]/[S] + 1/(Kf.[S]) + 1)/2 - (([CD]/[S] + 1/(Kf.[S]) + 1)2/4 - [CD]/[S]))1/2
(eqn. 5.24).
Kf and D are then obtained by non-linear regression analysis of the variation of A  5 with 
cyclodextrin concentration.
Wenz and von der Bey (1988) have compared results obtained by the two approaches. For 
the complex of perpentyl-3-cyclodextrin with para-nitrophenol, use of equation 5.18 led to a 
Kf value of 1530 dm3 moM while use of equation 5.24 led to the value 3560 dm3 mol'1. The 
significant difference between values obtained by the two methods was attributed to the the
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approximation inherent in the Benesi-Hildebrand method that the mole fraction of complex 
present at equilibrium is small. Bergeron et al (1977a) also pointed out that, under certain 
experimental conditions, this approximation might give rise to significant error.
5.1.5 Determination of complex geometry and structure
A variety of NMR measurements have been used to give information concerning the 
structure and geometry of cyciodextrin complexes.
The magnitude of the proton chemical shift changes in cyclodextrin cavity protons on 
complex formation have been used to estimate the depth of penetration of aromatic guests 
into the cavity (Komiyama and Hirai (1981), Inoue et a / (1984)). The shielding effect of an 
aromatic ring on a proton at a given position relative to the ring has been mapped by 
Johnson and Bovey (1958). From this theory, curves relating specifically to the inclusion of 
an aromatic guest in a cyclodextrin have been computed (Komiyama and Hirai (1980). The 
intrinsic chemical shifts of the cyclodextrin H-3 and H-5 protons in the complex, determined 
from equation 5.18 have been compared with the theoretical Johnson-Bovey curves, and 
an estimate made for the time-averaged position of the centre of the aromatic ring in the 
cyclodextrin cavity.
Changes in 13C chemical shifts have also been used to estimate the position of a guest 
within the cavity (Gelb et al (1981), Inoue efa/(1984,1985a), Komiyama and Hirai (1981), 
Suzuki et a / (1990)). The basis of these calculations is that changes in substrate 13C 
chemical shifts are caused mainly by moving from solvent (water) into the relatively 
hydrophobic cyclodextrin cavity, and that the magnitude of these changes is directly related 
to the depth of cavity penetration. Inoue et al (1985a) have shown that this change is 
equivalent to moving from water into dioxan, and has carried out semi-empirical MO 
calculations using the dielectric constants of water and dioxan to predict the intrinsic
187
chemical shift change expected for a given cavity penetration.
Studies of the molecular dynamics of cyclodextrin-substrate systems have been used to 
gain structural information. The inclusion of a substrate in the cyclodextrin cavity causes a 
reduction in its molecular motion. This results in an increase in spin-lattice relaxation and 
hence a decrease in the spin-lattice relaxation time Tv This effect has been widely reported 
from measurements of 13C and 2H ^  values, and has been used to probe cyclodextrin- 
guest orientation (Uekama et al (1977b), Bergeron and Channing (1979), Behr and Lehn 
(1976), Smith and et al (1989), Suzuki et a / (1990), Inoue et al (1987a)).
Nuclear Overhauser effects (nOe) have been demonstrated in cyclodextrin complexes. The 
nuclear Overhauser effect is a ‘through-space’ effect. Cyclodextrin-substrate intramolecular 
nOe’s therefore indicate the proximity of cyclodextrin and substrate protons. This can give 
precise structural information. Bergeron and Rowan (1976) produced a 9% enhancement in 
the meta- protons signals of sodium 2,6-dimethyl-4-nitrophenolate by irradiation of the 
alpha-cyclodextrin H-3 cavity protons in a one-dimensional nOe difference experiment.
From this, they were able to deduce that the substrate was entering the cyclodextrin cavity 
at the wide (2-,3- end) nitro- group first.
The results of a 2D-NOESY experiment on the alpha-cyclodextrin - pNP system were 
reported by Yamamoto et al (1987). Cross-peaks were observed connecting the cyclodext­
rin H-3 resonance to both ortho- and meta- substrate protons, while the cyclodextrin H-5 
resonance connected only to the meta- substrate protons. From this information, a very 
clear picture of the complex structure in solution could be obtained.
Kitchin et al (reported at 2nd Int. Symp. Pharm. Biomed. Anal., York (1990)) used 
2D-NOESY spectroscopy to investigate the structure of the 6-cyclodextrin-ibuprofen 
complex, and were able thereby to deduce the probable mode of inclusion. Greatbanks and
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Pickford (1987) used 1 D-nOe measurements to postulate the structure of the B-cyclodext- 
rin-propanolol complex.
Some authors, however, have reported difficulty in observing nOe effects in cyclodextrin 
complexes (Casy and Mercer (1988), Divakar (1990), Inoue et a / (1989)). While this may in 
part be due to low complex stabilities and/or loose binding, there is a more fundamental 
reason why such experiments might fail, based on the way the magnitude of nuclear 
Overhauser effects depends on molecular weight (Neuhaus and Williamson (1989)).
The size of nOe's specifically depends on molecular tumbling rate, as described by the 
correlation time tc Small molecules, which tumble rapidly, give positive nOe’s. Large 
molecules, which tumble slowly and thus have large ^  values, give negative nOe’s. There is 
a cross-over point where nOe's are zero. This occurs when
^ —1.12 (eqn. 5.25),
where w= Larmor frequency ^  spectrometer frequency x 2n  and ^  — mol. wt. x 10-12 in 
typical solvents. Depending on solvent, temperature and spectrometer frequency, this 
condition is often met for molecules in the molecular-weight range 1 0 0 0  to 2 0 0 0 .  It is 
therefore not surprising that cyclodextrin complexes often have small or zero nOe’s 
measured in the laboratory frame of reference.
An experiment overcoming this limitation, known as ROESY or CAMELSPIN, was first 
described by Bothner-By et a / (1984). Its application to cyclodextrin complexes has recently 
been described (Inoue efa/(1989)). In the ROESY experiment, nOe’s are measured in a 
frame of reference rotating at the Larmor frequency. This is achieved by the application of 
a “spin-locking" field, generated by the spectrometer transmitter or decoupler during the 
nOe relaxation period or the NOESY mixing period. Viewed in this rotating frame, relative 
w is close to zero and positive nOe’s are obtained across the whole molecular weight 
range.
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Inoue et al (1989) have demonstrated intramolecular cross-peaks in the 2D-ROESY 
spectrum of pNP with 6-0-( « -D-glucopyranosyl)- 0 -cyclodextrin, a system for which no 
nOe’s could be observed in the laboratory frame. This data allowed them to postulate a 
structure for the complex.
5.1.6 Cyclodextrins as NMR chiral shift reagents
The changes in substrate chemical shifts caused by cyclodextrin complexation enable their 
use as NMR shift reagents. This was first demonstrated by MacNicol (1975), who used 
B-cyclodextrin to simplify the proton spectrum of p-cumene. Much greater interest has been 
shown in the use of cyclodextrins as chiral shift reagents. This relies on the fact that the 
NMR spectra and/or stabilities of diastereomeric complexes formed between a pair of 
enantiomers and a cyclodextrin may be different. Thus, enantiotropic signals may be 
distinguished in the NMR spectrum of a racemate on addition of an appropriate cyclodext­
rin. This phenomenon was first reported by MacNicol and Rycroft (1977), who demonstr­
ated enantiotropic splittings in the 19F-NMR spectrum of racemic 1 -phenyl-2,2,2-trifluoroet- 
hanol on addition of an excess of alpha-cyclodextrin.
Numerous subsequent reports of chiral discrimination induced in the NMR spectra of 
racemates by cyclodextrins have appeared. Dyllick-Brenzinger and Roberts (1980) reported 
chiral recognition induced in the 15N spectrum of 8-benzyl-5,6,7,8-tetrahydroquinoline. 
Several 2-arylpropionic acids, including pirprofen (Uekama et a / (1985)), ibuprofen (Casy 
and Mercer (1988)), and flurbiprofen (C.A. March ant, Univ. of Bath, unpubl. data), have 
shown enantiotropic proton splittings in the presence of 8-cyclodextrin. A number of basic 
drugs have also shown chiral discrimination with cyclodextrins, including pheniramine 
antihistamines, analgesics such as alphaprodine and methadone (Casy and Mercer
(1988)), and 8-blockers such as propanolol (Greatbanks and Pickford (1987)). Murakami et 
al (1988) investigated chiral recognition in mandelic add, methyl mandelate, and
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N-acetyl- a-phenylglycine. They found that considerably larger effects were induced by an 
acetylamino-derivatised B-cyclodextrin than by the native compound. Certain amino acid 
derivatives have also shown chiral discrimination with cyclodextrins. (Smith and Spotswood
(1989), Yamashoji et a / (1990)).
The application of such phenomena to optical purity analysis has been discussed (Great- 
banks and Pickford (1987), Casy and Mercer (1988)). Whilst resolution of enantiotropic 
signals is not great enough in every case to detect low levels of an enantiomeric purity, trials 
have shown that optical impurities can be detected to the 1% level in several cases. The 
advantages of cyclodextrins as chiral shift reagents over other reagents (e.g. lanthanides, 
chiral solvents) are that experiments can be conducted in aqueous media (which can be 
important for water soluble chiral molecules), that cyclodextrins do not induce line- 
broadening in substrate spectra and that cyclodextrin proton resonances are in a relatively 
favourable region of the spectrum (i.e. they do not obscure most substrate resonances).
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5.2 TetrahydrQlsQqulnolines
5.2.1 1H-NMR spectrum of TQ1
Chemical shifts of proton signals of TQ1 were assigned as shown in table 5.2. Assignments 
were made with the aid of an nOe experiment. Irradiation of the aromatic proton singlet at 
6.5ppm caused clear enhancement of the C-H triplet at 4.8ppm (2.9%), the methoxyl singlet 
at 3.6ppm (2.7%) and the benzylic methylene signal at 3.4ppm (1.8%), allowing assign­
ments to be made as shown. The H-8 proton was observed to be highly shielded, 
presumably due to its proximity to the phenyl ring in the preferred conformation.
5.2.2 Effect of cyclodextrins on 1H-NMR spectrum of ±-TQ1
Changes in chemical shifts of TQ1 protons were observed on addition of a mole equivalent 
of B-cyclodextrin, as shown in table 5.2, and illustrated in figure 5.2. The most noticeable 
effect was an upfield shift in the H-8 signal, accompanied by significant chiral discrimin­
ation. This increased shielding was thought to be indicative of a conformational change in 
the substrate on complexation, with the H-8 proton moving nearer the region of high 
electron density around the phenyl ring. The cavity protons (H-3) and (H-5) of B-cyclodext- 
rin were shielded on interaction with TQ1, indicating inclusion of an aromatic moiety.
Interaction with TQ1 with a number of other cyclodextrins was investigated. The results are 
summarised in table 5.2. In all cases, some chiral discrimination in the H-8 signal was 
observed. The stereospecific interaction of a solute with all three underivatised cyclodext­
rins is previously unreported. It may be that the tetrahydroisoquinoline moiety includes in 
the larger host cavities, with the phenyl group including in smaller cyclodextrins, although 
there is no direct evidence to support this hypothesis. The largest changes in chemical shift, 
and most significant chiral discrimination, were observed with methyl-B-cyclodextrin.
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Table 5 .2 .1H-NMR chemical shifts of ±-TQ1 (a) alone (b) on addition of cyclodextrin 
(one mole equivalent). In cases where chiral discrimination is observed, chemical 
shifts of signals due to both enantiomers are noted. Abbreviations as Table 5.1, 
except n.r. = not resolved from other signals; HP-betaCD = hydroxypropyl-B- 




proton(s) chemical shifts, ppm
no CD + alphaCD + betaCD + gammaCD + HP-betaCD +Me-betaCD
H-1 4.79 (t) n.r. n.r. 4.79 n.r. n.r.
3-CH2 3.44 (m) 3.44 3.38 3.46 3.30 n.r.
4-CH2 3.12 (m) 3.12 3.14 3.12 3.10 n.r.
9-CH2 3.58 (ddd) 3.3 3.50 3.28 3.51 n.r.
H-5 6.92(s) 6.95 6.93 6.93 6.91 6.904, 6.896
H-8 6.57(s) 6.50, 6.60 6.40, 6.32 6.40, 6.35 6.41,6.39 6.19, 6.00
H-10 7.30 (dd) 7.32 7.28 7.31 n.r. n.r.
H-11 7.4 (m) 7.4 7.4 7.4 n.r. n.r.
H-12
CH3-0 3.85 (s) 3.90 3.87 3.88 3.84 3.90





Figure 5.2. Aromatic proton regions of 270MHz 1H-NMR spectra of ±-TQ1 in D20  (a) 
alone (b) in the presence of B-cyclodextrin (one mole equivalent).
Near-baseline (>90%) resolution of enantiotropic signals at270MHz was induced by 
addition of betaCD, gammaCD and Me-betaCD to TQ1, with greatest resolution in the latter 
case. The optical purity of partially resolved samples of this compound might therefore be 
determined by NMR using cyclodextrins as chiral shift reagents.
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5.2.3 Effect of B-cyclodextrin on 1H-NMR spectra of other tetrahydroisoquinolines.
The changes induced in NMR spectra on addition of a mole equivalent of B-cyclodexfrin to 
racemic solutes in this series are summarised in Table 5.3. Five of the seven compounds 
exhibited chiral discrimination with B-cyclodextrin, although not to such a large degree as 
TQ 1. In contrast to TQ 1, de-shielding of the H-8 protons on complexation was observed in 
several cases. Thus, the conformational changes induced by complexation in this series 
differ from compound to compound. In the case of TQ4, slight chiral discrimination was also 
observed in the H-5 aromatic signal. TQ3 and TQ7 showed no chiral discrimination, and 
there was no evidence for inclusion either through changes in cyclodextrin or substrate 
signals. This suggests that the presence of methoxyl groups on the phenyl ring hinders 
complexation.
Table 5.3. Chemical shifts of H-8 protons of tetrahydroisoquinolines (a) alone (b) on 
addition of one mole equivalent of B-cyclodextrin. In cases where chiral discrimin­
ation is observed, chemical shifts of signals due to both enantiomers are noted.
substrate H-8 chemical shifts, ppm
no CD + betaCD
TQ1 6.57 6.40, 6.32
TQ2 6.49 6.540, 6.545
TQ3 6.49 6.50
TQ4 6.52 6.540, 6.547
TQ5 6.52 6.440, 6.458
TQ6 6.40 6.390, 6.403
TQ7 6.75 6.78
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Only in one case (TQ5) was near-baseline resolution of enantiotropic signals observed 
under the conditions employed. In this case, the experiment performed here might form the 
basis of a method of optical purity determination.
The effect of B-cyclodextrin on 1,2,3,4-tetrahydroisoquinoline itself was investigated in an 
analogous NMR experiment. Shielding of cyclodextrin cavity protons was observed, 
indicating that inclusion was occurring. Thus, the presence of a phenyl substituent on the 
tetrahydroisoquinoline is not necessary for complexation, although there is evidence above 
that such a substituent affects the complexation of the solutes studied here.
5.2.3 Formation constant determination for the B-CD:±-TQ1 system
The Kf values for the complexation of TQ1 enantiomers with B-cyclodextrin were deter­
mined from the variation of H-8 chemical shifts with cyclodextrin concentration, as illustrated 
in figure 5.3. The Kf values and NMR parameters determined are given in Table 5.4.
The formation constants were fairly low by comparison with reported values for some other 
substrates. The Kf values for the two enantiomers were not significantly different {i.e. the 
standard error of the difference between them was greater than the difference, as shown in 
table 5.4). The difference in chemical shifts of the two diastereomeric complexes was 
shown to have greater statistical significance, and is therefore more likely to account for the 
observed enantioselectivity.
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Table 5.4 Stability and 1H-NMR chemical shifts of the complexes formed by TQ1 
enantiomers with B-cyclodextrin in D20  at pH 5. Values obtained from data in Figure
5.3 according to Appendix 1 using MINSQ. 
parameter
complex formation constant, M*1, 
chemical shift change on complexation, ppm
difference in stability constants, M*1 
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Figure 5.3. Variation in chemical shifts of H-8 protons of TQ1 enantiomers with 
B-cyclodextrin concentration. TQ1 racemate concentration = 2.026 mM in 0.1 M 
phosphate buffered D20  at pH 5. Curves fitted to the equations A.16 and A.17 
(appendix 1) by non-linear least-squares regression using MINSQ.
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5.3 PhenQthlazlnes
5.3.1 Chiral discrimination induced by B-cyclodextrin and derivatives
B-cyclodextrin was found to induce chiral discrimination in the proton NMR spectra of a 
number of chiral phenothiazines. The most marked effects were observed for trimeprazine, 
as illustrated in Table 5.5, where B-cyclodextrin caused enantiotropic splitting of the 
dimethylamino (2.8ppm) and C-methyi (1.1 ppm) signals. In the former case, the enantiotro­
pic signals were baseline resolved at 270MHz. This experiment would therefore provide the 
basis for a sensitive optical purity determination method for this material.
Interpretation of the spectra was complicated by non-equivalence of prochiral N-methyl 
groups. Thus in the spectra of the achiral solute prothipendyl, duplication of the dimethyla­
mino signal was observed on addition of B-cyclodextrin. In the spectra of trimeprazine 
tartrate (Table 5.5), the two N-methyl groups were equivalent in the absence of 6- 
cyclodextrin, but became non-equivalent in the presence of B-cyclodextrin. Only one of the 
N-methyl signals exhibited enantiotropic splitting at 270MHz, giving three signals in all. In 
the spectra of the trifluoroacetate salt (Figure 5.4), the N-methyl groups were non­
equivalent in the absence of B-cyclodextrin (due perhaps to the formation of a tight ion-pair 
with greater conformational rigidity than the tartrate). On addition of B-cyclodextrin, both 
N-methyl signals were duplicated (although only one was well resolved), giving four signals 
in all.
On addition of B-cyclodextrin to a resolved sample of one of the enantiomers, produced by 
the method described in chapter 4, only two major N-methyl signals were observed, with 
some evidence of optical impurity (Figure 5.4d).
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Table 5.5. NMR chemical shifts of methyl protons of racemic phenothlazine salts in 
D20  (a) alone (b) on addition of one mole equivalent of cyclodextrin. Where splitting of 
enantiotropic and/or prochiral methyl signals occurred, the chemical shift of each 
observed signal is given.
substrate cyclodextrin 5 N-iuie > PPm 5  c-Me >PPm
no CD + CD no CD + CD
trimeprazine betaCD 2.42 2.75, 0.86 1.16,1.19
tartrate 2.62,2.53
Me-betaCD 2.69 1.18,1.20
promethazine.HCI betaCD 2.68 2.80,2.82 1.33 1.47,1.49
Me-betaCD 2.792,2.800 1.454.1.468
HP-betaCD 2.805,2.816 1.462,1.477
dimethothiazine betaCD 2.59 2.794,2.800 1.31 1.432,1.440
mesylate 2.72
isothipendyl.HCI betaCD 2.76 2.837,2.852 1.36 1.47,1.48
Me-betaCD 2.837,2.844 1.468,1.472
methotrimeprazine* betaCD 2.71 2.89,2.77, 1.17 1.31,1.34
2.69
*=1:1  mixture of (-)-methotrimeprazine maleate and (+)-methotrimeprazine tartrate.
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Figure 5.4. High-field regions of 270MHz spectra of trimeprazine trifluoroacetate in 
D20  (a) racemate alone: (b) racemate in the presence of one mole equivalent of 
B-cyclodextrin: (c) recovered HPLC peak 1 after semi-prep resolution: (d) HPLC peak 1 
in the presence of one mole equivalent of B-cyclodextrin.
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Table 5.5 also summarises the data obtained for the other phenothiazines studied. In all 
five cases, chiral discrimination was evidenced by duplication of alkyl methyl signals. 
Duplication or triplication of dimethylamino signals was also observed in all cases. Where 
duplication of the latter occurred, it was not clear whether this was due to enantiotropic 
splitting or induced N-methyl non-equivalence. Pure samples of the enantiomers of these 
compounds would therefore be required to validate any chiral assay based on this 
approach.
5.3.2. Variation of ±-trimeprazine tartrate chemical shifts with B-cyclodextrin concentration.
The effect of B-cyclodextrin concentration on the chemical shifts of enantiotropic trimepra- 
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Figure 5.5. Variation of the dimethylamino proton chemical shifts of trimeprazine 
enantiomers in D20  with B-cyclodextrin concentration. [±-trimeprazine hemi- 
(+)-tartrate] = 10.65mM.
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It seems unlikely from the shape of the curves obtained that the complexes formed have 
the same structure and/or composition across the cyclodextrin concentration range. This is 
particularly apparent in the lower curve, where the chemical shift change on complexation is 
positive at low cyclodextrin concentrations but negative at high cyclodextrin concentrations. 
Calculation of Kf for the complexes of trimeprazine enantiomers with B-cyclodextrin was not 
attempted, as the model (appendix 1) assumes constant 1 :1 complex stoichiometry across 
the concentration range.
Otagiri et al (1976) postulated that dimerisation of B-cyclodextrin-phenothiazine complexes 
may occur, due to hydrogen bond formation between the amino group of one complex and 
the cyclodextrin hydroxyls of another. This may account for the observed behaviour, both 
the induced N-methyl non-equivalence in the presence of B-cyclodextrin and deviations 
from the expected varation of chemical shifts with cyclodextrin concentration. The latter may 
occur due to changes in the extent of dimerisation across the cyclodextrin concentration 
range.
5.4 Mandelic acids and related compounds
5.4.1 Chiral discrimination induced by cyclodextrins
A number of aromatic acids and esters exhibited chiral discrimination with cyclodextrins, as 
shown in Table 5.6. Of the 21 compounds studied in this group, 18 caused shielding of 
B-cyclodextrin cavity protons, indicating complex formation. Of these, 13 showed chiral 
discrimination induced by B-cyclodextrin. In some cases, particularly monosubstituted acids, 
this took the form of duplication of the signal for the methine proton at the chiral centre. 
Where the aromatic ring was disubstituted, chiral discrimination in aromatic proton signals 
was frequently observed, particularly in signals due to protons meta- to the chiral substi­
tuent. In the cases of the mandelate esters studied, duplication of ester alkyl signals was 
observed.
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Table 5.6. Summary of results of 270MHz1H-NMR experiments Involving the addition 
of a mole equivalent of cyclodextrins to mandelic acids and related compounds In 
D20. Upfield shifts in cyclodextrin cavity proton signals taken to indicate complex 
formation. Substrate signal duplication taken to indicate chiral discrimination.
compound cyclodextrin evidence of chiral
complexation discrimination
mandelic acid betaCD yes yes
alphaCD no no
methyl-betaCD yes no
sodium salt betaCD yes no
tropic acid betaCD yes no
alphaCD yes no
3-phenyl-lactic acid betaCD yes yes
alphaCD no no
" sodium salt betaCD yes yes
2-phenyl propionic acid betaCD yes yes
hydroxypropyl-betaCD yes yes
methyl-G-CD yes yes
sodium salt betaCD yes no





compound cyclodextrin evidence of chiral
complexation discrimination




sodium salt betaCD yes no
2-chloro-mandelic acid betaCD yes no
methyl-betaCD yes yes
4-chloro-mandelic acid betaCD yes no
3-hydroxy-mandelic acid betaCD yes yes
4-hydroxy-mandelic acid betaCD yes yes
" sodium salt betaCD yes no
2-methoxy-mandelic acid betaCD yes no
3-methoxy-mandelic acid betaCD yes yes
sodium salt betaCD yes no
4-methoxy-mandelic acid betaCD yes yes
hydroxypropyl-betaCD yes yes
cyclohexylphenylacetic acid (Na salt) betaCD yes yes
phenylalanine betaCD no no
3,4-dihydroxyphenylalanine betaCD no no
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Table 5.6 (contd.)
compound cyclodextrin evidence of chiral
complexation discrimination
tryptophan betaCD yes yes
aminophenylacetic acid betaCD no no
methyl mandelate betaCD yes yes
ethyl mandelate betaCD yes yes
benzoin betaCD yes yes
In general, complexation of sodium salts of acids in this group was not strong, i.e. shifts in 
cyclodextrin cavity protons on addition of substrate were small. Chiral discrimination was 
absent in all of these cases except 3-phenyllactic acid sodium salt
Of the five compounds tested with alpha-cyclodextrin, only three showed any evidence for 
complex formation, and even in these cases no chiral discrimination was observed. This 
result is surprising considering the small size of the substrates studied in this group, which 
might be thought to be ideal for inclusion into the smaller alpha-cyclodextrin cavity.
Three of the compounds were tested with hydroxypropyl-B-cyclodextrin (DS = 0.6). Similar 
results to those seen with unsubstituted B-cyclodextrin were obtained.
Five of the racemates were tested with methyl-B-cyclodextrin (DS = 1.8). In one case 
(2-chloromandelic acid), chiral discrimination was observed where none had been obtained 
with B-cyclodextrin itself. Some qualitative and quantitative differences were observed in 
other cases, possibly indicating different modes of complexation for the two cyclodextrins 
under comparison.
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Near-baseline resolution of enantiotropic signals under the conditions employed was only 
observed in a few cases. The best case was O-acetylmandelic acid with B-cyclodextrin, 
where more than 90% resolution of the acetyl methyl singlet was observed. In several 
cases, complex signal multiplicities hindered resolution. In other cases, the degree of 
enantiotropic splitting was not large enough for baseline resolution to be observed even in 
singlet signals.
5.4.2 Formation constant determination for the methyl mandelate:B-cyclodextrin system.
The formation constants for the complexes of R-(-)-methyl mandelate and S-(+)-methyl 
mandelate with B-cyclodextrin were calculated from the experimental variation of methyl 
mandelate chemical shifts with cyclodextrin concentration. The data are illustrated in 
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Figure 5.6 Variation in methine proton chemical shifts of the enantiomers of methyl 
mandelate in D20  with B-cyclodextrin concentration. [±-methyl mandelate] = 1.11mM. 
Curves fitted to equations A.16 and A.17 (appendix 1) using MINSQ.
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Table 5.7. Stability and chemical shift data for the complexation of methyl mandelate 
enantiomers with B-cyclodextrin, determined from separate NMR measurements on 
the individual enantiomers. The data was treated according to Smith et a / (1989), and 
parameters were determined using MINSQ.
substrate parameter value std. dei
R(-)-MM complex formation constant, M*1, KfR 91.1 3.9
methine shift change on complexation, ppm D(CH) R -0.1098 0.0026
ester Me shift change on complexation, ppm D(CH3) R 0.0355 0.0010
correlation coefficient r 0.9999
S(+)-MM complex formation constant, M'1 KfS 89.6 5.1
methine shift change on complexation, ppm D(CH) s -0.0961 0.0030
ester Me shift change on complexation, ppm D(CH3) S 0.0456 0.0015
correlation coefficient r 0.9998
difference stability constants, M'1 KfR-Kfs 1.6 6.5
methine complex shifts, ppm, D(CH),S '  D(CH),R 0.0137 0.0040
ester Me complex shifts, D(CH3),S " D(CH3),R 0.0100 0.0018
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Table 5.8. Stability and chemical shift data for the complexation of methyl mandelate 
enantiomers with B-cyclodextrin, determined simultaneously according to appendix 1 
from measurements on the racemate. Non-linear regression analysis was carried out 
using MINSQ.
parameter value std. dev.
complex formation constant, M-1 Kf1 104.4 7.0
K,2 99.6  6.1
methine shift change on complexation, ppm Di -0.0934 0.0032
D2 -0.1051 0.0033
difference in stability constants, M-1 K^-Kf1 4.8 9.3
difference in complex methine shifts, ppm D i *D2 0 .0117 0.0046
correlation coefficient r 0 .9993
Table 5.9. Statistical comparison of parameters for methyl mandelate-B-cyclodextrin 
complexes determined from measurememts on the individual enantiomers (Table 5.7) 
or on the racemate (Table 5.8).
comparison difference std. dev.
formation constants, Kf1-K(S 14.8 8.7
Kf2-K fR 8.5 7.2
complex chemical shifts d2_d(ch),r 0.0047 0.0042
D r D(CH),s 0.0027 0.0044
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Table 5.9 illustrates that the parameters deduced from experimental measurements on the 
racemate were not significantly different from those obtained from experiments on the 
individual enantiomers. This indicates that the use of racemate data may be a valid 
approach, even though the equations are not explicitly soluble for such a system. Greater 
precision, however was obtained in experiments on the individual enantiomers (Table 5.7). 
More definite conclusions could therefore be drawn from these data sets.
The difference in stabilities {i.e. Kf values) of the complexes of the two enantiomers was not 
statistically significant {i.e. the difference was smaller than the standard deviation of the 
difference), but the chemical shifts of the complexes were seen to be significantly different 
Thus, the differences in complex shifts were 3 to 5 times the standard errors of those 
quantities. The observed enantioselectivity was therefore thought to arise largely from this 




5.5.1 Assignment of proton NMR spectrum of ±-TA1
Assignment of signals in the 400MHz 1H spectrum of TA1 were made as shown in Table
5.10. Aromatic (phenol and pyridyl) signals were well resolved and assigned on the basis of 
their chemical shifts and multiplicities. Other assignments were made using spin decoupling 
experiments, and from a 1H-1H COSY spectrum of ±-TA1 in CD3OD. These demonstrated 
the existence of spin-spin coupling between CH2-pyr and dioxan H-2; between dioxan H-4 
and H-5; between H-5 and H-4, 6-CH2 and side-chain 7-CH2; between alkene H-8 and H-9 
and 7-CH2; between alkene H-9 and 10-CH2; and between 10-CH2 and 11-CH2. The cis- 
(1,2 axial-equatorial) relationship of substituents at positions 4 and 5 was confirmed by 
measurement of the small (3Hz) coupling between H-4 and H-5.
A 1H-nOe experiment was conducted in order to ascertain the stereochemical relationship 
between dioxan ring protons H-2 and H-4. Irradiation of the H-2 signal caused an 
enhancement of the H-4 signal, confirming their close proximity, which can only be 
explained in terms of a cis- (1,3-diaxial) relationship.
5.5.2 Chiral discrimination induced in the 1H-NMR spectrum of ±TA1 by 13-cyclodextrin
The effect of the addition of a mole equivalent of 13-cyclodextrin on the 1H-NMR spectrum of 
±-TA1 sodium salt is illustrated in Figure 5.7. The most significant effects were observed in 
the aromatic region of the spectrum, which was clearly resolved. Duplication of all four 
pyridyl proton signals and one of the phenol signals was observed. Some changes were 
also observed in the alkyl chain signals (1.5 - 2.5ppm region), but these signals were not 
clearly resolved. Resolution of enantiotropic signals was most marked for the pyridyl H-2‘ 
signal, which might usefully be applied to optical purity determination for partially resolved 
samples of this compound. Changes were also induced in the cyclodextrin proton signals.
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Table 5.10. Effect of addition of B-cyclodextrin (one mole equivalent) on the 400MHz 
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Figure 5.7. Aromatic proton regions of 400MHz 1H-NMR spectra of ±-TA1 (sodium 
salt) in D20  (a) alone (b) on addition of B-cyclodextrin (one mole equivalent).
5.5.3 NMR chiral discrimination in other thromboxane antagonists
In all, seventeen thromboxane antagonist sodium salts were tested for chiral discrimination 
in NMR using B-cyclodextrin. The results obtained are summarised in Table 5.11. All 
seventeen compounds caused shielding of cyclodextrin cavity protons, indicating that 
complexation was occurring. All but four compounds exhibited chiral discrimination. 
Enantiotropic splittings were most commonly observed in pyridyl signals, perhaps reflecting 
the well resolved nature of these signals in the spectrum of the uncomplexed solute.
212
Table 5.11. Summary of results of 270MHz 1H-NMR experiments involving the 
addition of one mole equivalent of B-cyclodextrin to thromboxane antagonist sodium























































































Other signals, notably those due to phenolic protons, dioxan ring protons and side-chain (R) 
protons exhibited chiral discrimination. Poor resolution, particularly of signals with high 
multiplicity, may have hindered observation of chiral discrimination in some cases. Thus, 
even in cases where no enantiotropic splittings were observed, it could not be categorically 
stated that the stabilities or chemical shifts of the diastereomeric complexes were identical.
Baseline resolution of enantiotropic signals was observed in six cases under the conditions 
employed. In these cases at least, this method might be used as the basis for chiral
analysis.
5.5.4 NMR evidence for inclusion of model compounds.
2-isopropylphenol and 3-ethylpyridine were chosen as model compounds to mimic 
structural features of some of the thromboxane antagonists studied above. On addition to 
13-cyclodextrin in 1:1 mole ratio, significant upfield shifts in cyclodextrin cavity proton signals 
were observed in both cases. It was thus demonstrated that both aromatic moieties in 
compounds such as TA1 might be capable of inclusion in (3-cyclodextrin.
5.5.5 Job (Continuous Variation) Plot for the ±-TA1-B-cyclodextrin system
The stoichiometry of complexation between ±-TA1 (sodium salt) and B-cyclodextrin was 
determined by Job's method. Changes in cyclodextrin proton signals were used for this plot, 
as these were larger than the changes in substrate chemical shifts. The resulting con­
tinuous variation plots are shown in Figure 5.8. All three curves showed a y maximum close 
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Figure 5.8. Job (continuous variation) plot for changes in cyclodextrin chemical 
shifts with ±TA1:B-cyclodextrin ratio.
5.5.6 Determination of the formation constant for the ±-TA1-6-cyclodextrin constant.
The formation constant for the ±-TA1-B-cyclodextrin 1:1 complex was determined from the 
variation of the pyridyl H-2' chemical shifts with cyclodextrin concentration, treating the 
racemate as a single compound and fitting the data to equation 5.24. Individual values for 
the two enantiomers could not be obtained from measurements on the racemate, owing to 
the failure of MINSQ to successfully carry out non-linear regression analysis of the data for 
this system. The data obtained for the racemate are illustrated in Figure 5.9, and the 
parameters obtained are given in Table 5.12.
It can be seen from Figure 5.9 that the variation in chemical shift with cyclodextrin 
concentration quickly reaches a plateau. This indicates that the complexation is strong. 
Table 5.12 shows that the formation constant is indeed large. The failure of the model 
outlined in appendix 1 to produce parameters for the individual enantiomers in this case 
appeared to be due to the high Kf values rendering the equations insoluble even iteratively.
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Table 5.12. Stability and chemical shift data for complex of ±-TA1 with 13-cyclodextrin 
at pD 7.4, determined from equation 5.24 using MINSQ.
parameter value std. dev.
complex formation constant, M*1, Kf 8765 908
shift change on complexation, ppm D 0.0850 0.0006
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Figure 5.9. Variation in chemical shift of ±TA1 pyridyl H-2 signal with 6-cyclodextrin 
concentration at pD 7.4 in D20. [±TA1] = 1.44mM. Data fitted to equation 5.24 using 
MINSQ.
216
The degree of enantiotropic splitting in this case also reached a plateau as cyclodextrin 
concentration was increased. This indicates that the diastereomeric complexes differ 
significantly in their chemical shifts. No conclusions could be inferred regarding the relative 
stabilities of the complexes of the two enantiomers from the available data.
5.5.7 ROESY experiment on the ±-TA1-B-cyclodextrin system.
A 1 D-nOe experiment on ±-TA1 (sodium salt)-B-cyclodextrin (1:1 in D20 ) failed to reveal 
any enhancements (intra- or inter-molecular). Since the molecular weight of the B- 
cyclodextrin-TA1 complex (about 1500) is in the range in which nOe’s in the laboratory 
frame of reference are close to zero, it was decided that a rotating frame (ROESY) 
experiment might be more appropriate. The result of such an experiment is shown in Figure
5.10.
Intramolecular ROESY cross-peaks (i.e. cyclodextrin - cyclodextrin and substrate - 
substrate) appeared as expected, confirming the previous assignments of signals. Of more 
interest, however, was the appearance of intermolecular cyclodextrin-substrate ROESY 
cross-peaks These suggest proximity of cyclodextrin cavity protons (H-3, H-5 and 6-CH2) to 
both aromatic moieties (phenol and pyridyl) of ±-TA1. Bearing in mind the 1:1 complex 
stoichiometry deduced from the Job plot for this system, it seems likely that two different 
1:1 complexes may be formed by this compound, one with the pyridyl group included, the 
other with the phenol group included. Such “bimodal” inclusion has been previously 
reported. Thus, Kotake and Janzen (1989) reported ESR evidence for the formation of two 
types of 1:1 complex of an aromatic nitroxide with B-cyclodextrin.
217
Figure 5.10. 3-9 ppm region of ROESY spectrum of ±-TA1 (3.88mg/ml) as sodium salt 
with B-cyclodextrin (11.44mg/ml) in D20  at 25°C with solvent pre-saturation. The 
contours represent resonances opposite to the diagonal peak. 1D spectra are also 
shown.
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There is good reason to believe that the observed intermolecular ROESY cross-peaks are 
due to genuine nuclear Overhauser effects. Other signals can arise in ROESY spectra 
(Neuhaus and Williamson (1989)), but these could not account for the observed cross-peaks 
in this case. The spectrum as presented in Figure 5.10 shows only cross-peaks that have a 
sign opposite to the diagonal peaks. This eliminates the possibility of interference from 
cross-peaks arising due to HOHAHA transfer, indirect nOe transfer and saturation transfer 
effects, as these give rise to peaks with the same sign as the diagonal. Coherence transfer 
(COSY) and false transverse nOe transfer (TOCSY-ROESY) cross-peaks may appear in a 
spectrum such as Figure 5.10, but these effects only occur between protons in the same 
spin-spin coupling network. They therefore cannot account for cyclodextrin-substrate 
cross-peaks.
The symmetry of Figure 5.10 about the diagonal is high, and the general level of noise is 
low, which suggests that observed cross-peaks are genuine and not artefactual. In order to 
eliminate the possibility of spurious effects arising due to the saturation of the water signal, 









With the large number of chiral separation methods now available, it is of importance to be 
able to rapidly select the best method for a given racemate, particularly since any one 
approach may only be appropriate for a limited range of compounds. Several approaches to 
this problem have been devised and applied to the assessment of the applicability of 
cyclodextrins as resolving agents.
(a) NMR studies
NMR experiments have been used to investigate the chiral discrimination induced by 
potential chromatographic chiral selectors. Of particular note in this respect is the work of 
Shah et al (1987). Correlation was found between the magnitude of chemical shift changes 
induced in the NMR spectra of the two enantiomers of a substrate on addition of the chiral 
(Pirkle-type) selector and the retention order of the enantiomers on a CSP incorporating the 
same selector. Pirkle and Pochapsky (1987a) observed nuclear Overhauser enhancements 
between substrate enantiomers and a chiral selector. These indicated that one enantiomer 
was more closely bound to the selector, and correlated with chromatographic elution order.
Bertucci et al (1990) have reported the results of similar experiments involving B- 
cyclodextrin and chiral benzodiazepinones. The magnitude of NMR chemical shift changes 
of substrate protons on addition of cyclodextrin were taken to indicate strength of 
complexation, and correlation with enantiomeric elution order obtained using Cyclobond I.
Mularz et al (1988a) carried out NMR experiments in an attempt to rationalise the fact that 
pseudoephedrine enantiomers could be resolved using B-cyclodextrin mobile phases while 
ephedrine enantiomers could not. Correlations between NMR chiral discrimination and
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HPLC enantioselectivity were found in this case.
A variety of other NMR experiments have been used to investigate complex structure, 
stoichiometry, and stability. These have already been reviewed (Chapter 5), and have 
obvious application to the rationalisation of chiral discrimination.
(b) Molecular modelling
Computer modelling studies have been widely applied to the investigation of chiral 
recognition mechanisms, particularly for Pirkle-type chiral selectors, where the analyte- 
selector interactions are relatively well characterised. Some success has been achieved in 
rationalising retention order on the basis of computed interaction energies (Taylor, D.R., 
presented at 2nd Int. Symp. Chiral Sepns, Guildford, UK (1989)).
Computer modelling has been used to rationalise the retention order of propanolol 
enantiomers on Cyclobond I (Armstrong, R.D. (1987)). The more retained enantiomer was 
found to be capable of more effective hydrogen-bonding with the cyclodextrin secondary 
hydroxyls.
Taylor (1989) has pointed out that the assumptions inherent in current molecular modelling 
may limit applicability to rationalisation of chiral separations. Most importantly, solvation 
interactions are ignored. These may play an important part in chiral recognition, particularly 
in hydrogen-bonding solvents. The time-scale of such computational studies is such that 
they are unlikely to form the basis for rapid “screening” of analytes for potential chiral 
recognition on a given phase.
A less involved approach to modelling of complex structures has been used by Mularz 
(1988). CPK (space-filling) models were used to assess the “fit” of analytes into the 
6-cyclodextrin cavity, and some deductions regarding potential enantioselective interactions
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made. While far from perfect, several chiral separations were successfully predicted by this 
rapid approach.
(c) Structural correlations
A widely-used approach to prediction of chiral separations has been to identify structural 
features necessary in a substrate for chiral recognition by a given technique. A database 
has recently been devised where reported chiral separations are classified in terms of 
structural fragments (Roussel, C., presented at 3rd. Int. Symp. Pharm. Biomed. Anal., 
Boston, USA(1991)). This may prove to play an important role in the future selection of 
chiral chromatographic methods, although the database only covers chiral stationary 
phases at present.
Pirkle-type CSP's, where the enantioselective interactions are well-defined, have proved the 
easiest for which to relate structural features with enantioselectivity, and achiral derivatis- 
ation is frequently employed to introduce the necessary functionalities. With chiral selectors 
such as cyclodextrins, however, where the mechanism of chiral recognition is less 
well-defined, the development of such rules has proved more problematic.
Armstrong and his co-workers have published a number of papers in which structure- 
selectivity relationships have been investigated. In one such study (Han e ta l{1988)), 43 
compounds were investigated. High chiral selectivity was reported for multi-ring compounds 
in which at least one ring was aromatic, and where the chiral centre was between two 
aromatic rings or an aromatic ring and a carbonyl group. In a more extensive recent review 
(Berthod et al (1990)), these generalisations were modified. Highest chiral recognition was 
found in compounds where the chiral centre was part of a ring, or where the chiral centre 
was attached to at least two sp2 hybridised carbons. A study of 19 racemic nicotine 
analogues has also been reported (Seeman et a / (1988)). In this series, enantioselectivity
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was seen to be highly sensitive to small structural changes. The presence of aromatic 
groups was found to be important in chiral recognition, and fluorine substituents were found 
to be advantageous.
6.1.2 Optimisation of semi-preparative separations in elution mode
The chromatographic resolution, Rs, of two components of a mixture under “ideal” 
conditions of low column loading and Gaussian peak shape is related to selectivity, a  , 
retention, k’, and column efficiency, N, by equation 6.1 (Hamilton and Sewell (1982)).
Rs = 1/4 . NP/ 2  . ( « -1 ) (k’/1+k’) (eqn. 6.1).
At high sample loading, where the approximation that all adsorption sites are equivalent no 
longer holds, peak shapes deviate markedly from Gaussian, retention falls, and resolution is 
no longer adequately described by equation 6.1. Attempts to develop mathematical models 
to describe chromatographic behaviour under conditions of column overload have only 
been partly successful. However, a number of useful generalisations regarding optimisation 
of preparative separations have been made (McDonald and Bidlingmeyer (1987),
Ghodbane and Guiochon (1 9 8 8 ,1988a)), Snyder et a / (1987,1989), Guiochon and Katti 
(1987)).
Selectivity is thought to be the most important factor, the maximisation of which leads to 
maximised throughput. For example, an increase in a  from 1.05 to 1.2 leads to a 15-fold 
increase in loading for the same resolution (McDonald and Bidlingmeyer (1987)). The 
optimisation of selectivity under analytical conditions is therefore useful in producing an 
optimised preparative separation.
The influence of retention is somewhat more complex. It is well established that analytical 
resolution increases significantly with increasing k’, up to a k’ of 20, due to the k7(1+k’) term 
in equation 6.1. However, since a more retained analyte is present at higher relative
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concentration on the stationary phase, capacity (i.e. loadability) is inversely related to 
retention. Furthermore, increases in retention at constant loading perse  result in decreased 
throughput. Snyder e ta l(1987) have suggested that k’ values between 0.5 and 1.5 may be 
optimal under conditions of column overload. This is somewhat less than that generally 
considered optimal for analytical resolution. Consequently, direct scale-up of an optimised 
analytical separation will not necessarily lead to optimised preparative resolution of solutes.
Column efficiency, which determines peak widths, also plays an important part in 
determining resolution in both analytical and preparative separations. This is largely 
determined by particle size and column length. The rate at which column efficiency 
decreases with column loading has been shown to depend on particle size, with larger 
particles giving a smaller rate of decrease. McDonald and Bidlingmeyer (1987) have 
therefore argued that the use of long columns packed with large particles gives optimal 
throughput. This conclusion was supported by Snyder et a / (1987), from computer 
simulation data.
Optimisation of semi-preparative separations must take account of all these factors. For 
resolution of enantiomers, where selectivity is often low compared to that achievable in 
other separations, it is clear that the maxmisation of selectivity and the use of highly 
efficient stationary phases will be critical if optically pure materials are to be produced at 
high throughput.
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6.2 Correlations between HPLC and NMR data
It is of value to seek correlations between data produced using 13-cyclodextrin (i) in NMR,
(ii) bonded to an HPLC stationary phase, and (iii) as an HPLC eluent additive, because of 
the potential predictive value of the former techniques with respect to the latter. The NMR 
experiment employed in these studies occupied only 20 minutes per solute, allowing the 
rapid screening of racemates for chiral discrimination with 6-cyclodextrin. It is also quicker 
to carry out initial chromatographic studies on a Cyclobond column rather than using 
6-cyclodextrin-containing eluents, because stationary phase type and cyclodextrin 
concentration (which are important variables in the latter technique) need not be considered 
using the cyclodextrin bonded-phase. The greater flexibility of the cyclodextrin eluent 
approach, as well as its greater applicability to preparative separations, may mean that this 
is the technique of choice for a racemate for which chiral discrimination has been identified.
6.2.1 Observed correlations between available data
The chiral discrimination induced by B-cyclodextrin achieved in all the HPLC and NMR 
studies reported herein is summarised in Table 6.1. Literature data is also included where 
appropriate.
Table 6.1 gives data for 83 racemates. 80 of these were investigated with G-cyclodextrin- 
containing eluents, of which 32 were resolved to some degree. 75 were investigated with a 
Cyclobond I stationary phase, of which 27 exhibited chiral discrimination. NMR data are 
available for all 83 racemates, of which 53 exhibited chiral discrimination induced by 
B-cyclodextrin. Data from all three techniques are available in 72 cases. Of these, 21 
exhibited chiral discrimination by all three approaches.
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Table 6.1. Summary of enantioselectivity observed using beta-cyclodextrin (a) In 
HPLC mobile phases (b) in HPLC stationary phase (Cyclobond I) (c) in 1H-NMR (1:1 
substrate:cyclodextrin mole ratio)
solute resolution observed using beta-cyclodextrin in
(a) HPLC eluent (b) HPLC CSP (c) NMR
tetrahydroisoquinolines
TQ1 no no yes
TQ2 no no yes
TQ3 v no no no
TQ4 no no yes
TQ5 no no yes
TQ6 no no yes
TQ7 no no no
phenothiazines
trimeprazine tartrate yes yes yes
promethazine.HCI yes no yes
methotrimeprazine (tartrate / maleate) yes yes yes
isothipendyl.HCI no no yes
dimethothaizine mesylate no no yes
mandelic acids, etc.
mandelic acid yes no yes
sodium salt no no no
tropic acid no no
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solute resolution observed using beta-cyclodextrin in
(a) HPLC eluent (b) HPLC CSP (c) NMR
benzoin yes yes yes
thromboxane antagonists (sodium salts)
TA1 yes yes yes
TA2 yes yes yes
TA3 yes yes yes
TA4 yes yes yes
TA5 no yes no
TA6 yes yes yes
TA7 yes yes yes
TA8 no yes yes
TA9 yes yes yes
TA10 yes yes yes
TA11 yes yes no
TA12 yes yes no
TA13 yes yes yes
TA14 yes yes yes
TA15 no no yes
TA16 no yes no
TA17 yes yes yes
Other compounds
pseudo-ephedrine.HCI yes yes2
ephedrine.HCI no no no2
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Table 6.1 (contd.)
solute resolution observed using beta-cyclodextrin in
(a) HPLC eluent (b) HPLC CSP (c) NMR
norephedrine.HCI no no2
normetanephrine.HCI no no2
pheniramine maleate no no3 yes3
chlorpheniramine maleate yes yes3 yes3
brompheniramine maleate yes yes3 yes3
carbinoxamine maleate yes yes3 yes3
doxylamine succinate no4 no5 yes3
dimethindene maleate yes no3 yes3
mebrophenhydramine.HCI no no3 yes3
neobenodine.HCI no no3
meclizine.2HCI no no3 yes3
hydroxyzine.HCI no no3 yes3
nomifensine maleate yes yes no2
telemzepine.2HCI no no no2
methyl phenidate HCI yes yes5 yes2
tryptophan no yes2
disopyramide phosphate no no5 yes2
propanolol.HCI yes4 yes1 yes6
metoprolol tartrate no no yes2
bupranolol.HCI no no no2
bunolol.HCI no no no2
chlorthalidone yes yes no2
nefopam.HCI yes yes yes2
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Table 6.1 (contd.)
solute resolution observed using beta-cyclodextrin in
(a) HPLC eluent (b) HPLC CSP (c) NMR
tetramisole.HCI yes no yes2
oxyphenonium bromide yes no yes2
tropicamide yes no no2
phenindamine iartrate yes no no2
fenoldopam.HCI no no no2
prilocaine.HCI no no yes2
AM5(6) no no no2
verapamil.HCI no no no2
Notes: (a) Where information is derived from literature or other sources, this is indicated by 
superscript numerals, thus 1 = Armstrong (1986); 2 = A.F. Casy, University of Bath, 
unpublished results; 3 = Mercer (1989); 4 = Mularz (1988); 5 = Han (1988); 6 = Greatbanks 
(1987).
(b) Carboxylic acid sodium salts were chromatographed at pH 6. Free acids were 
chromatographed at pH 2. Salts of basic compounds were chromatographed at pH 3.
Of the 32 compounds resolved using B-cyclodextrin eluents, 27 were also resolved in NMR. 
Of the 31 compounds resolved using B-cyclodextrin eluents and for which Cyclobond data 
are available, 24 were also resolved on Cyclobond I. In only two cases were racemates 
resolved using B-cyclodextrin-containing eluents but not by either of the other techniques. It 
is clear, therefore, that there are strong but not perfect qualitative correlations between the 
three data sets. If either the NMR technique or the Cyclobond I column had been used to 
predict which racemates would be resolvable using B-cyclodextrin eluents, very few 
potential separations would not have been predicted. If NMR and Cyclobond I data had
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been used concurrently to identify potential resolution candidates for the B-cyclodextrin 
eluent, only two of the resolutions actually achieved would have been missed.
This conclusion is at first sight very promising with respect to the aim of predicting potential 
candidates for semi-preparative resolution using B-cyclodextrin mobile phases. However, a 
few cautionary points must be made:
(1) The 83 racemates investigated were by no means selected at random. In several cases 
(particularly the tetrahydroisoquinolines, phenothiazines, and many of the other basic 
pharmaceuticals), HPLC studies were prompted by the observation of chiral discrimination 
effects in NMR. In other cases (notably the mandelic acids and thromboxane antagonists), 
the observed or reported resolution by HPLC of one or more compounds in a series 
prompted investigation of a series of structurally related compounds by all three techniques.
(2) The NMR and Cyclobond experiments were conducted under non-optimised conditions. 
Thus, the standard NMR experiment simply involved the addition of a mole equivalent of 
B-cyclodextrin to the racemate or its salt in D20 , with no precise control of pH and no 
attempt to mimic HPLC conditions (particularly the addition of organic modifiers). The 
Cyclobond experiments involved the use of a limited range of buffers in acetonitrile-water 
eluents, with the acetonitrile content reduced from a high level until resolution was observed 
or retention reached a high level (k’ of about 20 was generally the limit used). The use of a 
wider range of conditions in these experiments may have led to resolution being observed 
in more cases, at the expense of speed (which, is of course a major requirement for such 
“predictive” experiments to be of any value).
(3) Only quantitative correlations are being considered. Thus, a racemate that is described 
as being “resolved” in Table 6.1 may not exhibit high enough selectivity to be useful on a 
semi-preparative scale. In order to partially counter this objection, literature data reporting
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small selectivity values from single enantiomer injections, where resolution of the racemate 
was not observed, were not included in Table 6.1.
As has been shown for the thromboxane antagonists (section 3.5.3), there are frequently 
semi-quantitative correlations between the selectivities seen in the two HPLC techniques. 
There are also sometimes correlations between the magnitude of enantiotropic splitting in 
NMR and HPLC enantioselectivity. Thus, for the five phenothiazines investigated a 
statistically significant positive correlation exists between chromatographic selectivity (Table 
3.5) and the degree of enantiotropic splitting in the alkyl methyl signal (Table 5.5), although 
this correlation is far from linear (r = 0.958).
Such correlations can only be sought within series of very closely related compounds, in 
order that chiral discrimination in related NMR signals can be compared. Even within series, 
such comparisons cannot always be made. For example, in the mandelic add series, direct 
comparison of enantiotropic splittings in the spectra of different compounds is meaningless 
as the enantiotropic splittings occur in different proton signals. Thus, mandelic acid, 
O-acetylmandelic acid, 3-phenyllactic add and the mandelate esters exhibit splittings in 
signals due to the the methine proton at the chiral centre, while other compounds in the 
series (notably the aryl-substituted analogues) exhibit splittings instead in aromatic proton 
signals.
6.2.2 Theoretical basis of correlations between NMR chiral discrimination and HPLC 
enantioselectivity
It is instructive to consider the theoretical basis of the chiral discrimination induced by 
8-cyclodextrin in NMR and the two HPLC techniques, in an attempt to rationalise the 
observed degree of correlation of three data sets.
The theory behind cyclodextrin eluent HPLC was introduced in section 3.1.6. In the
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rigourous treatment of Sybilska (1987), which leads to equation 3.11, chromatographic 
enantioselectivity may arise due to differences in the retentions (k’s CD) and/or the stability 
constants (Kf) of the diastereomeric complexes. The latter factor leads to separation via the 
resulting differences in proportions of the complexed forms of the two enantiomers at 
equilibrium. A number of authors have shown that the latter factor is principally responsible 
for the observed selectivity in most cases, and have simplified equation 3.11 to equation 
3.14. Chromatographic selectivity, a  , is then given by
a  = w2tw\ = (1 + Kf1[CD]m)/(1 + Kf2[CD]m) (eqn. 6.2),
which in the limit of infinite cyclodextrin concentration ([CD]m) tends to the ratio of the two 
stability constants.
The theoretical basis of chiral discrimination in NMR may be derived from the treatment 
outlined in section 5.1.4 and Appendix 1. The enantiotropic splitting induced in a proton 
signal by addition of cyclodextrin may be found by subtraction of equations A.17 and A.18. 
As in the HPLC case discussed above, chiral discrimination may arise due to the 
differences in stabilities of the diastereomeric complexes (Kf1 and K^), and/or due to 
differences in their intrinsic properties - in this case their chemical shifts (D1 and D2).
Clearly if, as in HPLC, it is complex stabilities that are the dominant factor, then strong 
correlations will arise between the two data sets.
A few cases have been investigated in detail, reported either in Chapter 5 or in the 
literature. In the cases of both ±-TQ1 (Table 5.4) and ±-methyl mandelate (Table 5.7), 
which are resolved by NMR but not chromatographically, it was shown that the observed 
NMR chiral discrimination was more likely to have arisen from differences in the intrinsic 
chemical shifts of the complexes than from differences in their Kf values. Similar findings 
have been reported by Smith et a / (1989), who found that the chiral discrimination induced 
by alpha-cyclodextrin in the 19F-NMR spectrum of racemic phenylalanine derivatives was 
attributable to differences in intrinsic chemical shifts rather than stabilities of the complexes.
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A similar conclusion was reached bu Uekama et aI (1985) in a 1H-NMR study of the 
±-pirprofen-B-cyclodextrin system.
Even in cases where measurement of intrinsic parameters was not made, there is evidence 
to suggest that complex stabilities do not contribute significantly to observed chiral 
discrimination in NMR. Consider the hypothetical example in Figure 6.1, which illustrates 
the properties to be expected of racemate spectra in the presence of cyclodextrin if 
complex stability is the major factor responsible for chiral discrimination.
Figure 6.1a shows the spectrum of a hypothetical racemic substrate in the absence of 
cyclodextrin, consisting of two singlets, at 2.0ppm and 7.0ppm. Figure 6.1b shows the 
spectrum of the complexed forms of both enantiomers; both complexes exhibiting chemical 
shifts of 1 .Oppm and 9.0ppm. Thus 0 ^ 0 2  = +2.0ppm for the 7.0ppm signal, and D’-, = D’2 
= -1 .Oppm for the 1 .Oppm signal. If the two enantiomers differ in their complex formation 
constants such that enantiomer 1 is 60% complexed at equilibrium and enantiomer 2 is 
90% complexed at equilibrium on addition of a mole equivalent of B-cyclodextrin, then the 
spectrum of the racemate under these conditions will be as shown in Figure 6.1c, with the 
chemical shifts of the signals due to each enantiomer being determined by a weighted 
average of the shifts of the complexed and uncomplexed forms in each case, as given by 
equations A.16 and A.17 (appendix 1). Two important properties of a case where such 
assumptions apply are illustrated by Figure 6.1c:
(1) The signals due to enantiotropic protons are shifted in the same direction relative to the 
uncomplexed material, i.e. A 8 t and A 5 2 are of the same sign.
(2) There is a linear relationship between the magnitude of the observed chemical shift 
change for a given proton (( a 8 1 +a 8 z ) / 2 ) and the magnitude of the enantiotropic 
splitting observed in that signal (a  8 2  - A 50
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(a) racemate (no CD)
(b) complex
D1 -  D2
10 chemical shift, ppm
10



















chemical shift, ppm 0
Figure 6.1. Effect of addition of cyclodextrin to a racemate with a two-line NMR 
spectrum, where the diastereomeric complexes formed differ in their stabilities but 
not in their intrinsic chemical shifts. For discussion see text.
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These properties will be found in racemate-B-cyclodextrin spectra where differences in 
complex stabilities are the major factor responsible for chiral discrimination.
Table 6.2 summarises the chemical shift changes in aromatic proton signals of throm­
boxane antagonists on addition of B-cyclodextrin. It is apparent that the above properties do 
not apply to this data. For example, in the case of the phenol H-3 signal of TA1 (and in 
several other cases), enantiotropic protons are shifted in opposite directions relative to the 
uncomplexed substrate. For no compound in this series is there a statistically significant 
correlation found between the chemical shift change and enantiotropic splitting. The fact 
that differences in complex stability do not appear to influence the NMR spectrum of ±-TA1 
with B-cyclodextrin is notable, since HPLC studies have shown that the differences in 
complex stabilities in this case must be large, giving rise to a chromatographic selectivity of 
over 1.6.
Examination of the NMR spectra of all the compounds studied reveals that in none of them 
are the above criteria satisfied, i.e. it appears to be differences in complex chemical shifts 
that are mainly responsible for enantiotropic splittings in every case.
The fact that differences in complex stabilties, which are known from HPLC to be significant 
in many cases, do not show up in NMR may be a reflection of the magnitudes of the 
intrinsic changes in properties involved in the two techniques. In HPLC the capacity factors 
of the uncomplexed solutes may be quite high (say 10 or above in many cases), while the 
retention of complexes is nearly zero. Differences in the fractions of the two enantiomers 
complexed at equilibrium may therefore give rise to comparatively large differences in 
retention. In NMR, the differences in chemical shift between complexed and uncomplexed 
forms of a substrate are often small relative to the resolution of the instrument (0.1 ppm or 
less in cases where data is available). Thus, the differences in chemical shifts of the two 
enantiomers at equilibrium arising from differences in stability constants, being the
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Table 6.2 Changes in chemical shifts (ppm) of aromatic proton signals of throm­
boxane antagonists on addition of beta-cyclodextrin (one mole equiv.). Where chiral 
discrimination was observed, the chemical shifts of both enantiotropic signals are 
given. Unresolved signals denoted n.r.. 
compound pyridyl signals aryl signals





























































































+0.38 +0.08 +0.04 +0.08
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difference of two fractions of a small quantity, are generally not observable. Only if the 
diastereomeric complexes differ in their intrinsic chemical shifts are enantiotropic splittings 
observable.
While the above argument may be an over-simplification, it would appear to provide 
rationalisation of the experimental observations. The NMR technique appears to be if 
anything more sensitive to differences in the structures of the diastereomeric complexes 
than is HPLC, as evidenced by the larger number of solutes showing chiral discrimination 
by NMR. The fact that qualitative correlations arise between the two data sets reflects the 
fact that structural differences (giving rise to chemical shift differences in NMR) are likely to 
be accompanied by energetic differences (giving rise to HPLC enantioseparation). The 
incomplete nature of this correlation is a reflection of a lack of direct connection between 
structural and energetic changes.
6.2.3. Theoretical basis for correlation between Cyclobond I and B-cyclodextrin eluent data.
The correlation between K( values and chromatographic enantioselectivity is much less 
direct in the cyclodextrin bonded-phase approach than is the case with cyclodextrin eluents. 
A couple of studies involving Cyclobond columns have been reported in which this factor 
was investigated.
Arnold et a /(1989) found strong correlations between complex stabilisation energies, 
derived computationally, and retention times on Cyclobond I within a series of disubstituted 
benzene isomers. However, strong correlations were not found between different series of 
compounds. They concluded that non-inclusion effects, particularly the energy barrier for 
polar substituents to enter the cyclodextrin cavity, remain fairly constant within a series of 
closely related substrates but vary significantly between series. A similar conclusion was 
arrived at by Wang et a / (1990), who compared literature thermodynamic data with retention
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times on Cyclobond I, and found little correlation except within series of related compounds.
This lack of correlation probably reflects the fact that the bonding of the cyclodextrin to the 
silica (via the primary hydroxyl groups) to form the Cyclobond phase changes its chemical 
nature, particularly by hindering interactions with the narrow side of the cavity. Interactions 
with the “spacer” linking the cyclodextrin to the silica, and with the silica itself, may also 
contribute to the retention process.
If similar processes are giving rise to enantioselectivity in both HPLC systems, one would 
anticipate the reversal of elution order of a pair of enantiomers on the Cyclobond I column 
relative to the B-cyclodextrin eluent approach. This aspect was not extensively investigated, 
owing to the non-availability of resolved samples of the enantiomers of most of the 
compounds studied. In cases where this could be investigated, e.g. trimeprazine, 
brompheniramine, TA1, TA12, elution order was indeed found to be reversed between the 
two systems. This may not always be the case, however.
The elution order of related racemates was also investigated. Here, reversal of elution order 
between the two HPLC systems is not necessarily expected. While, retention order may be 
determined largely by complex stabilities on the Cyclobond column, differences in retention 
of the uncomplexed solutes also influence retention order when using cyclodextrin- 
containing eluents. Only in cases (such as the phenothiazine series) where inclusion is 
known to be strong and thus dominates the retention order in both systems was reversal in 
order between the systems observed.
It is clear that the predictive value of both Cyclobond HPLC and NMR experiments with 
respect to cyclodextrin eluent HPLC is limited on theoretical grounds. However, the data 
presented herein suggests that such experiments may have empirical value.
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6.2.4. Practical considerations in predictive experiments
(a) NMR experiments
There are a number of refinements that could be made to the NMR experiments as 
currently carried out in order to enhance their predictive value with respect to the chrom­
atography. The primary objection to the NMR experiments reported here might be that they 
were carried out in deuterated water, whereas HPLC solvents contained buffer components 
and organic modifiers.
The effect of deuterated organic solvents on the chiral discrimination induced in the NMR 












0 5 10 15 20 25 30
% v/v  organic solvent  in D20
Figure 6.2. Effect of organic modifier on enantiotropic splitting between H-8 proton 
signals of TQ1 enantiomers on addition of B-cyclodextrin (one mole equivalent).
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The effect of organic modifiers on NMR chiral discrimination in this case was qualitatively 
similar to that reported in HPLC, i.e. a reduction in discrimination with increasing organic 
modifier content. Attenuation of enantioselectivity was least with methanol, as is generally 
reported to be the case in HPLC studies.
The use of triethylammonium acetate in NMR experiments was investigated in order to 
mimic the conditions used in chromatographic studies involving basic compounds . No 
difference in the spectra of ±-brompheniramine maleate with B-cyclodextrin with and without 
these additives (at constant pH) was observed. This is consistent with the observation in 
chromatographic studies that addition of triethylamine to eluents caused little change in 
selectivity (although improved peak shapes).
There might be some value in routinely carrying out NMR experiments in mixed aqueous- 
organic modified solvents. However, a number of considerations arise:
(1) There is no certainty that the effect of organic modifier in the NMR experiment will 
always be analogous to that in HPLC, since the change of solvent may induce changes in 
intrinsic chemical shifts of substrates or complexes.
(2) Practically, producing NMR spectra in mixed solvents can be problematic, particularly in 
ensuring that the spectrometer locks to the deuterated water signal rather than the organic 
modifer deuterium signal.
(3) If it is assumed that the effect of organic modifier is always to reduce the observed 
enantioselectivity in both HPLC and NMR, running NMR experiments in mixed solvents will 
only reduce the number of compounds exhibiting NMR chiral discrimination. Those 
compounds which are currently resolved by HPLC but not by NMR are even more likely to 
fall into this category in an experiment modified in this way.
NMR experiments reported herein were carried out without pH control. Since pH has been 
identified as a major variable in cyclodextrin complexation, it would be more appropriate in
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future studies to use buffered solutions. This can be achieved with little practical difficulty.
In a recent paper, Camilleri and Dyke (1990) have reported improved chiral separations on 
an a r acid glycoprotein CSP using D20  in place of H20  in mobile phases. Presumably, 
this effect arises due to differences in hydrogen-bonding properties of the isotopic forms of 
water. Since hydrogen-bonding is thought to be important in cyclodextrin chiral recognition, 
it is possible that such differences may also arise with this chiral selector. It might therefore 
be more appropriate to carry out predictive NMR experiments in H20  rather than D20 , 
using solvent suppression techniques to eliminate the resulting large water peak. Some 
experiments of this type were carried out. No significant differences in chiral discrimination 
between the two solvents were observed, and it was not found to be possible to effectively 
suppress the H20  peak without inducing severe baseline distortion which on occasions 
made spectral interpretation difficult. It seems, therefore, that the results may not differ by 
enough for experiments in non-deuterated water to be worthwhile, bearing in mind the 
practical difficulties.
The choice of cyclodextrin concentration in the NMR experiments reported herein was not 
arbitrary, although not necessarily optimal. Chiral discrimination might be expected to 
increase as cyclodextrin:substrate ratio is increased, due to increasing degree of substrate 
complexation. However, owing to the limited solubility of B-cyclodextrin, such an increase 
could only be achieved by reducing the substrate concentration. This would lead to the 
need for longer experiment times (i.e. a larger number of scans) to maintain signal-to-noise 
at acceptable levels. The 1:1 mole ratio employed in these studies provided the best 
balance between degree of complexation and sensitivity. This of course bears little relation 
to the HPLC situation, where selectivity is independent of substrate concentration at low 
column loading.
The experiments carried out on the Cyclobond I column were constructed as simply as
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possible, involving the use of one or two pH’s for each racemate. Control of retention was 
achieved by varying the acetonitrile content of the eluent. Whilst the use of a wider range of 
pH’s, buffer components and organic modifiers might have led to more racemates being 
resolved by this technique, the increase in experiment time involved would have diminished 
the predictive value of the results, since it would have then have been just as rapid to 
investigate the cyclodextrin-racemate interaction directly using cyclodextrin-containing 
eluents.
With the development of rapid optimisation strategies for cyclodextrin eluents, it may be that 
the predictive value of Cyclobond experiments is limited anyway. Since some racemates 
were better resolved on the Cyclobond I than with B-cyclodextrin eluents, this approach of 
course has great value as an analytical technique in its own right.
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6.3. NMR determination of complex stability, stoichiometry and structure
6.3.1 Formation constant determination
The determination of cyclodextrin complex formation constants for single compounds by 
NMR is widely reported in literature, and has been carried out successfully here for (+) and 
(-) methyl mandelate and for ±-TA1 (treated as a single compound). The experiment is 
relatively straightforward to carry out, and gives precise results (CV’s generally less than 
10%). This approach appears to be more facile than the HPLC method (also widely 
reported). Attempts to measure Kf values by HPLC in this work were not always successful, 
due mainly to variations in column retentivity during the course of such experiments. Such 
problems do not arise in the NMR method.
While Kf values determined on single compounds are of great value in inclusion studies, 
there is no direct connection between strength of complex formation of a racemic 
compound (i.e. the absolute magnitude of Kf values) and the chiral discrimination (i.e. the 
difference between the Kf values of the two enantiomers). Therefore, it would be even more 
useful to be able to routinely determine the Kf values for two enantiomers from measure­
ments on the racemate, i.e. without having pure samples of the two enantiomers. Such data 
may give a firm guide as to whether chromatographic separation of a pair of enantiomers is 
likely to be possible, from a relatively rapid series of NMR experiments.
To this end, the theory outlined in Appendix 1 was developed. The resulting equations were 
found to be circularly dependent, but could be solved iteratively in cases (such as ±-methyl 
mandelate and ±-TQ1) where the Kf values were small (around 100 M*1), and precise Kf 
values obtained. However, in strongly complexed cases (such as ±-TA1) solution of the 
equations was not possible, since the square root of a negative number cropped up during 
the iteration process. This may have been a function of the iteration method used by the 
software employed (MINSQ), in which case other software might have more success. As
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things stand, the utility of this method is limited by this problem. Routine Kf determination is 
unlikely to have much predictive value while the method fails for many racemates.
6.3.2 NMR determination of complex stoichiometry and structure
The use of Job’s method for determination of complex stoichiometry, and the ROESY 
technique for investigation of complex structure has been illustrated for ±-TA1. Such 
experiments are of little predictive value, because of the time involved in carrying them out 
and because the information they give is not directly related to enantioselectivity of 
inclusion. Carrying out experiments on resolved enantiomers rather than on racemates 
would be of greater value in thisrespect. These can only be carried out once samples of 
enantiomers are available in a given case.
The chief value of NMR experiments of this type may be in rationalising enantioselectivity 
already demonstrated in NMR or HPLC studies. At present, few examples have been 
investigated in this way. In the future, the results of NMR experiments on pure enantiomers, 
coupled with molecular modelling studies, may allow a clearer understanding of the 
interactions responsible for chiral discrimination, allowing stronger correlations between 
structure and selectivity to be drawn.
6.3.3 Analytical applications of NMR
As well as the use of the NMR experiment to predict and rationalise HPLC separations, it 
forms the basis of a useful analytical method in its own right. In several of the cases 
investigated here, baseline or near-baseline resolution of enantiotropic signals was 
observed. The observation of baseline resolution is in many cases prevented by the 
complex mulitiplicity of key proton signals, or by their being obscured by cyclodextrin or 
solvent resonances.
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6.4. Optimisation of semi-preparative separations using cvclodextrln-containlng
eluents
6.4.1. Summary of semi-preparative separations
The results of the semi-preparative separations reported in Chapter 4 are summarised in 
able 6.3. Optica! purity and throughput were in general reduced as enantioselectivity 
decreased. However, the results for brompheniramine show that feasible semi-preparative 
separations can be achieved, even when selectivity is relatively low, by using wider 
columns and passing partially resolved material through the system a second time.
Table 6.3. Summary of semi-preparative chiral separations carried out using 
beta-cyclodextrin-containing eluents.
compound % e.e. throughput,
mg racemate / hr/
a. peak 1 peak 2 g packing materia!
TA1 1.61 99.1 98.4 3.5
trimeprazine 1.33 >98 92 4.4
TA12 1.22 96.3 87.6 2.1
brompheniramine 1.14 95.4 88.0 0.7
Table 6.4 shows the effect of loading on resolution for a wider range of solutes. It is clear 
from this data that selectivity is crucial in determining loadability, and hence semi­
preparative throughput. For slightly more than half of the chiral separations reported in 
Chapter 3, selectivity ( a) was less than 1.2. The approach used to resolve bromphenira­
mine enantiomers semi-preparatively is therefore likely to be the rule rather than the 
exception.
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Table 6.4. Effect of loading on resolution of racemic solutes. Column dimensions: 
100 x 4mm in all cases (containing 0.77g packing material). Other conditions vary.
racemate
k’i




TA1 10.4 1.61 100 96
trimeprazine 7.0 1.30 99 47
TA3 9.6 1.29 100 86
TA12 20.2 1.22 100 45
TA11 9.1 1.22 100 65
TA7 5.6 1.16 66 36
TA4 7.2 1.14 93 47
TA2 7.3 1.13 81 0
TA10 13.3 1.12 61 0
benzoin 5.3 1.12 50 0
Since chiral separations by this technique are rarely facile, careful optimisation, under 
analytical conditions to maximise selectivity and at high loading to maximise overall 
throughput, is important.
6.4.2. Effect of organic modifiers
The choice of organic modifiers in cyclodextrin-containing eluents is influenced by a number 
of considerations:
(1) Effect on enantioselectivity
It is well established that the presence of organic modifiers in a cyclodextrin-containing
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eluent reduces the enantioselectivity by reducing the concentration of available cyclodext- 
rin. For this reason, only low levels (20% v/v or less) of organic modifiers were employed in 
the eluents used in this work. Methanol is reported to have the lowest affinity for 6- 
cyclodextrin and therefore gives rise to highest selectivity at a given level fo modifier and 
cyclodextrin in the eluent. These generalisations are borne out by data for chlorthalidone 
and benzoin (Table 6.5), and for brompheniramine (Table 4.13).
Table 6.5. Variation in resolution of benzoin and chlorthalidone enantiomers with 
eluent composition. Column: S5CN 250 x 4.6mm. Loading: 2pg racemate on col.
eluent [betaCD], benzoin chlorthalidone
mg/ml k*i a Rs k’i a Rs
ACN - water (10:90) 3.3 1.7 1.03 0.5 0.9 1.05 0.5
6.6 1.3 1.07 0.75 0.8 1.12 0.9
11.8 0.9 1.08 0.8 0.6 1.19 1.2
20 0.6 1.10 0.7 0.5 1.26 1.3
ACN - water (5:95) 6.4 1.6 1.11 0.95 1.0 1.24 1.4
12.8 1.0 1.12 0.95 0.7 1.31 1.5
20 0.7 1.13 0.85 0.6 1.37 1.5
MeOH - water (10:90) 7.6 2.2 1.13 1.0 1.1 1.28 1.3
11.0 1.7 1.14 0.9 0.9 1.33 1.5
MeOH - water (5:95) 6.8 4.0 1.15 1.0 1.8 1.31 1.6
12.0 2.5 1.15 0.9 1.2 1.39 2.6
DMSO - water (5:95) 12.0 1.7 1.13 1.0 1.0 1.27 1.3
22.0 1.1 1.14 0.9 0.7 1.36 1.5
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(2) Effect on cyclodextrin solubility
The variation in B-cyclodextrin solubility with solvent composition in illustrated in Table 6.6. 
Methanol was found to markedly reduce the solubility, while the other modifiers caused 
increased solubility, up to the 20% v/v level investigated.
Table 6.6. Solubility of Beta-cyclodextrin in aqueous-organic solvent mixtures, 
measured according to the method of Jozwiakowski and Connors (1985) at 20°C. 
Beta-cyclodextrin concentrations refer to anhydrous material. ‘ Results marked with 
an asterisk are the mean of 2 determinations.
solvent betaCD solubility, mg/ml std. dev.
water 15.7 0.1
acetonitrile - water (5:95, v/v) 20.6 0.2
acetonitrile - water (10:90, v/v) 25.7*
acetonitrile - water (20:80, v/v) 31.8 1.7
methanol - water (5:95, v/v) 13.0 1.4
methanol - water (10:90, v/v) 11.5*
methanol - water (20:80, v/v) 7.5*
acetonitrile - methanol - water (5:5:90, v/v) 15*
ethanol - water (5:95, v/v) 17.4 0.1
ethanol - water (10:90, v/v) 18.4 0.3
ethanol - water (20:80, v/v) 20.7*
tetrahydrofuran - water (5:95, v/v) 18.2 0.7
tetrahydrofuran - water (10:90, v/v) 21.9 1.8
tetrahydrofuran - water (20:80, v/v) 26.3*
250
While the reasons for this are not clear, this information has important implications in choice 
of HPLC eluent composition. Table 6.5 illustrates that, while methanol as organic modifier 
gives highest selectivity at a given cyclodextrin concentration, high selectivity may still be 
observed using solvents containing DMSO or acetonitrile, since these modifiers allow a 
higher concentration of cyclodextrin to be added to the mobile phase.
(3) Effect on column efficiency
As has been demonstrated for trimeprazine (Table 4.2), the presence of organic modifier in 
the eluent improves column efficiency, by “wetting” the hydrophobic alkyl chains on the 
stationary phase surface and thereby improving mass transfer kinetics. For this reason, 
studies were not routinely conducted using pure water as eluent. While this would have 
lead to high selectivity, resolution would have been decreased due to loss of column 
efficiency.
(4) Effect on retention
Choice of organic modifier was also influenced by the need to optimise retention. For 
brompheniramine, methanol was preferred as organic modifier because retention values 
were generally low on the column employed. In the other semi-preparative separations, 
retention was reduced by the use of acetonitrile in eluents.
6.4.3 Choice of stationary phase
In conventional chromatography, the nature of the stationary phase plays an important part 
in determining selectivity. In separation of enantiomers using cyclodextrin eluents, however, 
the role of the stationary phase appears to be small, owing to the low degree of interaction 
between the cyclodextrin complexes with the stationary phase. For example, Mularz (1988) 
found that the selectivity between brompheniramine enantiomers was independent of
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stationary phase type. This assumption may not hold on very hydrophobic stationary 
phases, or for derivatised cyclodextrins (Clark (1989), Zukowski and Nowakowski (1989)).
In studies reported here, however, stationary phases of low hydrophobicity were mainly 
used in order to give appropriate retention times with the largely aqueous eluents 
employed. The role of the stationary phase may therefore be largely limited to providing 
sufficient retention and efficiency to convert the relatively low selectivity imparted by 
cyclodextrin-containing eluents into useable resolution.
(a) Optimisation of column efficiency
A number of authors have reported changes in column efficiency on addition of cyclodext­
rins to HPLC eluents. Reductions of up to 30% were reported by Sybilska (1987). These 
were attributed either to modifications of the stationary phase by the cyclodextrin, or to 
mass transfer restrictions due to the large size of cyclodextrin and complex molecules 
relative to stationary phase pores. This factor was discussed at length by Mularz (1988). A 
series of wide-pore (300A) packings were investigated, and found to give impressive 
resolution of enantiomers in some cases.
Evidence for pore-size effects in the work reported herein was sparse. While many 
racemates were indeed resolved on a wide-pore column, good resolutions were also 
obtained on conventional (70 -100A pore size) stationary phases. It proved impossible to 
obtain columns of differing pore size but similar retentivity and efficiency, in order that direct 
comparison could be made.
All the columns employed for separation of enantiomers in these studies were packed with 
5pm particles. The use of 3pm particles would have lead to higher innate column efficiency, 
but placed limitations on column length and/or flow-rate (due to higher back-pressure). The 
use of larger particles, as suggested by McDonald and Bidlingmeyer (1987), was not
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investigated, since it was judged that efficiency would be insufficient to resolve racemates 
where only low to moderate selectivity was observed. This factor might be worth further 
study.
(b) Optimisation of retention
The other important factor affecting choice of stationary phase was optimisation of 
retention. Whereas in conventional chromatography, there are generally no limitations on 
the range of solvent compositions that can be used to optimise retention, in cyclodextrin 
chromatography there are fairly strict limitations on organic solvent content of eluents, and it 
is therefore more critical to select the appropriate stationary phase for use with the 
optimised mobile phase. For maximum flexibility in optimisation, the availability of a wide 
range of efficient columns of varying hydrophobicity would be desirable, although this is not 
always economically possible. The optimisation procedure for a given compound is best 
started on a column of low hydrophobicity, in order to minimise retention with low levels of 
eluent organic modifier. More hydrophobic columns can be used subsequently if increased 
retention is required to improve resolution.
It is difficult to generalise about the optimum k’ value for rapid and efficient semi-preparative 
separations from the data presented herein. For trimeprazine, a fairly high k’ (about 10) was 
found to be optimal, mainly on the grounds that on the short column employed lower 
retention would have made more critical the appropriate choice of switching times. By 
reduction of the cyclodextrin content of the eluent, retention was increased giving a greater 
margin for error in this respect.
For the thromboxane antagonists, and TA12 in particular, the retention times were probably 
somewhat greater than optimal (k’ greater than 10), resulting in sub-optimal throughput. 
Highest throughput for TA1 was achieved using the highest possible concentration of
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13-cyclodextrin, indicating that further decreases in retention might have been 
advantageous. However, the use of a less hydrophobic (CN) stationary phase gave 
retention that was too low for good resolution. Increases in eluent acetonitrile content 
resulted in markedly lower selectivity. In the absence of a stationary phase of intermediate 
hydrophobicity between the wide-pore C8 and the cyano phases that were available, the 
conditions used were about the best that could be achieved.
For brompheniramine, column selection was made mainly on the basis that the CN 
stationary phase was the only one for which a larger (250 x 10mm) column was available.
In the optimisation that was carried out, it was found that low organic modifier and 
cyclodextrin contents in the eluent, giving maximised retention, were optimal. Ideally, a 
stationary phase giving somewhat more retention than that achievable on the cyano phase 
(k’ less than 2) might give improved resolution for brompheniramine.
It is clear from the above that pragmatic considerations such as the availability of stationary 
phases and particular column configurations, and the need for “leeway” in column switching 
time programming, inevitably involve compromises in throughput.
Another factor affecting column choice is that the recovery system relies on a difference in 
hydrophobicity between separating and recovery columns. To this end, highly hydrophobic 
recovery phases were employed. In order to maximise recovery column capacity, the use of 
a separating column containing as polar a phase as possible, with a suitably “weak” eluent 
is advantageous. Thus, the recovery column capacities for brompheniramine, which was 
chromatographed on a cyanopropyl-silica column were significantly higher than those for 
trimeprazine, which was chromatographed on a octyl-silica phase.
6.4.4. Optimisation of eluent cyclodextrin concentration
In general, it is reported that increases in cyclodextrin concentration in the mobile phase
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result in improved enantioselectivity (e.g. Takeuchi e t a l ( 1986)). However, for highly 
complexed solutes the increase in selectivitywith cyclodextrin concentration may reach a 
plateau before the solubility of the cyclodextrin is reached. Resolution may be optimal at 
less than the maximum possible cyclodextrin concentration, since retention may be 
sub-optimal at high cyclodextrin concentration.
The rate of increase of selectivity with cyclodextrin concentration depends on the strength 
of complexation. This is illustrated in Figure 6.3.
Figure 6.3. Predicted variation of 
enantioselectivity with cyclodextrin 
concentration in the absence of 
organic modifier, simulated using 
MINSQ from eqn. 6.1.
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N.B.: Beta-cyclodextrin aq. solubility 
= 0.015M approx. at 20°C.
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In Figures 6.3a and b, the selectivity approaches the same value (1.1) as cyclodextrin 
concentration is increased, as the ratios of the formation constant values are the same. The 
plateau is reached more quickly in the more strongly complexed case (a). In cases such as
(b), the use of a high cyclodextrin concentration is likely to be more critical. In Figure 6.4c, 
the maximum selectivity is reached at the same rate as in (b), but its value is higher owing 
to the greater inherent selectivity of the complexation.
These points are further illustrated by the data for chlorthalidone and benzoin. As shown in 
Table 3.9, benzoin is more strongly complexed than chlorthalidone, although the latter 
exhibits greater enantioselectivity. The variation of benzoin selectivity with mobile phase 
composition (Table 6.5) is less marked than that for chlorthalidone, as the selectivity 
reaches a plateau at a lower cyclodextrin concentration. In a weakly complexed case such 
as chlorthalidone, the maximisation of cyclodextrin concentration and minimisation of 
organic modifier content is more likely to be critical than in a more strongly complexed case 
such as benzoin.
Urea has been reported to dramatically increase the aqueous solubility of B-cyclodextrin 
(Pharr et al (1989)). This effect was utilised by Hinze et al (1989) to achieve improved 
separations of isomeric benzene derivatives by TLC using B-cyclodextrin-containing 
eluents. The addition of 8M urea to the eluent was found to increase B-cyclodextrin 
solubility by a factor of 12. Formamide has been used for the same purpose (Collicott, R.J., 
presented at 2nd. Int. Symp. Chiral Sepns., Guildford, UK (1989)).
Urea-containing mobile phases were used to achieve improved separations of some 
thromboxane antagonists (Table 3.7). In a number of otherwise unresolved cases, partial 
resolution was observed in the presence of urea (up to 240mg/ml) and increased amounts 
of B-cyclodextrin (up to 10Omg/ml). Clark (1989) has reported that the use of such eluents 
gave problems with baseline stability and back-pressure. Such problems were noted in
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studies reported herein, but did not prove insurmountable.
The use of urea-containing mobile phases in semi-preparative separations was not 
investigated, but is a potentially promising approach. The on-line recovery system would 
probably allow the recovery of resolved enantiomers free from urea as well as the other 
eluent additives, since urea is highly polar and therefore weakly retained on reversed-phase 
stationary phases. This approach will only yield benefits for weakly complexed solutes, 
where the plateau in the selectivity-cyclodextrin concentration relationship is only reached 
at cyclodextrin concentrations above its solubility in the absence of urea.
6.4.5. Use of triethylamine /  base deactivated stationary phases
It is well established (Nahum and Horvath (1981)) that the poor peak shapes observed for 
basic solutes in RP-HPLC may be attributed to strong (ion-exchange) interactions with 
acidic residual (unbonded) silanols on the stationary phase. This problem is conventionally 
overcome by the addition of an excess of a small amine molecule to the eluent, which can 
effectively compete for these silanol groups. Solute peak asymmetry and retention are 
thereby reduced (Bij et a / (1981)).
Mularz (1988) has argued that triethylamine and other amines also improve the kinetics of 
the cyclodextrin-substrate inclusion process. He showed that markedly improved separ­
ations of racemic bases using cyclodextrin-containing eluents could be achieved by use of 
triethylamine and similar buffers. Berthod et a / (1990) have suggested that a similar 
improvement in chromatography on Cyclobond I induced by triethylamine is due to the 
triethylamine competing with the solute for the cyclodextrin hydroxyl groups. It is not, of 
course, possible to distinguish the effect of triethylamine on the silanols of a reversed- 
phase stationary phase from the effect on the inclusion process in the mobile phase.
The addition of triethylamine to eluents has proved to be necessary in work reported here
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to obtain good resolution of basic racemates on conventional stationary phases. The 
recovery of the resolved enantiomers free from the triethylamine, however, proved 
problematic. This prompted the investigation of base-deactivated stationary phases as a 
means of achieving good peak shapes for bases without triethylamine. The results obtained 
for trimeprazine on Hypersil BDS are reported in section 4.2.2. This phase gave very poor 
results without triethylamine in the eluents, and therefore offered no advantages. Engel- 
hardt and Jungheim (1990) have proposed a test whereby if aniline elutes before phenol a 
phase may be considered base-deactivated. On the Hypersil BDS phase, phenol was found 
to elute before aniline.
Zorbax RX-C8, on which aniline was found to elute before phenol, gave more promising 
results. On this phase, reasonable resolution of a number of basic racemates was achieved 
without triethylamine in eluents. This material might have some utility in semi-preparative 
applications. However, even on this column, peak shapes were improved by the addition of 
triethylamine, indicating that base deactivation was not complete. This improvement 
occurred whether or not cyclodextrin was present in the eluent. No conclusion could 
therefore be drawn as to the existence of specific interactions between B-cyclodextrin and 
triethylamine.
6.4.6 Effect of eluent pH
As has been demonstrated for the thromboxane antagonists (section 3.5.1), pH can be an 
important determinant of resolution for those compounds whose pKa falls within the pH 
range (2 to 7) accessible in HPLC on silica-based stationary phases. For such compounds, 
optimisation of pH is important. pH effects were found to be smaller for most of the basic 
compounds studied, since their pKa’s are generally above pH 7. Clark (1989) has shown 
that improved chiral resolution of bases can be achieved at high pH on pH-stable materials 
such as porous graphitic carbon. The preparative application of this has yet to be
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investigated.
6.4.7 Use of ion-pairing agents
Szepesi and Gazdag (1988) found that mobile phases containing cyclodextrins and 
ion-pairing agents such as sodium dodecylsulphate (achiral) or d-camphorsulphonic acid 
(chiral) exhibited selectivity for the enantiomers of tobanum, where none was observed in 
absence of either component. This effect was thought to arise due to enhanced inclusion of 
ion-pairs formed in the mobile phase.
The use of sodium hexanesulphonate as an alternative to triethylamine in eluents for the 
resolution of trimeprazine enantiomers has already been described (section 4.2.2). Similar 
results were obtained for other phenothiazines, and for the use of tetrabutylammonium 
bromide as ion-pairing agent in the chromatography of mandelic acids, i.e. increases in 
resolution without apparent improvement in selectivity or peak shapes. It seems likely that 
ion-pairing offers no specific advantage to chiral separations with cyclodextrin-containing 
mobile phases under the conditions employed here, except as a means of increasing 
retention. The success reported by Gazdag and Szepesi might be attributable to the higher 
levels of organic modifier used in their work, solubilising ion-pairs formed in the mobile 
phase. Such an approach involves compromises in cyclodextrin enantioselectivity, and is 
therefore unlikely to be widely applicable.
6.4.8 Use of modified cyclodextrins
The use of derivatives of 6-cyclodextrin was investigated on an analytical scale (see section 
3.9). The results were distinctly umpromising, with no improvements in selectivity found 
relative to unmodified 6-cyclodextrin, even at high levels in eluents. This contrasts with the 
results reported by Clark (1989), and Zukowski and Nowakowski (1989). These additives 
appear to offer advantages only in “dynamic CSP” mode, where they are adsorbed onto a
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hydrophobic stationary phase. The preparative application of such an approach has yet to 
be investigated, but may have advantages over the use of bonded cyclodextrin columns in 
terms of flexibility and capacity. Recovery of resolved enantiomers free from the more 
hydrophobic derivatised cyclodextrins may be more problematic than with the highly polar 
B-cyclodextrin itself.
6.4.8 Solute solubility
One of the major limitations on the applicability of B-cyclodextrin-containing eluents to the 
semi-preparative separation of enantiomers of pharmaceutical importance is the low 
solubility of hydrophobic solutes in the largely aqueous eluents employed. In order to 
separate enantiomers of TA1 (section 4.3), it was necessary to dissolve the racemate in a 
solvent with a much higher organic content than the mobile phase. This caused some 
problems with precipitation of cyclodextrin and solute in the injector, which had to be 
disassembled and cleaned at regular intervals. Attempts to resolved benzoin enantiomers 
had to be abandoned, owing to the low aqueous solubility (less than 0.1 mg/ml) of this 
solute. The use of very large injections of weak saturated solutions will be the only way of 
resolving such racemates semi-preparatively.
6.4.9 Recovery of enantiomers following chiral separation
The on-line recovery procedure described in chapter 4 has proved to be effective at 
recovering resolved enantiomers free from mobile phase components. Careful optimisation 
was required, however. The most effective procedure was found to be to load the recovery 
columns to only 50 - 75% of their capacity, allowing the prolonged flushing necessary to 
remove B-cyclodextrin and triethylamine. It is therefore important during method develop­
ment to determine recovery column capacity for the solute in question under the chosen 
mobile phase conditions.
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Of the two recovery phases investigated, the polymeric PRP-1 material was found to have 
greater capacity than Lichroprep RP18 in all cases. This was presumably due to its greater 
hydrophobicity. It was thought that the PRP-1 phase, being an aromatic polymer might 
selectively retain aromatic solutes compared to the non-aromatic cyclodextrin and buffer 
components (due to pi-pi interactions). There was little evidence for this, however. Other 
hydrophobic stationary phases might prove useful as recovery columns, and might be 
investigated in future work.
The feasability of solvent extraction as a recovery procedure was demonstrated for 
trimeprazine. While this failed to remove triethylamine from the product in this case, the 
results suggest that solvent extraction would be a viable alternative for acidic or neutral 
solutes, where no triethylamine is used. Even in these cases, the on-line solid-phase 
extraction procedure described has several advantages. The resolved enantiomers are 
concentrated during the recovery procedure, and may be eluted in a volatile solvent. This 
may be important for thermally labile solutes where the heating needed to evaporate largely 
aqueous mobile phases would be disadvantageous. The on-line recovery procedure is also 
ideally suited to automation, with the possibility of overnight operation increasing throughput 
and saving labour costs.
6.4.1 Q Semi-preparative separations in displacement mode
The recent publications by Vigh et al (1989,1989a, 1990), demonstrating the possibility of 
achieving semi-preparative separations on Cyclobond I columns in displacement mode, 
have brought to the fore the advantages of this mode over elution chromatography in terms 
of loadability and hence throughput. It seems likely that cyclodextrin-silicas, which have 
previously not been much used for preparative separations owing to their low capacity, may 
now find application in this area. The advantage of the cyclodextrin bonded-phase over the 
cyclodextrin eluents is that recovery of resolved material from the resolving agent is not
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necessary, although separation of products from other frequently-used additives such as 
triethylamine may still be problematic, as has been observed here.
This begs the question as to whether displacement chromatographic separations on achiral 
stationary phases using cyclodextrin eluents might be possible. If they were, the higher 
capacity of achiral stationary phases compared to Cyclobond phases might again prove 
advantageous. Carrying out separations in this mode, however, requires fairly sophisticated 
instrumentation and considerable method development, and has not been investigated 
here, or reported in literature using cyclodextrin eluents. Investigation of this approach will 
clearly be a priority in any continuation of this work.
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Appendix-1
Theoretical basis for the simultaneous determination of the stability constants of the 
complexes formed by two enantiomers with cyclodextrin using NMR measurements 
on the racemate.
The theory outlined by Smith et al (1989) and described in section 5.1.4. does not hold if 
more than one entity capable of complex formation is present, since the equilibrium 
concentration of the host, [CDfree], will be reduced by the complexation of the competing 
entity.
Thus, for enantiomeric guest species St and S2 , and by analogy with equation 5.12, we 
may define complex stability constants Kf1 and Kf2, given by equations A.1 and A.2:
Kn = [St C D M S i H S t.CDMCDHS, CDJ-^.CD ])) (eqn. A.1),
Kf2  = [S2.CD]/(([S2]-[S2.CD])([CD]-[S2.CDHSt .CD])) (eqn. A.2).
By analogy with equation 5.15, the chemical shift changes observed on addition of 
cyclodextrin will be given by
A 6 1  = ([St.CD]/[St]).Dt (eqn. A.3)
and A 8 2 = ([S2.CD]/[S2]).D2 (eqn. A.4),
where A5t and A 82 are the observed (equilibrium) chemical shift changes for the 
enantiotropic proton signals on addition of cyclodextrin concentration [CD] and Dt and D2 
are the limiting values of a <5 t and a<52 at infinite host concentration.
We may now simplify the algebra as before by defining normalised quantities thus:
y, = [S, .CD]/[S,] = A i  ,/D, (eqn. A.5),
y2 = [S2.CD]/[S2] = A 5 2/D2 (eqn. A.6),
x = [CD]/[St] = [CD]/[S2 ] (eqn. A.7),
if St and S2 are in racemic mixture.
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ki = 1 /(Kfi-[S-,]) (eqn. A.8),
k2 = 1/(Kf2.[S2]) (eqn. A.9).
Equations A.1 and A.2 then become
ki = (x-yr y2)(i-yi)/yi (eqn A.10)
and k2 = (x-yr y2)(1-y2)/y2 (eqn.A.11)
which may be rearranged to
0 = (x-y2)-y i(x + k r y2+ 1 )+ y 12 (eqn. A.12)
and 0 = (x-y^ - y2(x+k2-y1+1) + y22 (eqn. A.13)
and solved to give
yi = ( (x+kr y2+1) - ((x+kr y2+1)2 - 4(x-y2))1'2 ) /  2 (eqn. A.14)
and y2 = ( (x+k2-y1+1) - ((x+k2-y1+1)2 - 4(x-y1))i/2 ) / 2 (eqn. A.15).
Resubstitution then yields
A 6 1 = D1 . (A, - (A12+( A 8 2/D2)-([CD]/[S1]))1/2 ) (eqn. A.16)
and a « 2 = D 2 . ( A 2 - (A22+( A 81/D1)-([CD]/IS2]))1'2 ) (eqn. A.17)
where A, = (([CDJ/fSJ) + lAK^.fS^) - ( A 6 ^ D 2) + 1)/2
and A2 = (([CD/[S2]) + 1/(Kf2.[S2]) - ( A 5 ,/D ^  + 1 )/2
and [S^ = [S^ = 0.5 x racemate concentration.
It can be seen that equations A.16 resembles equation 5.24, with the introduction of 
additional A 8 2/D2 terms reflecting the degree of complexation of the second enantiomer. 
Similarly, equation A.17 contains a 5 1/D -1 terms to reflect the influence of the first 
enantiomer.
Equations A.16 and A.17 are thus circularly dependent, and contain four unknowns (D^ D2, 
Kf1, and Kf2). They are therefore not explicitly soluble, but might be solved iteratively.
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